


02/18/98



Jc494 U.S. PTO

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 5/1213

Total Pages 212

First Named Inventor or Application Identifier

Hauel, Norbert; et al

Express Mail Label No. EM 507234131US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 203]
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC 113) [Total Sheets ☐
4. ☐ Oath or Declaration [Total Pages ☐
- a. ☒ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 4b,
is considered as being part of the disclosure of the
accompanying application and is hereby incorporated by
reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application,
Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other: _____

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____**18. CORRESPONDENCE ADDRESS**☐ Customer Number or Bar Code Labelor ☐ Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME Robert P. Raymond
Boehringer Ingelheim CorporationADDRESS 900 Ridgebury Road
P.O. Box 368

CITY Ridgefield

STATE CT

ZIP CODE 06877-0368

COUNTRY U.S.A.

TELEPHONE 203-798-9988

FAX 203-791-6183

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

<h2 style="margin: 0;">FEE TRANSMITTAL</h2> <p style="font-size: small; margin: 5px 0;">Note: Effective October 1, 1997. Patent fees are subject to annual revision.</p>	<p>Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%;">Application Number</td><td></td></tr> <tr><td>Filing Date</td><td></td></tr> <tr><td>First Named Inventor</td><td>Hauel, Norbert; et al</td></tr> <tr><td>Group Art Unit</td><td></td></tr> <tr><td>Examiner Name</td><td></td></tr> <tr><td>Attorney Docket Number</td><td>5/1213</td></tr> </table>	Application Number		Filing Date		First Named Inventor	Hauel, Norbert; et al	Group Art Unit		Examiner Name		Attorney Docket Number	5/1213
Application Number													
Filing Date													
First Named Inventor	Hauel, Norbert; et al												
Group Art Unit													
Examiner Name													
Attorney Docket Number	5/1213												
TOTAL AMOUNT OF PAYMENT	(\$)	2468.00											

<p>METHOD OF PAYMENT (check one)</p> <p>1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any over payments to.</p> <p>Deposit Account Number: 02=2955</p> <p>Deposit Account Name: _____</p> <p><input checked="" type="checkbox"/> Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 <input type="checkbox"/> Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance</p> <p>2. <input type="checkbox"/> Payment Enclosed: <input type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other</p> <p>FEE CALCULATION</p> <p>1. FILING FEE</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Large Entity Fee Code (\$)</th> <th>Small Entity Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr><td>101 790</td><td>201 395</td><td>Utility filing fee</td><td>790.00</td></tr> <tr><td>106 330</td><td>206 165</td><td>Design filing fee</td><td></td></tr> <tr><td>107 540</td><td>207 270</td><td>Plant filing fee</td><td></td></tr> <tr><td>108 790</td><td>208 395</td><td>Reissue filing fee</td><td></td></tr> <tr><td>114 150</td><td>214 75</td><td>Provisional filing fee</td><td></td></tr> <tr> <td colspan="3" style="text-align: right;">SUBTOTAL (1)</td> <td>(\$) 790.00</td> </tr> </tbody> </table> <p>2. CLAIMS</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Total Claims</th> <th>Extra</th> <th>Fee from below</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>71 - 20 =</td> <td>51</td> <td>X 22 =</td> <td>1122</td> </tr> <tr> <td>Independent Claims 6 - 3 =</td> <td>3</td> <td>X 82 =</td> <td>246</td> </tr> <tr> <td>Multiple Dependent Claims 1</td> <td>X 270 =</td> <td></td> <td>270</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Large Entity Fee Code (\$)</th> <th>Small Entity Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr><td>103 22</td><td>203 11</td><td>Claims in excess of 20</td><td></td></tr> <tr><td>102 82</td><td>202 41</td><td>Independent claims in excess of 3</td><td></td></tr> <tr><td>104 270</td><td>204 135</td><td>Multiple dependent claim</td><td></td></tr> <tr><td>109 82</td><td>209 41</td><td>Reissue independent claims over original patent</td><td></td></tr> <tr><td>110 22</td><td>210 11</td><td>Reissue claims in excess of 20 and over original patent</td><td></td></tr> <tr> <td colspan="3" style="text-align: right;">SUBTOTAL (2)</td> <td>(\$) 1638</td> </tr> </tbody> </table>	Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	101 790	201 395	Utility filing fee	790.00	106 330	206 165	Design filing fee		107 540	207 270	Plant filing fee		108 790	208 395	Reissue filing fee		114 150	214 75	Provisional filing fee		SUBTOTAL (1)			(\$) 790.00	Total Claims	Extra	Fee from below	Fee Paid	71 - 20 =	51	X 22 =	1122	Independent Claims 6 - 3 =	3	X 82 =	246	Multiple Dependent Claims 1	X 270 =		270	Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	103 22	203 11	Claims in excess of 20		102 82	202 41	Independent claims in excess of 3		104 270	204 135	Multiple dependent claim		109 82	209 41	Reissue independent claims over original patent		110 22	210 11	Reissue claims in excess of 20 and over original patent		SUBTOTAL (2)			(\$) 1638	<p>3. ADDITIONAL FEES</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Large Entity Fee Code (\$)</th> <th>Small Entity Fee Code (\$)</th> <th>Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr><td>105 130</td><td>205 65</td><td>Surcharge - late filing fee or oath</td><td></td></tr> <tr><td>127 50</td><td>227 25</td><td>Surcharge - late provisional filing fee or cover sheet</td><td></td></tr> <tr><td>139 130</td><td>139 130</td><td>Non-English specification</td><td></td></tr> <tr><td>147 2,520</td><td>147 2,520</td><td>For filing a request for reexamination</td><td></td></tr> <tr><td>112 920*</td><td>112 920*</td><td>Requesting publication of SIR prior to Examiner action</td><td></td></tr> <tr><td>113 1,840*</td><td>113 1,840*</td><td>Requesting publication of SIR after Examiner action</td><td></td></tr> <tr><td>115 110</td><td>215 55</td><td>Extension for reply within first month</td><td></td></tr> <tr><td>116 400</td><td>216 200</td><td>Extension for reply within second month</td><td></td></tr> <tr><td>117 950</td><td>217 475</td><td>Extension for reply within third month</td><td></td></tr> <tr><td>118 1,510</td><td>218 755</td><td>Extension for reply within fourth month</td><td></td></tr> <tr><td>128 2,060</td><td>228 1,030</td><td>Extension for reply within fifth month</td><td></td></tr> <tr><td>119 310</td><td>219 155</td><td>Notice of Appeal</td><td></td></tr> <tr><td>120 310</td><td>220 155</td><td>Filing a brief in support of an appeal</td><td></td></tr> <tr><td>121 270</td><td>221 135</td><td>Request for oral hearing</td><td></td></tr> <tr><td>138 1,510</td><td>138 1,510</td><td>Petition to institute a public use proceeding</td><td></td></tr> <tr><td>140 110</td><td>240 55</td><td>Petition to revive - unavoidable</td><td></td></tr> <tr><td>141 1,320</td><td>241 660</td><td>Petition to revive - unintentional</td><td></td></tr> <tr><td>142 1,320</td><td>242 660</td><td>Utility issue fee (or reissue)</td><td></td></tr> <tr><td>143 450</td><td>243 225</td><td>Design issue fee</td><td></td></tr> <tr><td>144 670</td><td>244 335</td><td>Plant issue fee</td><td></td></tr> <tr><td>122 130</td><td>122 130</td><td>Petitions to the Commissioner</td><td></td></tr> <tr><td>123 50</td><td>123 50</td><td>Petitions related to provisional applications</td><td></td></tr> <tr><td>126 240</td><td>126 240</td><td>Submission of Information Disclosure Stmt</td><td></td></tr> <tr><td>581 40</td><td>581 40</td><td>Recording each patent assignment per property (times number of properties)</td><td>40</td></tr> <tr><td>146 790</td><td>246 395</td><td>Filing a submission after final rejection (37 CFR 1.129(a))</td><td></td></tr> <tr><td>149 790</td><td>249 395</td><td>For each additional invention to be examined (37 CFR 1.129(b))</td><td></td></tr> <tr><td colspan="3">Other fee (specify) _____</td><td></td></tr> <tr><td colspan="3">Other fee (specify) _____</td><td></td></tr> <tr> <td colspan="3" style="text-align: right;">SUBTOTAL (3)</td> <td>(\$) 40.00</td> </tr> </tbody> </table> <p>* Reduced by Basic Filing Fee Paid</p>	Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid	105 130	205 65	Surcharge - late filing fee or oath		127 50	227 25	Surcharge - late provisional filing fee or cover sheet		139 130	139 130	Non-English specification		147 2,520	147 2,520	For filing a request for reexamination		112 920*	112 920*	Requesting publication of SIR prior to Examiner action		113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action		115 110	215 55	Extension for reply within first month		116 400	216 200	Extension for reply within second month		117 950	217 475	Extension for reply within third month		118 1,510	218 755	Extension for reply within fourth month		128 2,060	228 1,030	Extension for reply within fifth month		119 310	219 155	Notice of Appeal		120 310	220 155	Filing a brief in support of an appeal		121 270	221 135	Request for oral hearing		138 1,510	138 1,510	Petition to institute a public use proceeding		140 110	240 55	Petition to revive - unavoidable		141 1,320	241 660	Petition to revive - unintentional		142 1,320	242 660	Utility issue fee (or reissue)		143 450	243 225	Design issue fee		144 670	244 335	Plant issue fee		122 130	122 130	Petitions to the Commissioner		123 50	123 50	Petitions related to provisional applications		126 240	126 240	Submission of Information Disclosure Stmt		581 40	581 40	Recording each patent assignment per property (times number of properties)	40	146 790	246 395	Filing a submission after final rejection (37 CFR 1.129(a))		149 790	249 395	For each additional invention to be examined (37 CFR 1.129(b))		Other fee (specify) _____				Other fee (specify) _____				SUBTOTAL (3)			(\$) 40.00
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid																																																																																																																																																																																														
101 790	201 395	Utility filing fee	790.00																																																																																																																																																																																														
106 330	206 165	Design filing fee																																																																																																																																																																																															
107 540	207 270	Plant filing fee																																																																																																																																																																																															
108 790	208 395	Reissue filing fee																																																																																																																																																																																															
114 150	214 75	Provisional filing fee																																																																																																																																																																																															
SUBTOTAL (1)			(\$) 790.00																																																																																																																																																																																														
Total Claims	Extra	Fee from below	Fee Paid																																																																																																																																																																																														
71 - 20 =	51	X 22 =	1122																																																																																																																																																																																														
Independent Claims 6 - 3 =	3	X 82 =	246																																																																																																																																																																																														
Multiple Dependent Claims 1	X 270 =		270																																																																																																																																																																																														
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid																																																																																																																																																																																														
103 22	203 11	Claims in excess of 20																																																																																																																																																																																															
102 82	202 41	Independent claims in excess of 3																																																																																																																																																																																															
104 270	204 135	Multiple dependent claim																																																																																																																																																																																															
109 82	209 41	Reissue independent claims over original patent																																																																																																																																																																																															
110 22	210 11	Reissue claims in excess of 20 and over original patent																																																																																																																																																																																															
SUBTOTAL (2)			(\$) 1638																																																																																																																																																																																														
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid																																																																																																																																																																																														
105 130	205 65	Surcharge - late filing fee or oath																																																																																																																																																																																															
127 50	227 25	Surcharge - late provisional filing fee or cover sheet																																																																																																																																																																																															
139 130	139 130	Non-English specification																																																																																																																																																																																															
147 2,520	147 2,520	For filing a request for reexamination																																																																																																																																																																																															
112 920*	112 920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																																															
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																																															
115 110	215 55	Extension for reply within first month																																																																																																																																																																																															
116 400	216 200	Extension for reply within second month																																																																																																																																																																																															
117 950	217 475	Extension for reply within third month																																																																																																																																																																																															
118 1,510	218 755	Extension for reply within fourth month																																																																																																																																																																																															
128 2,060	228 1,030	Extension for reply within fifth month																																																																																																																																																																																															
119 310	219 155	Notice of Appeal																																																																																																																																																																																															
120 310	220 155	Filing a brief in support of an appeal																																																																																																																																																																																															
121 270	221 135	Request for oral hearing																																																																																																																																																																																															
138 1,510	138 1,510	Petition to institute a public use proceeding																																																																																																																																																																																															
140 110	240 55	Petition to revive - unavoidable																																																																																																																																																																																															
141 1,320	241 660	Petition to revive - unintentional																																																																																																																																																																																															
142 1,320	242 660	Utility issue fee (or reissue)																																																																																																																																																																																															
143 450	243 225	Design issue fee																																																																																																																																																																																															
144 670	244 335	Plant issue fee																																																																																																																																																																																															
122 130	122 130	Petitions to the Commissioner																																																																																																																																																																																															
123 50	123 50	Petitions related to provisional applications																																																																																																																																																																																															
126 240	126 240	Submission of Information Disclosure Stmt																																																																																																																																																																																															
581 40	581 40	Recording each patent assignment per property (times number of properties)	40																																																																																																																																																																																														
146 790	246 395	Filing a submission after final rejection (37 CFR 1.129(a))																																																																																																																																																																																															
149 790	249 395	For each additional invention to be examined (37 CFR 1.129(b))																																																																																																																																																																																															
Other fee (specify) _____																																																																																																																																																																																																	
Other fee (specify) _____																																																																																																																																																																																																	
SUBTOTAL (3)			(\$) 40.00																																																																																																																																																																																														

SUBMITTED BY		Complete (if applicable)	
Typed or Printed Name	Alan R. Stempel	Reg. Number	28,991
Signature		Date	2/18/98
		Deposit Account User ID	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

5 Reference to Prior Provisional Application

10 Description of the Invention

$$R_a - A - \text{Het} - B - \text{Ar} - E \quad , \quad (I)$$

20 The compounds of general formula I above wherein E denotes a cyano group are valuable intermediates for preparing the other compounds of general formula I, and the compounds of general formula I above wherein E denotes an $R_bNH-C(=NH)-$

25 group, and the tautomers and stereoisomers thereof have useful pharmacological properties, particularly a thrombin-inhibiting activity and the effect of extending thrombin time.

Attorney Docket No. 5/1213

In the above general formula

A denotes a carbonyl or sulphonyl group linked to the
benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno
5 moiety of the group Het, whilst moreover the abovementioned
moieties may not contain an R_1 group,

B denotes an ethylene group, wherein a methylene group,
linked either to the group Het or Ar, may be replaced by an
10 oxygen or sulphur atom or by a sulphinyl, sulphonyl,
carbonyl or $-NR_1$ group, wherein

R_1 denotes a hydrogen atom or a C_{1-6} -alkyl group,

15 E denotes a cyano or $R_bNH-C(=NH)-$ group wherein


R_b denotes a hydrogen atom, a hydroxy group, a
 C_{1-3} -alkyl group or a group which may be cleaved in
vivo,

20

Ar denotes a phenylene or naphthylene group optionally
substituted by a fluorine, chlorine or bromine atom or by a
trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,

25 a thienylene, thiazolylene, pyridinylen, pyrimidinylene,
pyrazinylen or pyridazinylene group optionally substituted
in the carbon skeleton by a C_{1-3} -alkyl group,

Het denotes a bicyclic heterocycle of formula
30



, wherein





X is a nitrogen atom and


Y is an oxygen or sulphur atom or a nitrogen atom
optionally substituted by a C₁₋₆-alkyl or
C₃₋₇-cycloalkyl group, whilst additionally one or two
non-angular methyne groups in the phenyl moiety of the
above-mentioned bicyclic heterocycle may each be
replaced by a nitrogen atom,

or X denotes a methyne group optionally substituted by
the group R₁, wherein R₁ is as hereinbefore defined,
and


Y denotes a nitrogen atom optionally substituted by a
C₁₋₆-alkyl or C₃₋₇-cycloalkyl group,

or Het denotes a group of the formula





or



, wherein

5

R_1 is as hereinbefore defined,

10

Z denotes an oxygen or sulphur atom,

one of the groups D or G denotes a nitrogen atom and
the other group D or G denotes a methyne group,

15

and R_a denotes a C_{1-6} -alkyl group, a C_{3-7} -cycloalkyl group
optionally substituted by a C_{1-3} -alkyl group, wherein the
 C_{1-3} -alkyl group may additionally be substituted by a
carboxyl group or by a group which may be converted *in vivo*
into a carboxy group,

20

or an R_2NR_3 - group wherein

25

R_2 denotes a C_{1-4} -alkyl group, which may be substituted
by a carboxy, C_{1-6} -alkyloxycarbonyl, benzyloxycarbonyl,
 C_{1-3} -alkylsulphonylaminocarbonyl,
phenylsulphonylaminocarbonyl, trifluorosulphonylamino,
trifluorosulphonylaminocarbonyl or 1H-tetrazolyl
group,

30

a C_{2-4} -alkyl group substituted by a hydroxy, phenyl-
 C_{1-3} -alkoxy, carboxy- C_{1-3} -alkylamino, C_{1-3} -
alkoxycarbonyl- C_{1-3} -alkylamino, N-(C_{1-3} -alkyl)-carboxy-
 C_{1-3} -alkylamino or N-(C_{1-3} -alkyl)- C_{1-3} -alkoxycarbonyl- C_{1-3} -
alkylamino group, whilst in the abovementioned groups

the carbon atom in the α -position relative to the adjacent nitrogen atom may not be substituted, or

5 a piperidiny1 group optionally substituted by a C₁₋₃-alkyl group and

R₃ denotes a hydrogen atom, a C₁₋₆-alkyl group, a C₃₋₇-cycloalkyl group optionally substituted by a C₁₋₃-alkyl group, a C₃₋₆-alkenyl or alkynyl group, 10 wherein the unsaturated part may not be linked directly to the nitrogen atom of the R₂NR₃- group,


a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or 15 C₁₋₃-alkoxy group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl or imidazolyl group or

20 R₂ and R₃ together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxymethyl or C₁₋₄-alkoxycarbonyl group, onto which a phenyl ring may additionally be fused.

25 The compounds of the above general formula I which contain a group capable of being cleaved *in vivo* are thus prodrugs and compounds of general formula I which contain two groups capable of being cleaved *in vivo* are so-called double 30 prodrugs.

The phrase "a group which may be converted *in vivo* into a carboxy group" denotes, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol, in which the 35 alcoholic moiety is preferably a C₁₋₆-alkanol, a phenyl-C₁₋₃-alkanol, a C₃₋₉-cycloalkanol, wherein a C₅₋₈-cycloalkanol may additionally be substituted by one or

two C₁₋₃-alkyl groups, a C₅₋₈-cycloalkanol, in which a methylene group in the 3- or 4-position is replaced by an oxygen atom or by an imino group optionally substituted by a C₁₋₃-alkyl, phenyl-C₁₋₃-alkyl, phenyl-C₁₋₃-alkoxycarbonyl or C₂₋₆-alkanoyl group, and the cycloalkanol moiety may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₄₋₇-cycloalkenol, a C₃₋₅-alkenol, a phenyl-C₃₋₅-alkenol, a C₃₋₅-alkynol or phenyl-C₃₋₅-alkynol, with the proviso that no bond to the oxygen atom emanates from a carbon atom which carries a double or triple bond, a C₃₋₈-cycloalkyl-C₁₋₃-alkanol, a bicycloalkanol having a total of 8 to 10 carbon atoms, which may additionally be substituted in the bicycloalkyl moiety by one or two C₁₋₃-alkyl groups, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula



wherein

R₄ denotes a C₁₋₈-alkyl, C₅₋₇-cycloalkyl, phenyl or phenyl-C₁₋₃-alkyl group,

R₅ denotes a hydrogen atom, a C₁₋₃-alkyl, C₅₋₇-cycloalkyl or phenyl group and

R₆ denotes a hydrogen atom or a C₁₋₃-alkyl group,

or the phrase "a group which may be cleaved *in vivo* from an imino or amino group" denotes for example a hydroxy group, an acyl group such as a benzoyl- or pyridinoyl group or a C₁₋₁₆-alkanoyl group such as the formyl-, acetyl-, propionyl-, butanoyl-, pentanoyl- or hexanoyl group, an allyloxycarbonyl group, a C₁₋₁₆-alkoxycarbonyl group such as the methoxycarbonyl-, ethoxycarbonyl-, propoxycarbonyl-, isopropoxycarbonyl-, butoxycarbonyl-, tert.-butoxycarbonyl-, pentoxycarbonyl-, hexoxycarbonyl-, octyloxycarbonyl-, nonyloxycarbonyl-, decyloxycarbonyl-,

undecyloxycarbonyl-, dodecyloxycarbonyl- or
hexadecyloxycarbonyl group, a phenyl-C₁₋₆-alkoxycarbonyl
group such as the benzyloxycarbonyl-, phenylethoxycarbonyl-
or phenylpropoxycarbonyl group, a C₁₋₃-alkylsulphonyl-
5 C₂₋₄-alkoxycarbonyl-, C₁₋₃-alkoxy-C₂₋₄-alkoxy-
C₂₋₄-alkoxycarbonyl- or R₄CO-O-(R₅CR₆)-O-CO-group, wherein
R₄ to R₆ are as hereinbefore defined.

Examples of preferred prodrug groups for a carboxy group
10 include a C₁₋₆-alkoxycarbonyl group such as the
methoxycarbonyl, ethoxycarbonyl, n-propyloxycarbonyl,
isopropyloxycarbonyl, n-butyloxycarbonyl,
n-pentyloxycarbonyl, n-hexyloxycarbonyl or cyc-
lohexyloxycarbonyl group or phenyl-C₁₋₃-alkoxycarbonyl
15 group such as the benzyloxycarbonyl group and
for an imino or amino group a C₁₋₉-alkoxycarbonyl group
such as the methoxycarbonyl, ethoxycarbonyl,
n-propyloxycarbonyl, isopropyloxycarbonyl,
20 n-butyloxycarbonyl, n-pentyloxycarbonyl,
n-hexyloxycarbonyl, cyclohexyloxycarbonyl,
n-heptyloxycarbonyl, n-octyloxycarbonyl or
n-nonyloxycarbonyl group, a phenyl-C₁₋₃-alkoxycarbonyl
group such as the benzyloxycarbonyl group, a phenylcarbonyl
25 group optionally substituted by a C₁₋₃-alkyl group such as
the benzoyl or 4-ethyl-benzoyl group, a pyridinoyl group
such as the nicotinoyl group, a C₁₋₃-alkylsulphonyl-
n-C₂₋₃-alkoxycarbonyl or C₁₋₃-alkoxy-C₂₋₃-alkoxy-
C₂₋₄-alkoxycarbonyl group such as the
30 2-methylsulphonylethoxycarbonyl or 2-(2-ethoxy)-
ethoxycarbonyl group.

Moreover, the saturated alkyl and alkoxy moieties
containing more than 2 carbon atoms as well as alkanoyl and
35 unsaturated alkyl moieties containing more than 3 carbon

atoms as mentioned in the foregoing definitions also include the branched isomers thereof such as for example the isopropyl, tert.-butyl and isobutyl group, etc.

- 5 Preferred compounds of the above general formula I, however, are those wherein

A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno
10 moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R_1 group,

B denotes an ethylene group, in which a methylene group, linked either to the group Het or Ar, may be replaced by an
15 oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or $-NR_1-$ group, wherein

R_1 denotes a hydrogen atom or a C_{1-5} -alkyl group,

- 20 E denotes an $R_bNH-C(=NH)-$ group wherein

R_b denotes a hydrogen atom, a hydroxy group, a C_{1-3} -alkyl group or a group which may be cleaved *in vivo*,


25

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,

- 30 a thienylene, thiazolylene, pyridinylen, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C_{1-3} -alkyl group,

Het denotes a bicyclic heterocycle of formula

35



, wherein

X is a nitrogen atom and



5 Y is an oxygen or sulphur atom or a nitrogen atom optionally substituted by a C₁₋₆-alkyl or C₃₋₇-cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the above-mentioned bicyclic heterocycle may each be
10 replaced by a nitrogen atom,

or X denotes a methyne group optionally substituted by the group R₁, wherein R₁ is as hereinbefore defined, and




15 Y denotes a nitrogen atom optionally substituted by a C₁₋₆-alkyl or C₃₋₇-cycloalkyl group,

or Het denotes a group of the formulae


20



25



or



, wherein

R₁ is as hereinbefore defined,

Z denotes an oxygen or sulphur atom,

one of the groups D or G denotes a nitrogen atom and the other group D or G denotes a methyne group,

and R_a denotes a C₁₋₆-alkyl group, a C₃₋₇-cycloalkyl group optionally substituted by a C₁₋₃-alkyl group, wherein the C₁₋₃-alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted *in vivo* into a carboxy group,

or a R₂NR₃- group wherein

R₂ denotes a C₁₋₄-alkyl group, which may be substituted by a carboxy, C₁₋₆-alkyloxycarbonyl, benzyloxycarbonyl, C₁₋₃-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, trifluorosulphonylamino, trifluorosulphonylaminocarbonyl or 1H-tetrazolyl group,

a C₂₋₄-alkyl group substituted by a hydroxy, phenyl-C₁₋₃-alkoxy, carboxy-C₁₋₃-alkylamino, C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl)-carboxy-C₁₋₃-alkylamino or N-(C₁₋₃-alkyl)-C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino group, whilst in the abovementioned groups the carbon atom in the α-position relative to the adjacent nitrogen atom may not be substituted, or

a piperidinyl group optionally substituted by a C₁₋₃-alkyl group and

R₃ denotes a hydrogen atom, a C₁₋₆-alkyl group, a C₃₋₇-cycloalkyl group optionally substituted by a C₁₋₃-alkyl group, a C₃₋₆-alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R₂NR₃- group,

a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl or piperidinyl group or

R₂ and R₃ together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or C₁₋₄-alkoxycarbonyl group, onto which a phenyl ring may additionally be fused, particularly those compounds wherein

Het denotes one of the abovementioned benzimidazolylene, benzothiazolylene, benzoxazolylene, indolylene, quinazolinylene, quinoxazolinonylene, imidazo[4,5-b]pyridinylene, imidazo[1,2-a]pyridinylene, 5 thiazolo[5,4-b]pyridinylene or thieno[2,3-d]imidazolylene groups,

10 the tautomers, the prodrugs, the double prodrugs, the stereoisomers and the salts thereof.

Particularly preferred compounds of general formula I above are those wherein

15 A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R_1 group,

20 B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an $-NR_1-$ group, wherein

25 R_1 denotes a hydrogen atom or a C_{1-4} -alkyl group,

E denotes an $R_bNH-C(=NH)-$ group wherein

30 R_b denotes a hydrogen atom, a hydroxy, C_{1-9} -alkoxycarbonyl, cyclohexyloxycarbonyl, phenyl- C_{1-3} -alkoxycarbonyl, benzoyl, p- C_{1-3} -alkyl-benzoyl or pyridinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned C_{1-9} -alkoxycarbonyl group may additionally be substituted by a C_{1-3} -alkyl- 35 sulfonyl or 2-(C_{1-3} -alkoxy)-ethyl group,

Ar denotes a 1,4-phenylene group optionally substituted by a chlorine atom or by a methyl, ethyl or methoxy group or it denotes a 2,5-thienylene group,

5 Het denotes a 1-(C₁₋₃-alkyl)-2,5-benzimidazolylene, 1-cyclopropyl-2,5-benzimidazolylene, 2,5-benzothiazolylene, 1-(C₁₋₃-alkyl)-2,5-indolylene, 1-(C₁₋₃-alkyl)-2,5-imidazo[4,5-b]pyridinylene, 3-(C₁₋₃-alkyl)-2,7-imidazo[1,2-a]pyridinylene or 1-(C₁₋₃-alkyl)-
10 2,5-thieno[2,3-d]imidazolylene group and

R_a denotes an R₂NR₃- group wherein

15 R₂ is a C₁₋₄-alkyl group substituted by a carboxy, C₁₋₆-alkyloxycarbonyl, benzyloxycarbonyl, C₁₋₃-alkylsulphonylaminocarbonyl or 1H-tetrazol-5-yl group,

20 a C₂₋₄-alkyl group substituted by a hydroxy, benzyloxy, carboxy-C₁₋₃-alkylamino, C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl)-carboxy-C₁₋₃-alkylamino or N-(C₁₋₃-alkyl)-C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino group, whilst in the abovementioned groups the carbon atom in the α -position to the adjacent nitrogen atom
25 may not be substituted,

30 R₃ denotes a C₃₋₇-cycloalkyl group, a propargyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R₂NR₃ group, a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, a pyrazolyl, pyridazolyl or pyridinyl group optionally substituted by a methyl group or

R₂ and R₃ together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or C₁₋₄-alkoxycarbonyl group, to which a phenyl ring may additionally be fused,

the tautomers, the stereoisomers and the salts thereof.

Most particularly preferred compounds of the above general formula I are those wherein

A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R₁ group,

B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an -NR₁- group, wherein

R₁ denotes a hydrogen atom or a methyl group,

E denotes an R_bNH-C(=NH)- group, wherein

R_b denotes a hydrogen atom or a hydroxy, C₁₋₉-alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p-C₁₋₃-alkyl-benzoyl or nicotinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned C₁₋₉-alkoxycarbonyl group may additionally be substituted by a C₁₋₃-alkylsulphonyl or 2-(C₁₋₃-alkoxy)-ethyl group,

Ar denotes a 1,4-phenylene group optionally substituted by a chlorine atom or by a methyl, ethyl or methoxy group, or it denotes a 2,5-thienylene group,

Het denotes a 1-methyl-2,5-benzimidazolylene, 1-cyclopropyl-2,5-benzimidazolylene, 2,5-benzothiazolylene, 1-methyl-2,5-indolylene, 1-methyl-2,5-imidazo[4,5-b]pyridinylene, 3-methyl-2,7-imidazo[1,2-a]pyridinylene or 1-methyl-2,5-thieno[2,3-d]imidazolylene group and

R_a denotes a R_2NR_3 - group wherein

10 R_2 denotes a C_{1-3} -alkyl group which may be substituted by a carboxy, C_{1-6} -alkyloxycarbonyl, benzyloxycarbonyl, methylsulphonylaminocarbonyl or 1H-tetrazol-5-yl group, a C_{2-3} -alkyl group substituted by a hydroxy, benzyloxy, 15 carboxy- C_{1-3} -alkylamino, C_{1-3} -alkoxycarbonyl- C_{1-3} -alkylamino, N-(C_{1-3} -alkyl)-carboxy- C_{1-3} -alkylamino or N-(C_{1-3} -alkyl)- C_{1-3} -alkoxycarbonyl- C_{1-3} -alkylamino group, whilst in the abovementioned groups the carbon atom in the α -position to the adjacent nitrogen atom 20 may not be substituted, and

R_3 denotes a propargyl group, wherein the unsaturated moiety may not be linked directly to the nitrogen atom of the R_2NR_3 group, a phenyl group optionally 25 substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, or denotes a pyridinyl group,

particularly those wherein

30 A denotes a carbonyl group linked to the benzo or thieno moiety of the group Het,

B denotes an ethylene group wherein the methylene group attached to the group Ar may be replaced by an $-NR_1$ group, 35 wherein

R_1 denotes a hydrogen atom or a methyl group,

E denotes an $R_b\text{NH}-\text{C}(=\text{NH})-$ group wherein

5

R_b is a hydrogen atom, a hydroxy, C_{1-9} -alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, $p\text{-C}_{1-3}$ -alkyl-benzoyl or nicotinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned C_{1-9} -alkoxycarbonyl group may additionally be substituted by a methylsulfonyl or 2-ethoxy-ethyl group,

10

Ar denotes a 1,4-phenylene group optionally substituted by a methoxy group, or denotes a 2,5-thienylene group,

15

Het denotes a 1-methyl-2,5-benzimidazolylenes, 2,5-benzothiazolylenes, 1-methyl-2,5-indolylenes or 1-methyl-2,5-thieno[2,3-d]imidazolylenes group and

20

R_a denotes an $R_2\text{NR}_3-$ group wherein

R_2 denotes a C_{1-3} -alkyl group which may be substituted by a carboxy, C_{1-6} -alkyloxycarbonyl, benzyloxycarbonyl, methylsulfonylaminocarbonyl or 1H-tetrazol-5-yl group,

25

a C_{2-3} -alkyl group substituted by a hydroxy, benzyloxy, carboxy- C_{1-3} -alkylamino, C_{1-3} -alkoxycarbonyl- C_{1-3} -alkylamino, N-(C_{1-3} -alkyl)-carboxy- C_{1-3} -alkylamino or N-(C_{1-3} -alkyl)- C_{1-3} -alkoxycarbonyl- C_{1-3} -alkylamino group, whilst in the abovementioned groups the carbon atom in the α -position to the adjacent nitrogen atom may not be substituted, and

30

R₃ denotes a phenyl group optionally substituted by a fluorine atom, or denotes a 2-pyridinyl group,

the tautomers, stereoisomers and the salts thereof.

5

The following are mentioned as examples of particularly preferred compounds:

10 (a) 2-[N-(4-amidinophenyl)-aminomethyl]-benzthiazole-5-carboxylic acid-N-phenyl-N-(2-carboxyethyl)-amide,

(b) 2-[N-(4-midinophenyl)-N-methyl-aminomethyl]-benzthiazol-5-yl-carboxylic acid-N-phenyl-N-(2-
15 hydroxycarbonylethyl)-amide,

(c) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
20 hydroxycarbonylethyl)-amide,

(d) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-hydroxycarbonylpropyl)-amide,

25 (e) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide,

(f) 1-Methyl-2-[2-(2-amidinothiophen-5-yl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
30 hydroxycarbonylethyl)-amide,

(g) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
35 hydroxycarbonylethyl)-amide,

(h) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide,

5 (i) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide,

(j) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide,

(k) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide,

(l) 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide,

(m) 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(3-pyridyl)-N-(2-hydroxycarbonylethyl)-amide,

(n) 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide,

(o) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[(N-hydroxycarbonylethyl-N-methyl)-2-aminoethyl]-amide,

(p) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(3-fluorophenyl)-N-(2-hydroxycarbonylethyl)-amide,

(q) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(4-fluorophenyl)-N-(2-hydroxycarbonylethyl)-amide,

5 (r) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide,

(s) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide,

(t) 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide
15 and

(u) 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide,


20

the tautomers, prodrugs, double prodrugs, stereoisomers and the salts thereof.

25 The new compounds may be prepared by methods known *per se*, for example by the following methods:

a. In order to prepare a compound of general formula I, wherein E denotes an $R_b\text{NH}-\text{C}(=\text{NH})-$ group, wherein R_b is a
30 hydrogen atom, a hydroxy or C_{1-3} -alkyl group:

By reacting a compound of general formula



35

optionally formed in the reaction mixture,

wherein

A, B, Ar, Het and R_a are as hereinbefore defined and
Z₁ denotes an alkoxy or aralkoxy group such as the methoxy,
ethoxy, n-propoxy, isopropoxy or benzyloxy group or an
5 alkylthio or aralkylthio group such as the methylthio,
ethylthio, n-propylthio or benzylthio group, with an amine
of general formula



10

wherein


R_b' denotes a hydrogen atom or a hydroxy or C₁₋₃-alkyl
group.

15 The reaction is conveniently carried out in a solvent such
as methanol, ethanol, n-propanol, water, methanol/water,
tetrahydrofuran or dioxane at temperatures between 0 and
150°C, preferably at temperatures between 20 and 120°C,
with a compound of general formula III or with a
20 corresponding acid addition salt such as ammonium
carbonate, for example.

A compound of general formula II may be obtained, for
example, by reacting a compound of general formula I
25 wherein E denotes a cyano group, with a corresponding
alcohol such as methanol, ethanol, n-propanol, isopropanol
or benzyl alcohol in the presence of an acid such as
hydrochloric acid or by reacting a corresponding amide with
a trialkyloxonium salt such as triethyloxonium-
30 tetrafluoroborate in a solvent such as methylene chloride,
tetrahydrofuran or dioxane at temperatures between 0 and
50°C, but preferably at 20°C, or a corresponding nitrile
with hydrogen sulphide, appropriately in a solvent such as
pyridine or dimethylformamide and in the presence of a base
35 such as triethylamine and subsequent alkylation of the
resulting thioamide with a corresponding alkyl or aralkyl
halide.

b. In order to prepare a compound of general formula I wherein the R_a -A- group and E are as hereinbefore defined, with the proviso that the R_a -A- group contains a carboxy group and E as hereinbefore defined or that the R_a -A- group is as hereinbefore defined and E denotes an $NH_2-C(=NH)-$ group, or that the R_a -A- group contains a carboxy group and E denotes an $NH_2-C(=NH)-$ group:

10 Converting a compound of general formula



wherein

A, B, Ar and Het are as hereinbefore defined and
15 the R_a' -A- group and E' have the meanings given for the R_a -A- group and E hereinbefore, with the proviso that the R_a' -A- group contains a group which may be converted into a carboxyl group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and E is as
20 hereinbefore defined or E' denotes a group which may be converted into an $NH_2-C(=NH)-$ group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and the R_a' -A- group has the meanings given for the R_a -A- group hereinbefore or the R_a' -A- group
25 contains a group which may be converted into a carboxyl group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis and E' denotes a group which may be converted into an $NH_2-C(=NH)-$ group by hydrolysis, treatment with an acid or base, thermolysis or
30 hydrogenolysis,

is converted by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis into a compound of general formula I, wherein the R_a -A- group and E are as
35 hereinbefore defined, with the proviso that the R_a -A- group contains a carboxy group and E is as hereinbefore defined or the R_a -A- group has the meanings given above and E

denotes an $\text{NH}_2\text{-C(=NH)}$ - group or the $\text{R}_a\text{-A-}$ group contains a carboxy group and E denotes an $\text{NH}_2\text{-C(=NH)}$ - group.

Examples of groups which may be converted into a carboxy group include a carboxyl group protected by a protecting group and the functional derivatives thereof, e.g. the unsubstituted or substituted amides, esters, thioesters, trimethylsilylesters, orthoesters or iminoesters which may conveniently be converted into a carboxyl group by hydrolysis,

the esters thereof with tertiary alcohols, e.g. the tert.butylester, which are conveniently converted into a carboxyl group by treatment with an acid or by thermolysis, and

the esters thereof with aralkanols, e.g. the benzylester, which are conveniently converted into a carboxyl group by hydrogenolysis.

The hydrolysis is expediently carried out either in the presence of an acid such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or mixtures thereof or in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water/methanol, water/ethanol, water/isopropanol, methanol, ethanol, water/tetrahydrofuran or water/dioxane at temperatures between -10 and 120°C , e.g. at temperatures between room temperature and the boiling temperature of the reaction mixture.

If the $\text{R}_a'\text{-A-}$ group and/or E' in a compound of formula IV contains the tert.-butyl or tert.-butyloxycarbonyl group, for example, these may also be cleaved by treating with an acid such as trifluoroacetic acid, formic acid, p-toluenesulphonic acid, sulphuric acid, hydrochloric acid,

phosphoric acid or polyphosphoric acid, optionally in an inert solvent such as methylene chloride, chloroform, benzene, toluene, diethylether, tetrahydrofuran or dioxane, preferably at temperatures between -10 and 120°C, e.g. at
5 temperatures between 0 and 60°C, or thermally optionally in an inert solvent such as methylene chloride, chloroform, benzene, toluene, tetrahydrofuran or dioxane and preferably in the presence of a catalytic quantity of an acid such as p-toluenesulphonic acid, sulphuric acid, phosphoric acid or
10 polyphosphoric acid, preferably at the boiling temperature of the solvent used, e.g. at temperatures between 40 and 120°C.

If the R_a' -A- group and/or E' in a compound of formula IV
15 contains the benzyloxy or benzyloxycarbonyl group, for example, these may also be cleaved by hydrogenolysis in the presence of a hydrogenation catalyst such as palladium/charcoal in a suitable solvent such as methanol, ethanol, ethanol/water, glacial acetic acid, ethyl acetate,
20 dioxane or dimethylformamide, preferably at temperatures between 0 and 50°C, e.g. at room temperature, under a hydrogen pressure of 1 to 5 bar.

c. In order to prepare a compound of general formula I
25 wherein the R_a -A- group contains one of the ester groups mentioned in the definition of the R_a -A- group hereinbefore:

Reaction of a compound of general formula
30



wherein
B, E, Ar and Het are as hereinbefore defined and
35 the R_a'' -A- group has the meanings given for the R_a -A- group hereinbefore, with the proviso that the R_a'' -A- group

$$5 \quad \text{HO} - \text{R}_7 \quad , \text{ (VI)}$$

wherein
R₇ is the alkyl moiety of one of the above-mentioned groups
which may be cleaved *in vivo*, with the exception of the
R₆-CO-O-(R₅CR₆)- group for a carboxyl group, or with the
formamide acetals thereof.

$$Z_2 = R_8, \quad (\text{VII})$$

wherein
R₈ denotes the alkyl moiety of one of the above-mentioned groups which may be cleaved *in vivo*, with the exception of the R₆-CO-O-(R₅CR₆)- group for a carboxyl group and
20 Z₂ denotes a leaving group such as a halogen atom, e.g. a chlorine or bromine atom.

Attorney Docket No. 5/1213


in the presence of a base such as potassium carbonate, N-ethyl-diisopropylamine or N,N-dimethylamino-pyridine, conveniently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 80°C.

5

With a compound of general formula VII the reaction is usefully carried out in a solvent such as methylene chloride, tetrahydrofuran, dioxane, dimethylsulphoxide, dimethylformamide or acetone, optionally in the presence of a reaction accelerator such as sodium or potassium iodide and preferably in the presence of a base such as sodium carbonate or potassium carbonate or in the presence of a tertiary organic base such as N-ethyl-diisopropylamine or N-methyl-morpholine, which may act as solvent at the same time, or optionally in the presence of silver carbonate or silver oxide at temperatures between -30 and 100°C, but preferably at temperatures between -10 and 80°C.

d. In order to prepare a compound of general formula I wherein R_b denotes a group which may be cleaved *in vivo*:

Reacting a compound of general formula



25

wherein

R_a , A, Het, B and Ar are as hereinbefore defined, with a compound of general formula

30



wherein

R_5 denotes a group which may be cleaved *in vivo* and


Z_2 denotes a nucleofugic leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom.

The reaction is preferably carried out in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, toluene, dioxane, dimethylsulphoxide or dimethylformamide, optionally in the presence of an inorganic or tertiary organic base, preferably at temperatures between 20°C and the boiling temperature of the solvent used.

With a compound of general formula IX, wherein Z₂ denotes a nucleofugic leaving group, the reaction is preferably carried out in a solvent such as methylene chloride, acetonitrile, tetrahydrofuran, toluene, dimethylformamide or dimethylsulphoxide, optionally in the presence of a base such as sodium hydride, potassium carbonate, potassium tert.-butoxide or N-ethyl-diisopropylamine at temperatures between 0 and 60°C.

e. In order to prepare a compound of general formula I wherein B denotes an ethylene group, in which a methylene group is replaced by a sulphinyl or sulphonyl group:

Oxidation of a compound of general formula



wherein

A, E, Ar, Het and R_a are as hereinbefore defined and B' denotes an ethylene group, wherein a methylene group is replaced by a sulphenyl or sulphinyl group.

The oxidation is preferably carried out in a solvent or mixture of solvents, e.g. in water, water/pyridine, acetone, methylene chloride, glacial acetic acid, glacial acetic acid/acetic anhydride, dilute sulphuric acid or trifluoroacetic acid, and depending on the oxidising agent used, at temperatures between -80 and 100°C.


In order to prepare a corresponding sulphonyl compound of general formula I oxidation is conveniently carried out with one equivalent of the oxidising agent used, e.g. with
5 hydrogen peroxide in glacial acetic acid, trifluoroacetic acid or formic acid at 0 to 20°C or in acetone at 0 to 60°C, with a peracid such as performic acid in glacial acetic acid or trifluoroacetic acid at 0 to 50°C or with m-chloroperbenzoic acid in methylene chloride, chloroform or
10 dioxane at -20 to 80°C, with sodium metaperiodate in aqueous methanol or ethanol at -15 to 25°C, with bromine in glacial acetic acid or aqueous acetic acid, optionally in the presence of a weak base such as sodium acetate, with N-bromosuccinimide in ethanol, with tert.-butylhypochlorite
15 in methanol at -80 to -30°C, with iodobenzodichloride in aqueous pyridine at 0 to 50°C, with nitric acid in glacial acetic acid at 0 to 20°C, with chromic acid in glacial acetic acid or in acetone at 0 to 20°C and with sulphuryl chloride in methylene chloride at -70°C, the resulting
20 thioether chlorine complex is conveniently hydrolysed with aqueous ethanol.

In order to prepare a sulphonyl compound of general formula I, oxidation is carried out starting from a corresponding
25 sulphonyl compound, conveniently with one or more equivalents of the oxidising agent used, or starting from a corresponding sulphenyl compound, conveniently with two or more equivalents of the oxidising agent used, e.g. with hydrogen peroxide in glacial acetic acid/acetic anhydride,
30 trifluoroacetic acid or in formic acid at 20 to 100°C or in acetone at 0 to 60°C, with a peracid such as performic acid or with m-chloroperbenzoic acid in glacial acetic acid, trifluoroacetic acid, methylene chloride or chloroform at temperatures between 0 and 60°C, with nitric acid in
35 glacial acetic acid at 0 to 20°C, with chromic acid or

potassium permanganate in glacial acetic acid,
water/sulphuric acid or in acetone at 0 to 20°C. Thus, by
carrying out oxidation, for example, starting from a
corresponding sulphenyl compound, preferably in methylene
5 chloride, by treating with a corresponding amount of m-
chloroperbenzoic acid at temperatures between 20°C and the
reflux temperature of the reaction mixture, a corresponding
sulphonyl compound of general formula I is obtained which
may still contain a small amount of the corresponding
10 sulphinyl compound.

f. In order to prepare a compound of general formula I
wherein E is a cyano group and B is an ethylene group in
which a methylene group linked either to group Het or to Ar
15 is replaced by an oxygen or sulphur atom or by a sulphinyl,
sulphonyl, carbonyl or -NR₁- group:

Reacting a compound of general formula



with a compound of general formula



wherein


R_a, A, Ar and Het are as hereinbefore defined,
one of the groups U or V denotes an HO-, HS-, HOSO-, HOSO₂-
or HNR₁- group and the other group denotes a Z₃CH₂- group,
30 wherein R₁ is as hereinbefore defined and Z₃ denotes a
nucleofugic leaving group such as a halogen atom, e.g. a
chlorine, bromine or iodine atom.

The reaction is preferably carried out in a solvent such as
35 methanol, ethanol, methylene chloride, tetrahydrofuran,
toluene, dioxane, dimethylsulphoxide or dimethylformamide,
optionally in the presence of an inorganic or a tertiary

organic base, preferably at temperatures between 20°C and the boiling temperature of the solvent used.

g. In order to prepare a compound of general formula I,
5 wherein E is a cyano group and R_a denotes an R₂NR₃- group:


Reacting a compound of general formula



10

wherein

A, B, Het and Ar are as hereinbefore defined, with an amine of general formula



15

wherein

R₂ and R₃ are as hereinbefore defined, or with the reactive derivatives thereof.


20 The reaction of an acid of general formula XIII is optionally carried out in a solvent or mixture of solvents such as methylene chloride, dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane or in a corresponding
25 amine of general formula III, optionally in the presence of a dehydrating agent, e.g. in the presence of isobutylchloroformate, tetraethylorthocarbonate, trimethylorthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride,
30 phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1-hydroxy-benzotriazole, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-

benzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride and optionally with the addition of a base such as pyridine, 4-dimethylamino-pyridine, N-methyl-morpholine or triethylamine, conveniently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 100°C.

The reaction of a corresponding reactive compound of general formula XIII such as the esters, imidazolides or halides thereof with an amine of general formula XIV is preferably carried out in a corresponding amine as solvent, optionally in the presence of another solvent such as methylene chloride or ether and preferably in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine at temperatures between 0 and 150°C, preferably at temperatures between 50 and 100°C.


h. In order to prepare a benzimidazolyl, benzothiazolyl or benzoxazolyl compound of general formula I wherein B denotes an ethylene group:

Reacting a compound of general formula



wherein

R_a , A and Y are as hereinbefore defined, with a compound of general formula




wherein

Ar and E are as hereinbefore defined, or with the reactive derivatives thereof.

The reaction of a corresponding reactive compound of general formula XVI such as the esters, imidazolides or halides thereof with an amine of general formula XV is preferably carried out in a solvent such as methylene chloride, ether or tetrahydrofuran and preferably in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine, which may simultaneously be used as solvents, at temperatures between 0 and 150°C, preferably at temperatures between 50 and 100°C.


Attorney Docket No. 5/1213

Reacting a compound of general formula



wherein

- 5 R_a , R_1 and A are as hereinbefore defined, with a compound of general formula



wherein

- 10 Ar and E are as hereinbefore defined, or with the reactive derivatives thereof.

- The reaction is conveniently carried out in a solvent or mixture of solvents such as methylene chloride,
- 15 dimethylformamide, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran, ethanol or dioxan, optionally in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate,
- 20 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1-hydroxy-benzotriazole,
- 25 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally
- 30 with the addition of a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine, appropriately at temperatures of between 0 and 150°C, preferably at temperatures of between 0 and 100°C.

However, it is particularly preferred to carry out the reaction with a corresponding reactive compound of general formula XVIII such as the esters, imidazolides or halides thereof with an amine of general formula XVII in a solvent such as methylene chloride, ether, ethanol or tetrahydrofuran and optionally in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine, which may simultaneously serve as solvent, at temperatures of between 0 and 150°C, preferably at temperatures of between 50 and 100°C.

j. In order to prepare a compound of general formula I wherein R₂ denotes a C₁₋₄-alkyl group substituted by an alkylsulphonylaminocarbonyl group:

Reacting a compound of general formula




20

wherein

R₃, A, B, E, and Het are as hereinbefore defined and R₂' denotes a C₁₋₄-alkyl group substituted by a carboxy group, or the reactive derivatives thereof, with a salt of a compound of general formula

25



The reaction is preferably carried out with a corresponding reactive compound of general formula IXX such as the esters, imidazolides or halides thereof with a salt of a compound of general formula XX, preferably with an alkali metal salt thereof such as a sodium salt, in a solvent such as methylene chloride, ether, ethanol, tetrahydrofuran or

dimethylformamide at temperatures between 0 and 150°C, preferably at temperatures of between 50 and 100°C.

In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy, amino, alkylamino or imino groups may be protected during the reaction by means of conventional protecting groups which are removed by cleaving after the reaction.

For example, the protecting group for a hydroxy group may be the trimethylsilyl, acetyl, benzoyl, tert.butyl, trityl, benzyl or tetrahydropyranyl group,

the protecting group for a carboxyl group may be the trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group, and

the protecting group for an amino, alkylamino or imino group may be the acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.-butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and for the amino group the phthalyl group may also be considered.

The optional subsequent cleaving of a protecting group may, for example, be carried out hydrolytically in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or by ether cleaving, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 100°C, preferably at temperatures between 10 and 50°C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group may for example be cleaved hydrogenolytically, e.g. using hydrogen in the presence of a catalyst such as

A methoxybenzyl group may also be cleaved in the presence of an oxidising agent such as cerium(IV) ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile/water at temperatures between 0 and 50°C, but preferably at room temperature.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treatment with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxane, or ether.

A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, 25 ethanol, isopropanol, toluene/water or dioxane, at temperatures between 20 and 50°C.

An allyloxycarbonyl group is cleaved by treating with a catalytic amount of tetrakis-(triphenylphosphine)-
30 palladium(0), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of a base such as morpholine or 1,3-dimmedone, at temperatures between 0 and 100°C, preferably at room temperature and under inert gas, or by treating with a
35 catalytic amount of tris-(triphenylphosphine)-rhodium(I)-chloride, in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1,4-

diazabicyclo[2.2.2]octane, at temperatures between 20 and 70°C.

5 The compounds of general formulae II to XX used as starting materials, some of which are known from the literature, may be obtained by methods known from the literature and moreover their production is described in the Examples.

10 Thus, for example, a compound of general formula II is obtained by reacting a corresponding nitrile which in turn is conveniently obtained by processes f to h, with a corresponding thio or alcohol in the presence of hydrogen chloride or bromide.

15 A compound of general formulae IV, V, VIII, X and IXX used as starting material is conveniently obtained according to a process of the present invention.

20 A starting compound of general formula XI in which U denotes a halomethyl group is conveniently obtained by cyclisation of a corresponding ester which is substituted in the o-position by a suitable halogen atom and a methoxyacetamido group, to form a corresponding bicyclic 2-alkoxymethyl compound, optionally subsequent hydrolysis and
25 optionally subsequent amidation of a resulting carboxylic acid with a corresponding amine, converting the alkoxymethyl compound thus obtained into the corresponding halomethyl compound, which can if necessary be subsequently converted into the desired compound by means of a suitable
30 compound. If the cyclisation is carried out with a suitable carbonic acid derivative, a starting compound of general formula XI is obtained wherein U denotes a hydroxy, mercapto or amino group.

35 A starting compound of general formula XIII is obtained by cyclisation of a corresponding o-disubstituted ester, followed by saponification of the resulting ester and

subsequent amidation of the carboxylic acid thus obtained with a corresponding amine.

Furthermore, an imidazopyridine substituted in the 5-
5 position by a methyl group and obtained by cyclisation can be converted, via the corresponding N-oxide, into the corresponding hydroxymethyl compound which is converted by oxidation into the desired carboxylic acid of general formula XIII.

10

The compounds of general formulae III, VI, VII, IX and XII used as starting materials are obtained by conventional methods, for example by reducing an aromatic ester substituted in the o-position by an optionally substituted
15 amino group and a nitro group, and optionally subsequent cyclisation of the resulting o-diamino compound with a corresponding carboxylic acid.

Furthermore, the compounds of general formula I obtained
20 may be separated into their enantiomers and/or diastereomers.

Thus, for example, the compounds of general formula I obtained which occur in racemate form may be separated by
25 methods known *per se* (see Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes, and compounds of general formula I having at least 2 asymmetric carbon atoms may be separated on the basis of their physical-chemical
30 differences using known methods, e.g. by chromatography and/or fractional crystallisation, into the diastereomers thereof, which, if they occur in racemic form, may subsequently be separated into the enantiomers as mentioned above.

35

The separation of enantiomers is preferably effected by column separation on chiral phases or by recrystallisation

from an optically active solvent or by reacting with an optically active substance, especially acids and the activated derivatives thereof or alcohols, which forms salts or derivatives such as e.g. esters or amides with the racemic compound, and separation of the diastereomeric salt mixture or derivative thus obtained, e.g. on the basis of their different solubilities, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Particularly common, optically active acids are, for example, the D- and L-forms of tartaric acid, and dibenzoyltartaric acid, di-o-tolyl tartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid and quinaldic acid. Examples of optically active alcohols include for example (+)- or (-)-menthol and examples of optically active acyl groups in amides include, for example, (+)- or (-)-menthyloxycarbonyl.

Moreover, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts thereof with inorganic or organic acids. Examples of suitable acids include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

In addition, the new compounds of formula I thus obtained, if they contain a carboxyl group, may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, more particularly, for pharmaceutical use, into the physiologically acceptable salts thereof. Examples of suitable bases include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

As already mentioned, the new compounds of general formula I and the salts thereof have valuable properties. Thus, the compounds of general formula I wherein E denotes a cyano group are valuable intermediate products for
5 preparing the other compounds of general formula I and the compounds of general formula I wherein E denotes an $R_bNH-C(=NH)-$ group and the tautomers, the stereoisomers and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly a thrombin-
10 inhibiting effect, an effect of prolonging the thrombin time and an inhibitory effect on related serine proteases such as e.g. trypsin, urokinase factor VIIa, factor Xa, factor IX, factor XI and factor XII, whilst a few compounds such as for example the compound of Example 16
15 simultaneously also have a slight inhibitory effect on thrombocyte aggregation.

For example, the following compounds:

- 20 A = 2-[N-(4-amidinophenyl)-aminomethyl]-benzthiazole-5-carboxylic acid-N-phenyl-N-(2-carboxyethyl)-amide,
- B = 1-methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-hydroxycarbonyl-
25 propyl)-amide,
- C = 1-methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid -N-phenyl-N-(hydroxycarbonylmethyl)-amide,
30
- D = 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide,
- 35 E = 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide,

F = 1-methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide and

5

G = 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide

10 were investigated as follows for their effects on thrombin time:

Materials: plasma, from human citrated blood.
Test thrombin (bovine), 30U/ml, Behring Werke,
15 Marburg
Diethylbarbiturate acetate buffer, ORWH 60/61, Behring Werke, Marburg
Biomatic B10 coagulometer, Sarstedt

20 Method:

The thrombin time was determined using a Biomatic B10 coagulometer made by Messrs. Sarstedt.

25 As the test substance, 0.1 ml of human citrated plasma and 0.1 ml diethylbarbiturate buffer (DBA buffer) were added to the test strip prescribed by the manufacturer. The mixture was incubated for one minute at 37°C. The clotting reaction was started by the addition of 0.3 U test thrombin
30 in 0.1 ml DBA buffer. The time is measured using the apparatus from the addition of the thrombin up to the clotting of the mixture. Mixtures to which 0.1 ml of DBA buffer were added were used as the controls.

35 According to the definition, a dosage-activity curve was used to determine the effective concentration of the

substance, i.e. the concentration at which the thrombin time is double compared with the control.

The Table which follows contains the results found:

5

Substance	Thrombin time (ED ₂₀₀ in μ M)
A	0.04
B	0.06
C	0.15
D	0.03
E	0.09
F	0.03
G	0.03

By way of example, no acute toxic side effects were observed when compounds A, D, E and G were administered to rats in doses of up to 10 mg/kg i.v. The compounds are thus well tolerated.

In view of their pharmacological properties the new compounds and the physiologically acceptable salts thereof are suitable for the prevention and treatment of venous and arterial thrombotic diseases, such as for example the treatment of deep leg vein thrombosis, for preventing reocclusions after bypass operations or angioplasty (PT(C)A), and occlusion in peripheral arterial diseases such as pulmonary embolism, disseminated intravascular coagulation, for preventing coronary thrombosis, stroke and the occlusion of shunts or stents. In addition, the compounds according to the invention are suitable for antithrombotic support in thrombolytic treatment, such as for example with rt-PA or streptokinase, for preventing long-term restenosis after PT(C)A, for preventing metastasis and the growth of clot-dependent tumours and fibrin-dependent inflammatory processes.

5 The dosage required to achieve such an effect is
appropriately 0.1 to 30 mg/kg, preferably 0.3 to 10 mg/kg
by intravenous route, and 0.1 to 50 mg/kg, preferably 0.3
to 30 mg/kg by oral route, in each case administered 1 to 4
times a day. For this purpose, the compounds of formula I
prepared according to the invention may be formulated,
optionally together with other active substances, with one
or more inert conventional carriers and/or diluents, e.g.
with corn starch, lactose, glucose, microcrystalline
10 cellulose, magnesium stearate, polyvinylpyrrolidone, citric
acid, tartaric acid, water, water/ethanol, water/glycerol,
water/sorbitol, water/polyethyleneglycol, propyleneglycol,
cetylstearyl alcohol, carboxymethylcellulose or fatty
substances such as hard fat or suitable mixtures thereof,
15 to produce conventional galenic preparations such as plain
or coated tablets, capsules, powders, suspensions or
suppositories.

20 The Examples which follow are intended to illustrate the
invention:

Preliminary remarks

Unless otherwise specified, the R_f values were always determined using polygram silica gel plates produced by
5 Messrs. E. Merck of Darmstadt.

The EKA mass spectra (electrospray mass spectra of cations) are described, for example, in "Chemie unserer Zeit 6, 308-316 (1991).

10

Example 1

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]-pyridine-6-carboxylic acid -N-phenyl-N-(2-ethoxycarbonyl-ethyl)-amide
15

a) Methyl 6-methylamino-5-nitro-nicotinate

1.6 g (7.4 mMol) of methyl 6-chloro-5-nitro-nicotinate (see Bernie et al. in J. Chem. Soc. 1951, 2590) were stirred in
20 20 ml of 40% aqueous methylamine solution at room temperature for 30 minutes. The reaction mixture was then diluted with ice water, the yellow precipitate formed was filtered off and dried.

Yield: 1.2 g (80 % of theory),

25 R_f value: 0.66 (silica gel; ethyl acetate/ethanol/glacial acetic acid = 90:5:5)

b) Methyl 5-amino-6-methylamino-nicotinate

To a solution of 3.1 g (15 mMol) of methyl 6-methylamino-5-nitro-nicotinate in 100 ml of ethanol/dichloromethane
30 (3:1) was added 1 g of palladium on charcoal (10%) and the resulting suspension was hydrogenated at room temperature under 5 bar of hydrogen pressure for 1.5 hours. The catalyst was then filtered off and the solvent was
35 distilled off *in vacuo*. The crude oily product obtained was further reacted directly.

Yield: 2.4 g (92 % of theory),

R_f value: 0.44 (silica gel; ethyl acetate/ethanol/ammonia = 90:10:1)

c) Methyl 5-[2-(4-cyanophenyl)ethylcarbonylamino]-6-methylamino-nicotinate

A solution of 2.6 g (15 mMol) of 3-(4-cyanophenyl)propionic acid in 25 ml of absolute tetrahydrofuran was mixed with 2.4 g (15 mMol) of N,N'-carbonyldiimidazole and stirred for 20 minutes at room temperature. Then the imidazolide was mixed with a solution of 2.3 g (13 mMol) of methyl 5-amino-6-methylamino-nicotinate in 25 ml of dimethylformamide and heated for 3 hours to 100°C. After the removal of the solvent *in vacuo* the crude product obtained was taken up in ethyl acetate, the organic phase was washed with water and after drying over sodium sulphate it was again freed from solvent. The residue obtained was purified by flash chromatography (silica gel; gradient: dichloromethane to dichloromethane/ethanol = 19:1).
Yield: 2.1 g (50 % of theory) of beige solid
R_f value: 0.54 (silica gel; ethyl acetate/ethanol/ammonia = 90:10:1)

d) Methyl 3-methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylate

A solution of 2.0 g (5.9 mMol) of methyl 5-[2-(4-cyanophenyl)ethylcarbonylamino]-6-methylamino-nicotinate in 50 ml glacial acetic acid was heated to 100°C for one hour. After removal of the solvent the residue was taken up in dichloromethane, washed with sodium hydrogen carbonate solution, dried with sodium sulphate and the solvent was distilled off again.
Yield: 1.7 g brown solid (89 % of theory),
R_f value: 0.50 (silica gel; ethyl acetate/ethanol/ammonia = 90:10:1)

e) 3-Methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid

A solution of 3.2 g (10 mMol) of methyl 3-methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylate in
5 150 ml methanol was mixed with a solution of 1.5 g lithium hydroxide in 20 ml water and stirred for 24 hours at room temperature. Then the mixture was diluted with 50 ml of water, the alcohol was distilled off and the aqueous phase was washed with ethyl acetate. After acidification with
10 dilute hydrochloric acid the mixture was extracted several times with dichloromethane/methanol (9:1), the organic phase was dried with sodium sulphate and the solvent was distilled off.

Yield: 2.1 g beige solid (70 % of theory),

15 R_f value: 0.38 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5)

f) 3-Methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2-ethoxycarbonyl-ethyl)-amide

A solution of 2.0 g (6.5 mMol) of 3-methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid in 100 ml dichloromethane was mixed with 20 ml thionyl chloride and refluxed for 2 hours. After the liquid
25 components had been distilled off the crude product was taken up twice more in dichloromethane and the solvent was distilled off each time. The crude acid chloride thus obtained (2 g) was suspended in 100 ml of tetrahydrofuran and mixed with 1.2 g (6.5 mMol) of N-(2-ethoxycarbonyl-ethyl)aniline. Then within 5 minutes 0.73 g (7.2 mMol) of
30 triethylamine were added dropwise. After 1 hour's stirring the solvent was distilled off *in vacuo*, the residue was taken up in ethyl acetate, the organic phase was washed with water and dried with sodium sulphate. After
35 distillation of the solvent and flash chromatography (silica gel; dichloromethane to dichloromethane/ethanol = 49:1) the desired compound was isolated as a brownish oil.

Yield: 1.9 g (65 % of theory),

R_f value: 0.44 (silica gel; ethyl acetate/ethanol/ammonia = 90:10:1)

5 g) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]-pyridine-6-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

1.8 g (3.7 mMol) of 3-methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide were stirred into 100 l of ethanol saturated with hydrogen chloride for 16 hours first at 0°C and then at room temperature until no more starting material could be detected by thin layer chromatography. Then the solvent was distilled off, the oily residue was taken up in 50 ml of absolute ethanol and mixed with 3.6 g (37 mMol) of ammonium carbonate. After 4 hours the solvent was distilled off *in vacuo*, the crude product obtained was purified by flash chromatography (silica gel; gradient: dichloromethane/ethanol 19:1 to 4:1) and evaporated down again.

Yield: 1.6 g of beige solid (80 % of theory),

R_f value: 0.30 (silica gel; ethyl acetate/ethanol/ammonia = 90:5:5)

25 Example 2

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]-pyridine-6-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide

30 A solution of 535 mg (1.0 mMol) of 3-methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]pyridine-6-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide in 10 ml ethanol was mixed with 5 ml of 2N sodium hydroxide solution and stirred for 2 hours at room temperature. Then the mixture was diluted with 10 ml water, the alcohol was distilled off, the aqueous phase was washed with 20 ml

ethyl acetate and acidified with concentrated hydrochloric acid, whereupon the desired compound was precipitated in the form of white crystals.

Yield: 375 mg (74 % of theory),

5 R_f value: 0.23 (silica gel; ethyl acetate/ethanol/ammonia = 90:5:5)

$C_{26}H_{26}N_6O_3$ (470.54)

Mass spectrum: $(M+H)^+ = 471$

10 Example 3

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonyl-ethyl)-amide-hydrochloride

15

Prepared analogously to Example 1 from 3-methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonyl-ethyl)-amide, methanolic hydrochloric acid, methanol and ammonium carbonate.

20

Yield: 75 % of theory,

$C_{26}H_{27}N_7O_3$ (485.55)

R_f value: 0.31 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5)

25 EKA mass spectrum: $(M+H)^+ = 486$

Example 4

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-ethoxycarbonylmethyl-amide-hydrochloride

30

Prepared analogously to Example 1 from 3-methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-ethoxycarbonylmethyl-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.

35

Yield: 84 % of theory,

$C_{27}H_{28}N_6O_3$ (484.56)

R_f value: 0.44 (silica gel; ethyl acetate/ethanol/ammonia
= 50:45:5)

5 EKA mass spectrum: $(M+H)^+ = 485$

Example 5

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[4,5-
10 b]pyridin-6-yl-carboxylic acid-N-phenyl-N-
hydroxycarbonylmethyl-amide-hydrochloride

Prepared analogously to Example 2 from 3-methyl-2-[2-(4-
amidinophenyl)ethyl]-imidazo[4,5-b]pyridin-6-yl-carboxylic
15 acid-N-phenyl-N-ethoxycarbonylmethyl-amide-hydrochloride
and sodium hydroxide solution.

Yield: 85 % of theory,

$C_{25}H_{24}N_6O_3$ (456.51)

R_f value: 0.19 (silica gel; ethyl acetate/ethanol/ammonia
20 = 50:45:5)

EKA mass spectrum: $(M+H)^+ = 457$

Example 6

25 2-[2-(4-amidinophenyl)ethyl]-3-methyl-6-(2-methoxycarbonyl-
2,3-dihydroindol-1-yl-carbonyl)-imidazo[4,5-b]pyridine-
hydrochloride

Prepared analogously to Example 1 from 2-[2-(4-
30 cyanophenyl)ethyl]-3-methyl-6-(2-methoxycarbonyl-
2,3-dihydroindol-1-yl-carbonyl)-imidazo[4,5-b]pyridine,
methanolic hydrochloric acid, methanol and ammonium
carbonate.

Yield: 20 % of theory,

35 $C_{27}H_{26}N_6O_3$ (482.54)

R_f value: 0.30 (silica gel; ethyl acetate/ethanol/ammonia

= 50:45:5)

EKA mass spectrum: $(M+H)^+ = 483$

Example 7

5

2-[2-(4-amidinophenyl)ethyl]-3-methyl-6-(2-carboxy-
2,3-dihydroindol-1-yl-carbonyl)-imidazo[4,5-b]pyridine-
hydrochloride

10 Prepared analogously to Example 2 from 2-[2-(4-
amidinophenyl)ethyl]-3-methyl-6-(2-methoxycarbonyl-
2,3-dihydroindol-1-yl-carbonyl)-imidazo[4,5-b]pyridine-
hydrochloride and sodium hydroxide solution.

Yield: 90 % of theory,

15 $C_{26}H_{24}N_6O_3$ (468.52)

R_f value: 0.24 (silica gel; ethyl acetate/ethanol/ammonia
= 50:45:5)

EKA mass spectrum: $(M+H)^+ = 469$

$(M+Na)^+ = 491$

20

Example 8

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-
imidazo[4,5-b]pyridin-5-yl-carboxylic acid-N-(2-pyridyl)-N-
25 (2-ethoxycarbonyl-ethyl)-amide

a) 2-Amino-3-methylamino-6-methyl-pyridine

8.35 g (50 mMol) of 2-Methyl-5-methylamino-6-nitro-pyridine
(Heterocycles 38, 529 (1994)) were dissolved in 300 l ethyl
30 acetate and hydrogenated with 1.5 g Raney nickel for 3.5
hours at room temperature. Then the catalyst was filtered
off and the filtrate was evaporated down. After
crystallisation of the resulting residue from petroleum
ether, 5.75 g (84 % of theory) were obtained as olive-green
35 crystals.

$C_7H_{11}N_3$ (137.20)

Melting point: 112-113°C

b) 1,5-Dimethyl-2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]-pyridine

5 11.4 g (63 mMol) of 4-cyano-phenoxyacetic acid were dissolved in 200 ml of absolute tetrahydrofuran and mixed at room temperature with 10.2 g (63 mMol) of N,N'-carbonyldiimidazole. After 15 minutes at 60°C, 5.70 g (41.5 mMol) of 2-amino-3-methylamino-6-methyl-pyridine were
10 added. After 2 hours at 60°C the solvent was distilled off and the crystalline residue was mixed with water, washed with water and dried. After crystallisation from ethanol 9.95 g (91 % of theory) were obtained in the form of white crystals.

15 $C_{16}H_{14}N_4O$ (278.32)

Mass spectrum: $M^+ = 278$

c) 1,5-Dimethyl-2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]pyridin-4-N-oxide

20 2.62 g (10 mMol) of 1,5-dimethyl-2-[(4-cyanophenyl)-oxymethyl]-imidazo[4,5-b]pyridine were suspended in 125 ml dichloromethane and mixed with 2.62 g (12.7 mMol) of m-chloroperbenzoic acid, whereupon a clear solution was obtained. After 2 hours at room temperature the solvent
25 was distilled off and the residue obtained was mixed with a sodium hydrogen carbonate solution. After 30 minutes the white crystalline product obtained was suction filtered, washed with water and dried at 40°C.

Yield: 2.45 g (83 % of theory),

30 $C_{16}H_{14}N_4O_2$ (294.30)

Mass spectrum: $M^+ = 294$

d) 1-Methyl-2-[(4-cyanophenyl)oxymethyl]-5-hydroxymethyl-imidazo[4,5-b]pyridine

35 2.40 g (8.2 mMol) of 1,5-dimethyl-2-[(4-cyanophenyl)-oxymethyl]-imidazo[4,5-b]pyridin-4-N-oxide were suspended in 75 ml dichloromethane and mixed with 2.4 ml of

trifluoroacetic acid anhydride (16.9 mMol), whereupon a clear solution was obtained. After 16 hours at room temperature the solvent was distilled off, the viscous residue obtained was taken up in 50 ml dichloromethane and covered with 50 ml of 2M sodium hydrogen carbonate solution. After 3 hours' vigorous stirring the precipitate formed was suction filtered, washed with water and dried at 40°C.

Yield: 1.85 g white powder (78 % of theory),

10 $C_{16}H_{14}N_4O_2$ (294.30)

Melting point: 172°C

e) 1-Methyl-2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]-pyridine-5-carbaldehyde

15 3.65 g (12.5 mMol) of 1-methyl-2-[(4-cyanophenyl)-oxymethyl]-5-hydroxymethyl-imidazo[4,5-b]pyridine were dissolved in 500 ml dichloromethane and mixed with 15.0 g of manganese dioxide. After 96 hours at room temperature the mixture was filtered through kieselgur and the solvent
20 was distilled off. The filtrate obtained was evaporated down, the crystalline precipitate was triturated with ether, suction filtered and dried.

Yield: 3.05 g white powder (84 % of theory),

$C_{16}H_{12}N_4O_2$ (292.30)

25 Melting point: 231-234°C

f) 1-Methyl-2-[(4-cyanophenyl)oxymethyl]-5-carboxy-imidazo-[4,5-b]pyridine

1.25 g (4.3 mMol) of 1-methyl-2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]pyridine-5-carbaldehyde were dissolved in 10
30 ml formic acid and mixed at 0°C with 1.0 ml hydrogen peroxide (33% strength). After 12 hours at 4°C the white precipitate formed was suction filtered, washed with water and dried at 40°C.

35 Yield: 0.81 g (61 % of theory),

$C_{16}H_{12}N_4O_3$ (308.7)

g) 1-Methyl-2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]pyridin-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide

308 mg (1.0 mMol) of 1-methyl-2-[(4-cyanophenyl)oxymethyl]-
5 5-carboxy-imidazo[4,5-b]pyridine were suspended in 5 ml of
dimethylformamide and mixed with 303 mg (3.0 mMol) of
N-methyl-morpholine and 321 mg (1.0 mMol) of
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium
tetrafluoroborate. After 10 minutes at room temperature a
10 solution of 215 mg (1.2 mMol) of methyl N-(2-pyridyl)-
3-amino-propionate in 2 ml of dimethylformamide was added,
whereupon a clear solution was obtained. After 12 hours at
room temperature the reaction solution was stirred into
ice-water. After extracting 3 times with ethyl acetate the
15 combined organic extracts were washed with a saline
solution, dried over sodium sulphate and evaporated down.
The residue obtained was chromatographed on silica gel with
dichloromethane/ethanol (90:1 to 25:1).
Yield: 165 mg of white powder (35 % of theory),
20 $C_{25}H_{12}N_6O_4$ (407.50)
Melting point: 139-140°C

h) 1-Methyl-2-[(4-amidinophenyl)oxymethyl]-imidazo[4.5-b]-pyridin-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonyl-ethyl)-amide

25 Prepared by reacting 140 mg (0.3 mMol) of 1-methyl-
2-[(4-cyanophenyl)oxymethyl]-imidazo[4,5-b]pyridin-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-
amide with ethanol saturated by hydrogen chloride and with
30 ammonium carbonate/ethanol analogously to Example 1g. The
resulting product was purified by chromatography over
silica gel with dichloromethane/ethanol (19:1 to 4:1).
Yield: 48 mg of white powder (36 % of theory),
 $C_{26}H_{27}N_7O_4$ (501.57)
35 Mass spectrum: $(M+H)^+ = 502$

Example 9

2- [N- (4-amidinophenyl) -aminomethyl] -benzothiazole-5-
carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide

5

a) Ethyl 4-fluoro-3-methoxyacetamido-benzoate

A solution of 2.8 g (15.3 mMol) of ethyl 3-amino-4-fluoro-
benzoate (cf. L.S. Fosdick, A.F. Dodds in J. Amer. Chem.
Soc. 65, 2305 (1943)) and 1.56 ml (1.85 g = 17.0 mMol) of
10 methoxyacetylchloride in 50 ml chlorobenzene was stirred
for 1 hour at 50°C and then refluxed for 15 minutes. Then
the solvent was distilled off *in vacuo* and the crude
product obtained was purified by flash chromatography
(silica gel; dichloromethane/ethanol = 100:1). The desired
15 compound, initially oily, solidified within a few days.
Yield: 3.8 g (98 % of theory),
R_f value: 0.38 (silica gel; dichloromethane/ethanol = 19:1)

b) Ethyl-2-methoxymethyl-benzothiazole-5-carboxylate

20 A mixture of 3.0 g (11.7 mMol) of 4-fluoro-3-
methoxyacetamido-benzoic acid and 2.1 g (5.2 mMol) of
Lawesson's reagent was refluxed for 6 hours in 90 ml
toluene, mixed with 1.0 g Lawesson's reagent and heated to
120°C for another 6 hours. After the solvent was replaced
25 with xylene the mixture was heated to 180°C for a further 8
hours in a pressurised vessel. Then the solvent was
distilled off *in vacuo*, the crude product obtained was
purified by flash chromatography (silica gel; ethyl
acetate/petroleum ether = 5:95) and evaporated down again.
30 Yield: 2.1 g of yellow crystals (72 % of theory),
R_f value: 0.55 (silica gel; ethyl acetate/petroleum ether =
3:7)

c) 2-Methoxymethyl-benzothiazole-5-carboxylic acid

35 A mixture of 2.1 g (8.36 mMol) of ethyl 2-methoxymethyl-
benzothiazole-5-carboxylate and 16 ml of 2N sodium
hydroxide solution was stirred into 60 ml ethanol for 1

hour at room temperature. Then the alcohol was distilled off, the crude product was taken up in 20 ml water, washed with 50 ml diethylether and the aqueous phase was acidified with concentrated hydrochloric acid whilst being cooled with ice. The pinkish-beige compound thereby precipitated was suction filtered, washed with water and dried. Yield: 1.6 g (86 % of theory),
R_f value: 0.12 (silica gel; dichloromethane/ethanol = 29:1)

10 d) 2-Methoxymethyl-benzothiazole-5-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

A suspension of 1.6 g (7.2 mMol) of 2-methoxymethyl-benzothiazole-5-carboxylic acid in 60 ml dichloromethane was mixed with 1.6 ml (22 mMol) of thionyl chloride and refluxed for 1 hour. The solid dissolved after 20 minutes. After distillation of the liquid components the crude product was taken up in dichloromethane twice more and each time the solvent was distilled off. The crude acid chloride thus obtained was taken up in 50 ml of tetrahydrofuran, added dropwise to a mixture of 1.4 g (7.2 mMol) of N-(2-ethoxycarbonylethyl)aniline and 3.0 ml (21 mMol) of triethylamine in 50 ml of tetrahydrofuran and stirred overnight at room temperature. Then the solvent was distilled off *in vacuo*, the residue was taken up in 30 ml of dichloromethane, this solution was washed with water and dried with sodium sulphate. After distillation of the solvent and flash chromatography (silica gel; gradient: dichloromethane/ethanol 98.5:1.5 to 80:20) the desired compound was isolated as a brownish oil.
Yield: 2.05 (72 % of theory),
R_f value: 0.40 (silica gel; ethyl acetate/petroleum ether = 1:1)

35 e) 2-[N-(4-Cyanophenyl)-aminomethyl]-benzothiazole-5-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

A mixture of 2.05 g (5.14 mMol) of 2-methoxymethyl-benzothiazole-5-carboxylic acid-N-phenyl-N-(2-

ethoxycarbonylethyl)-amide and 5.7 ml (5.7 mMol) of a 1M solution of boron tribromide in dichloromethane was dissolved in a further 60 ml of dichloromethane and stirred for 16 hours at room temperature. Then the mixture was washed with 40 ml of saturated sodium hydrogen carbonate solution, the organic phase was dried with sodium sulphate and the solvent was distilled off. The crude 2-bromomethyl-benzothiazole-5-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide thus obtained (2.4 g) was taken up in 5.0 ml of N,N-diisopropyl-ethylamine and mixed with 0.64 g (5.4 mMol) of 4-amino-benzonitrile. After 1 hour's heating to 130°C the solvent was distilled off *in vacuo* and the crude product obtained was purified by flash chromatography (silica gel; gradient: ethyl acetate/petroleum ether = 1:3 to 1:1), whilst an orange foam was obtained when the eluates were evaporated down. Yield: 1.1 g (44 % of theory), R_f value: 0.35 (silica gel; ethyl acetate/petroleum ether = 7:3)

f) 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazole-5-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide 1.1 g (2.27 mMol) of 2-[N-(4-cyanophenyl)-aminomethyl]-benzothiazole-5-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide was stirred in 100 ml of ethanol saturated with hydrogen chloride for 5 hours first at 0°C and then at room temperature until no more starting material could be detected by thin layer chromatography. Then the solvent was distilled off at a maximum bath temperature of 30°C and the oily residue was taken up in 100 ml of absolute ethanol and mixed with 1.6 g (22 mMol) of ammonium carbonate. After 18 hours stirring at room temperature the solvent was distilled off *in vacuo* and the crude product was purified by flash chromatography (silica gel; gradient: water/methanol = 19:1 to 4:1). When the eluates are evaporated down the desired compound is obtained as a white foam.

Yield: 0.77 g (63 % of theory),

R_f value: 0.19 (silica gel; dichloromethane/ethanol = 3:7)

C₂₇H₂₇N₅O₃S (501.60)

Mass spectrum: (M+H)⁺ = 502

5

Example 10

2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazole-
5-carboxylic acid-N-phenyl-N-(2-carboxyethyl)-amide

10

0.45 g (0.84 mMol) of 2-[N-(4-amidinophenyl)-aminomethyl]-
benzothiazole-5-carboxylic acid-N-phenyl-N-(2-
ethoxycarbonyl-ethyl)-amide were dissolved in 15 ml of
ethanol, mixed with 2 ml of 2N sodium hydroxide solution
and stirred for 4 hours at room temperature. Then the
mixture was acidified with 3 ml of 2N hydrochloric acid and
the solvent was distilled off. The crude product obtained
was taken up in 5 ml dichloromethane/ethanol (2:1) and
filtered to remove the insoluble sodium chloride. After
the distillation of the solvent the desired compound was
obtained as a yellow foam.

15

20

Yield: 0.26 g (67 % of theory),

R_f value: 0.47 (silica gel; methanol/5 % aqueous sodium
chloride = 6:4)

25 C₂₅H₂₃N₅O₃S (473.55)

Mass spectrum: (M+H)⁺ = 474

Example 11

30 2-[N-(4-amidinophenyl)-aminomethyl]benzothiazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonyl-ethyl)-
amide-dihydrochloride

35

Prepared analogously to Example 9 from 2-[N-(4-
cyanophenyl)-aminomethyl]benzothiazol-5-yl-carboxylic acid-
N-(2-pyridyl)-N-(2-methoxycarbonyl-ethyl)-amide, methanolic
hydrochloric acid, methanol and ammonium carbonate.

Yield: 68 % of theory,

$C_{25}H_{24}N_6O_3S$ (488.57)

R_f value: 0.13 (silica gel; methylene chloride/ethanol =
4:1 + a few drops of acetic acid)

5 EKA mass spectrum : $(M+H)^+ = 489$

Example 12

10 2-[2-(4-amidinophenyl)ethyl]-benzothiazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide-
dihydrochloride

15 Prepared analogously to Example 9 from 2-[2-(4-
cyanophenyl)ethyl]-benzothiazol-5-yl-carboxylic acid-N-(2-
pyridyl)-N-(ethoxycarbonylmethyl)-amide, ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 95 % of theory,

$C_{26}H_{25}N_5O_3S$ (487.58)

20 R_f value: 0.20 (silica gel; methylene chloride/ethanol =
4:1 + a few drops of acetic acid)

EKA mass spectrum: $(M+H)^+ = 488$

Example 13

25 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-
amide-dihydrochloride

30 Prepared analogously to Example 9 from 2-[N-(4-
cyanophenyl)-aminomethyl]-benzothiazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide,
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 68 % of theory,

35 $C_{25}H_{24}N_6O_3S$ (488.57)

R_f value: 0.14 (silica gel; methylene chloride/ethanol =

4:1 + a few drops of acetic acid)

EKA mass spectrum: $(M+H)^+ = 489$

Example 14

5

2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide-dihydrochloride

10 Prepared analogously to Example 10 from 2-[N-(4-amidinophenyl)-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide-dihydrochloride and sodium hydroxide solution.

Yield: 90 % of theory,

15 $C_{23}H_{20}N_6O_3S$ (460.52)

R_f value:

EKA mass spectrum: $(M+H)^+ = 461$

$(M+Na)^+ = 483$

$(M+2Na)^{++} = 253$

20

Example 15

2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

25

a) 2-[N-(4-Cyanophenyl)-N-methyl-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

30 Prepared analogously to Example 9e from 4-cyano-N-methylaniline and 2-methoxymethyl-benzothiazole-5-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide.

Yield: 57 % of theory,

R_f value: 0.46 (silica gel; dichloromethane/ethanol =

35 19:1).

b) 2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 9 from 2-[N-(4-

5 cyanophenyl)-N-methyl-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 73 % of theory,

10 $C_{28}H_{29}N_5O_3S$ (515.64)

R_f value: 0.29 (silica gel; methylene chloride/ethanol = 4:1 + a few drops of acetic acid)

EKA mass spectrum: $(M+H)^+ = 516$

15 Example 16

2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-hydrochloride

20

Prepared analogously to Example 10 from 2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-benzothiazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.

25 Yield: 96 % of theory,

$C_{26}H_{25}N_5O_3S$ (487.58)

R_f value: 0.48 (Merck RP-8, methanol/5% NaCl solution = 6:4)

EKA mass spectrum: $(M+H)^+ = 488$

30 $(M+2Na)^{++} = 266.5$

Example 17

2-[(4-amidinophenyl)thiomethyl]-benzothiazol-5-yl-
carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-
5 hydrochloride

Prepared analogously to Example 9 from 2-[(4-
cyanophenyl)thiomethyl]-benzothiazol-5-yl-carboxylic acid-
N-phenyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic
10 hydrochloric acid, ethanol and ammonium carbonate.

Yield: 61 % of theory,

$C_{27}H_{26}N_4O_3S_2$ (518.66)

R_f value: 0.27 (silica gel; methylene chloride/ethanol =
4:1 + a few drops of acetic acid)

15 EKA mass spectrum: $(M+H)^+ = 519$

Example 18

2-[(4-amidinophenyl)thiomethyl]-benzothiazol-5-yl-
20 carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-
hydrochloride

Prepared analogously to Example 10 from 2-[(4-
amidinophenyl)thio-methyl]-benzothiazol-5-yl-carboxylic
25 acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
and sodium hydroxide solution.

Yield: 95 % of theory,

$C_{25}H_{22}N_4O_3S_2$ (490.61)

R_f value: 0.25 (Merck RP-8, methanol/5% NaCl solution =
30 6:4)

EKA mass spectrum: $(M+H)^+ = 491$

$(M+Na)^+ = 513$

Example 19

2- [N- (4-amidinophenyl) -aminomethyl] -benzothiazol-5-yl-
carboxylic acid-N-phenyl-N- (ethoxycarbonylmethyl) -amide-
5 hydrochloride

Prepared analogously to Example 9 from 2- [N- (4-
cyanophenyl) -aminomethyl] -benzothiazol-5-yl-carboxylic
acid-N-phenyl-N- (ethoxycarbonylmethyl) -amide, ethanolic
10 hydrochloric acid, ethanol and ammonium carbonate.

Yield: 82 % of theory,

$C_{26}H_{25}N_5O_3S$ (487.58)

R_f value: 0.21 (silica gel; methylene chloride/ethanol =
4:1 + a few drops of acetic acid)

15 EKA mass spectrum: $(M+H)^+ = 488$

Example 20

2- [N- (4-amidinophenyl) -aminomethyl] -benzothiazol-5-yl-
20 carboxylic acid-N-phenyl-N- (hydroxycarbonylmethyl) -amide-
hydrochloride

Prepared analogously to Example 10 from 2- [N- (4-
amidinophenyl) -aminomethyl] -benzothiazol-5-yl-carboxylic
25 acid-N-phenyl-N- (ethoxycarbonylmethyl) -amide-hydrochloride
and sodium hydroxide solution.

Yield: 75 % of theory,

$C_{24}H_{21}N_5O_3S$ (459.53)

R_f value: 0.14 (silica gel; methylene chloride/ethanol =
30 4:1 + a few drops of acetic acid)

EKA mass spectrum: $(M+H)^+ = 460$

$(M+Na)^+ = 482$

Example 21

2-[2-(4-amidinophenyl)ethyl]-benzothiazol-5-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

5

Prepared analogously to Example 9 from 2-[2-(4-
cyanophenyl)ethyl]-benzothiazol-5-yl-carboxylic acid-N-
phenyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

10 Yield: 80 % of theory,

$C_{28}H_{28}N_4O_3S$ (500.62)

R_f value: 0.30 (silica gel; methylene chloride/ethanol =
4:1 + a few drops of acetic acid)

EKA mass spectrum: $(M+H)^+ = 501$

15

Example 22

2-[2-(4-amidinophenyl)ethyl]-benzothiazol-5-yl-carboxylic
acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-
20 hydrochloride

Prepared analogously to Example 10 from 2-[2-(4-
amidinophenyl)ethyl]-benzothiazol-5-yl-carboxylic acid-N-
phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and
25 sodium hydroxide solution.

Yield: 77 % of theory,

$C_{26}H_{24}N_4O_3S$ (472.57)

R_f value: 0.18 (silica gel; methylene chloride/ethanol =
4:1 + a few drops of acetic acid)

30 EKA mass spectrum: $(M+H)^+ = 473$

$(M+Na)^+ = 495$

$(M+H+Na)^{++} = 259$

Example 23

2- [N- (4-amidinophenyl) -aminomethyl] -benzothiazol-5-yl-
carboxylic acid-N- (n-propyl) -N- (2-ethoxycarbonylethyl) -
5 amide-hydrochloride

Prepared analogously to Example 9 from 2- [N- (4-
cyanophenyl) -aminomethyl] -benzothiazol-5-yl-carboxylic
acid-N- (n-propyl) -N- (2-ethoxycarbonylethyl) -amide,
10 ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 83 % of theory,

C₂₄H₂₉N₅O₃ (467.59)

R_f value: 0.31 (silica gel; methylene chloride/ethanol =
15 4:1 + a few drops of acetic acid)

EKA mass spectrum: (M+H)⁺ = 468

(2M+H)⁺ = 935

Example 24

20

2- [N- (4-amidinophenyl) -aminomethyl] -benzothiazol-5-yl-
carboxylic acid-N- (n-propyl) -N- (2-hydroxycarbonylethyl) -
amide-hydrochloride

25 Prepared analogously to Example 10 from 2- [N- (4-
amidinophenyl) -aminomethyl] -benzothiazol-5-yl-carboxylic
acid-N- (n-propyl) -N- (2-ethoxycarbonylethyl) -amide-
hydrochloride and sodium hydroxide solution.

Yield: 75 % of theory,

30 C₂₂H₂₅N₅O₃S (439.54)

R_f value: 0.14 (silica gel; methylene chloride/ethanol =
4:1 + a few drops of acetic acid)

EKA mass spectrum: (M+H)⁺ = 440

(M+H+Na)⁺⁺ = 231.6

35

Example 25

1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5 5-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -
amide-hydrochloride

a) 4-Methylamino-3-nitro-benzoic acid-N-phenyl-N- (2-ethoxy-
carbonylethyl) -amide

10 To a solution of 24.7 g (0.115 mol) of 4-methylamino-3-
nitro-benzoic acid chloride and 22.3 g (0.115 mol) of
N- (2-ethoxy-carbonylethyl) -aniline in 300 ml of
tetrahydrofuran, 13.1 g (0.13 mol) of triethylamine were
15 added dropwise in 15 minutes, with stirring, at room
temperature. After 2 hours stirring the solvent was
distilled off in a water-jet vacuum and the residue was
mixed with 700 ml of water with stirring. The mixture was
extracted 3 times with 200 ml of dichloromethane, the or-
20 ganic extract was washed twice with 200 ml of 2N
hydrochloric acid and twice with 300 ml of water and dried
over sodium sulphate. The solvent was then distilled off
and the oily product thus obtained was purified by column
chromatography (1 kg silica gel; eluant: petroleum
ether/ethyl acetate = 2:1).
25 Yield: 35.0 g (82 % of theory),
R_f value: 0.28 (silica gel; dichloromethane/ethanol = 50:1)

b) 3-Amino-4-methylamino-benzoic acid-N-phenyl-N- (2-ethoxy-
carbonylethyl) -amide

30 12.1 g (0.0326 mol) of 4-methylamino-3-nitro-benzoic acid-
N-phenyl-N- (2-ethoxycarbonylethyl) -amide were hydrogenated
in 300 ml ethanol and 150 ml dichloromethane after the
addition of about 4 g of palladium/charcoal (10%) at room
temperature and under a hydrogen pressure of 5 bar. Then
35 the catalyst was filtered off and the filtrate was
evaporated down. The crude product thus obtained was
reacted without further purification.

Yield: 10.6 g (95 % of theory),

R_f value: 0.19 (silica gel; dichloromethane/ethanol = 50:1)

c) 1-Methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

6.17 g (0.035 mol) of N-(4-cyanophenyl)glycine and 5.68 g (0.035 mol) of N,N'-carbonyldiimidazole were refluxed in 300 ml of tetrahydrofuran for 30 minutes, then 10.6 g (0.032 mol) of 3-amino-4-methylamino-benzoic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide were added and the mixture was refluxed for a further five hours. Then the solvent was distilled off *in vacuo*, the residue was dissolved in 150 ml of glacial acetic acid and refluxed for one hour. Then the glacial acetic acid was distilled off *in vacuo*, the residue was dissolved in about 300 ml of dichloromethane, the solution was washed twice with about 150 ml water and then dried over sodium sulphate. After evaporation of the solvent the crude product thus obtained was purified by column chromatography (800 g silica gel; eluant: dichloromethane with 1-2 % ethanol).

Yield: 8.5 g (57 % of theory),

R_f value: 0.51 (silica gel; dichloromethane/ethanol = 19:1)

d) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

1.2 g (2.49 mMol) of 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide were stirred in 100 ml of saturated ethanolic hydrochloric acid for 6 hours at room temperature. Then the mixture was evaporated to dryness *in vacuo*, the residue was dissolved in 100 ml of ethanol, mixed with 2.5 g (26 mMol) of ammonium carbonate and stirred overnight at room temperature. After distillation of the solvent the crude product thus obtained was purified by column chromatography (100 g silica gel; eluant:

dichloromethane/ethanol = 4:1). By concentrating the eluates the desired compound was obtained as a white, amorphous solid.

Yield: 1.10 g (83 % of theory),

5 R_f value: 0.18 (silica gel; dichloromethane/ethanol = 4:1)
 $C_{28}H_{30}N_6O_3 \times HCl$ (498.6)

EKA mass spectrum: $(M+H)^+$ = 499

$(M+2H)^{++}$ = 250

$(M+H+Na)^{++}$ = 261

10

Example 26

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-
15 amide

A mixture of 300 mg (0.56 mMol) of 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-
20 hydrochloride, 15 ml of ethanol, 4 ml of water and 120 mg (3.0 mMol) of sodium hydroxide was stirred for two hours at room temperature. Then the mixture was diluted with about 20 ml of water and made weakly alkaline with glacial acetic acid. The product which crystallised out was suction
25 filtered, washed with water and dried at 60°C *in vacuo*.

Yield: 250 mg (95 % of theory),

$C_{26}H_{26}N_6O_3$ (470.5)

EKA mass spectrum: $(M+H)^+$ = 471

$(M+H+Na)^{++}$ = 247

30

$(M+2Na)^{++}$ = 258

Example 27

1-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-
5 amide-hydrochloride

a) 4-Methylamino-3-chloracetamido-benzoic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide

A solution of 1.8 g (5.9 mMol) of 3-amino-4-methylamino-
10 benzoic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide
[prepared analogously to 3-amino-4-ethylamino-benzoic acid-
N-phenyl-N-(2-ethoxycarbonylethyl)-amide], 1.1g (6.8 mMol)
of N,N'-carbonyldiimidazole and 0.65 g (6.9 mMol) of
15 chloroacetic acid in 75 ml tetrahydrofuran was stirred for
1 hour at room temperature. Then the solvent was distilled
off *in vacuo*, and the crude product was purified by flash
chromatography (silica gel; methylene chloride/ethanol =
49:1).

Yield: 1.7 g (77% of theory) yellow oil,
20 R_f value: 0.58 (silica gel; ethyl acetate/ethanol/ammonia
= 90:10:1)

b) 2-Chloromethyl-1-methyl-benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide

25 1.6 g (4.3 mMol) of 4-methylamino-3-chloracetamido-benzoic
acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide were
heated to 100°C in 25 ml of acetic acid for 30 minutes.
Then the solvent was distilled off, the crude product was
taken up in 40 ml methylene chloride/ethanol (9:1) and
30 washed with 20 ml saturated sodium hydrogen carbonate
solution. The organic phase was dried with sodium sulphate
and evaporated down.

Yield: 1.5 g (100% of theory) of brown oil,
R_f value: 0.63 (silica gel; ethyl acetate/ethanol/ammonia
35 = 90:10:1)

c) 1-Methyl-2-[(4-cyanophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide

A mixture of 1.5 g (4.1 mMol) of 2-chloromethyl-1-methyl-
5 benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide and 0.65 g (4.8 mMol) of p-cyanothiophenol was heated in 10 ml of dimethylformamide and 10 ml of diisopropylethylamine for 1 hour to 100°C. The solvent was distilled off *in vacuo*, the crude product
10 was dissolved in 30 ml ethyl acetate, washed with 30 ml water, and after concentration purified by flash chromatography (silica gel; methylene chloride/ethanol (49:1 to 19:1).
Yield: 1.5 g (79% of theory) of brown oil,
15 R_f value: 0.65 (silica gel; ethyl acetate/ethanol/ammonia = 90:10:1)

d) 1-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

1.4 g (3.01 mMol) of 1-methyl-2-[(4-cyanophenyl)-
thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-
N-(2-ethoxycarbonylethyl)-amide were stirred in 50 ml of
ethanol saturated with hydrogen chloride for 5 hours first
25 at 0°C, later at room temperature, until no more starting material could be detected by thin layer chromatography. Then the solvent was distilled off at a maximum bath temperature of 30°C, the oily residue was taken up in 40 ml of absolute ethanol and mixed with 2.8 g of ammonium
30 carbonate. After 18 hours the solvent was distilled off *in vacuo* and the crude product was purified by flash chromatography (silica gel; methylene chloride/ethanol = 19:1 to 4:1).
Yield: 1.3 g (83% of theory) as a light beige solid,
35 R_f value: 0.29 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5)

$C_{25}H_{31}N_6O_3S$ (481.62)

EKA mass spectrum: $(M+H)^+ = 482$

Example 28

5

1-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-hydroxycarbonylethyl)-amide-hydrochloride

10 0.52 g (1.0 mMol) of 1-Methyl-2-[(4-amidinophenyl)-thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride was dissolved in 15 ml ethanol, mixed with 5 ml of 2N sodium hydroxide solution and stirred for 2 hours at room temperature. Then
15 5 ml of water were added, the alcohol was distilled off, and it was acidified with concentrated hydrochloric acid. The water was distilled off in vacuo, and the crude product was taken up in 5 ml of ethanol and filtered to remove the insoluble sodium chloride. After the solvent had been
20 distilled off the title compound was obtained as a white solid.

Yield: 0.43 g (88% of theory),

R_f value: 0.19 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5)

25 $C_{23}H_{27}N_5O_3S$ (453.57)

EKA mass spectrum: $(M+H)^+ = 454$

$(M+Na)^+ = 476$

Example 29

30

1-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-methylpropyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

35 Prepared analogously to Example 27 from 1-methyl-2-[(4-cyanophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-(N-(2-methylpropyl)-N-(2-ethoxycarbonylethyl)-amide,

ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 83 % of theory,

$C_{25}H_{31}N_6O_3S$ (495.65)

- 5 R_f value: 0.30 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5) :

EKA mass spectrum: $(M+H)^+ = 496$

Example 30

10

1-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

15

Prepared analogously to Example 27 from 1-methyl-2-[(4-cyanophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide, and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 90 % of theory,

20

$C_{28}H_{29}N_5O_3S$ (515.64)

R_f value: 0.24 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5)

EKA mass spectrum: $(M+H)^+ = 516$

$(M+H+Na)^{++} = 269.7$

25

Example 31

30

1-Methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-hydrochloride

35

Prepared analogously to Example 28 from 1-methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.

Yield: 76 % of theory,

$C_{26}H_{25}N_5O_3S$ (487.58)

R_f value: 0.31 (silica gel; ethyl acetate/ethanol/ammonia
= 50:45:5)

EKA mass spectrum: $(M+H)^+$ = 488

5 $(M+Na)^+$ = 510

Example 32

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-
10 sulphonic acid-N-(1-methyl-piperidin-4-yl)-N-methyl-amide-
hydrochloride

a) 4-Chloro-3-nitrobenzenesulphonic acid-N-(1-methyl-
piperidin-4-yl)-N-methyl-amide

15 To a solution of 2.2 ml (15 mMol) of 1-methyl-4-
methylamino-piperidine in 60 ml pyridine, 3.8 g (15 mMol)
of 4-chloro-3-nitro-benzenesulphonic acid chloride were
added, in batches, whilst cooling with ice. The mixture was
then stirred for two hours with cooling, then evaporated to
20 dryness, the residue was mixed with about 50 ml of water
and made alkaline with concentrated ammonia whilst stirring
vigorously. The crude product precipitated was suction
filtered and purified by column chromatography (250 g
silica gel, eluant: dichloromethane with 1.5% ethanol).

25 Yield: 1.6 g (31% of theory),

$C_{13}H_{18}ClN_3O_4S$ (347.8)

R_f value: 0.19 (silica gel; dichloromethane/ethanol = 19:1)

b) 4-Methylamino-3-nitrobenzenesulphonic acid-N-methyl-N-
30 (1-methylpiperidin-4-yl)-amide

1.6 g (4.6 mMol) of 4-chloro-3-nitrobenzenesulphonic acid-
N-methyl-N-(1-methyl-piperidin-4-yl)-amide was mixed with
30 ml of 40% methylamine solution and stirred in a sealed
flask for four hours at room temperature. Then the mixture
35 was diluted with about 40 ml of water, the product
precipitated was suction filtered, washed with water and
dried.

$$\text{C}_{14}\text{H}_{22}\text{N}_4\text{O}_4\text{S} \quad (343.4)$$

c) 3-Amino-4-methylaminobenzenesulphonic acid-N-methyl-N-(1-methylpiperidin-4-yl)-amide

Yield: 1.4 g (100% of theory),

R_f value: 0.33 (silica gel; dichloromethane/ethanol = 4:1)

d) 1-Methyl-2-[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-sulfonic acid-N-methyl-N-(1-methyl-piperidin-4-yl)-amide

Yield: 400 mg (39% of theory),

$$\text{C}_{23}\text{H}_{27}\text{N}_5\text{O}_3\text{S} \quad (453.6)$$

R_f value: 0.37 (silica gel; dichloromethane/ethanol = 4:1)

e) 1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-sulphonic acid-N-methyl-N-(1-methylpiperidin-4-yl)-amide-hydrochloride

- 5 Prepared analogously to Example 25d from 400 mg of 1-methyl-2-[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-sulphonic acid-N-methyl-N-(1-methylpiperidin-4-yl)-amide with ethanolic hydrochloric acid and ammonium carbonate. Yield: 370 mg (83% of theory),
- 10 $C_{23}H_{30}N_6O_3S$ (470.6)
- EKA mass spectrum: $(M+H)^+ = 471$
 $(M+2H)^{++} = 236$

Example 33

- 15 1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-sulphonic acid-N-methyl-N-phenyl-amide-hydrochloride

-
- 20 Prepared analogously to Example 32 from 1-methyl-2-[(4-cyanophenyl)-oxymethyl]-benzimidazol-5-yl-sulphonic acid-N-methyl-N-phenyl-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate. Yield: 46 % of theory,
 $C_{23}H_{23}N_5O_3S$ (449.5)
- 25 EKA mass spectrum: $(M+H)^+ = 450$
 $(M+H+Methanol)^+ = 482$
 $(M+2H)^{++} = 223$

Example 34

- 30 1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-sulphonic acid-N-(3-ethoxycarbonyl-n-propyl)-N-phenyl-amide-hydrochloride
-
- 35 Prepared analogously to Example 32 from 1-methyl-2-[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-sulphonic acid-N-

(3-ethoxycarbonyl-n-propyl)-N-phenyl-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 57 % of theory,

$C_{28}H_{31}N_5O_5S$ (549.7)

5 EKA mass spectrum: $(M+H)^+ = 550$

Example 35

1-Methyl-2-[(3-amidinophenyl)oxymethyl]-benzimidazol-5-yl-sulphonic acid-pyrrolidide-hydrochloride

Prepared analogously to Example 32 from 1-methyl-2-[(3-cyanophenyl)oxymethyl]-benzimidazol-5-yl-sulphonic acid-pyrrolidide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 71 % of theory,

$C_{20}H_{23}N_5O_3S$ (413.5)

EKA mass spectrum: $(M+H)^+ = 414$

20 Example 36

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-methoxycarbonylpropyl)-amide-dihydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[2-(4-cyanophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-tert.butyloxycarbonylpropyl)-amide and methanolic hydrochloric acid, methanol and ammonium carbonate.

Yield: 83.5 % of theory,

R_f value: 0.17 (silica gel; dichloromethane/ethanol = 4:1)

$C_{29}H_{31}N_5O_3$ (497.6)

EKA mass spectrum: $(M+H)^+ = 498$

35 $(M+H+Na)^{++} = 260.7$

Example 37

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-(3-hydroxycarbonylpropyl)-amide-
5 hydrochloride

Prepared analogously to Example 26 from 1-methyl-2-[(4-
amidinophenyl)aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(3-methoxycarbonylpropyl)-amide-
10 dihydrochloride and sodium hydroxide solution.

Yield: 92 % of theory,

R_f value: 0.09 (silica gel; dichloromethane/ethanol = 4:1)

C₂₈H₂₉N₅O₃ (483.6)

EKA mass spectrum: (M+H)⁺ = 484
15 (M+Na)⁺ = 506
(M+H+Na)⁺⁺ = 253.7

Example 38

20 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-phenyl-N-(3-ethoxycarbonylpropyl)-
amide-dihydrochloride

a) 1-Methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-
25 5-yl-carboxylic acid-N-phenyl-N-(3-tert.butyloxy-
carbonylpropyl)-amide

Prepared analogously to Example 25c from N-(4-cyanophenyl)-
glycine and 3-amino-4-methylamino-benzoic acid-N-phenyl-
N-(3-tert.butyloxycarbonylpropyl)-amide.

30 Yield: 65 % of theory,

R_f value: 0.17 (silica gel; dichloromethane/methanol =
19:1)

b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
35 benzimidazol-5-yl-carboxylic acid-N-phenyl-
N-(3-ethoxycarbonylpropyl)-amide-dihydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-tert.butyloxycarbonylpropyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium

5 carbonate.

Yield: 68 % of theory,

R_f value: 0.12 (silica gel; dichloromethane/ethanol = 4:1)

C₂₉H₃₂N₆O₃ (512.6)

EKA mass spectrum: (M+H)⁺ = 513

10 (M+H+Na)⁺⁺ = 268

Example 39

15 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-hydroxycarbonylpropyl)-amide-hydrochloride

20 Prepared analogously to Example 26 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-ethoxycarbonylpropyl)-amide-dihydrochloride and sodium hydroxide solution.

Yield: 73.5 % of theory,

C₂₇H₂₈N₆O₃ (484.6)

EKA mass spectrum: (M+H)⁺ = 485

25 (M+2H)⁺⁺ = 243

(M+H+Na)⁺⁺ = 254

Example 40

30 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride

35 Prepared analogously to Example 25d from 1-methyl-2-[2-(4-cyanophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-

phenyl-N-(ethoxycarbonylmethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 73 % of theory,

R_f value: 0.15 (silica gel; dichloromethane/ethanol = 4:1)

5 C₂₈H₂₉N₅O₃ (483.6)

EKA mass spectrum: (M+H)⁺ = 484

(M+H+Na)⁺⁺ = 253.7

Example 41

10

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(hydroxycarbonylmethyl)-amide-hydrochloride

15 Prepared analogously to Example 26 from 1-methyl-2-[2-(4-amidinophenyl)ethyl]benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride and sodium hydroxide solution.

Yield: 97 % of theory,

20 C₂₆H₂₅N₅O₃ (455.5)

EKA mass spectrum: (M+H)⁺ = 456

(M+Na)⁺ = 478

(M+2Na)⁺⁺ = 250.6

25 Example 42

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride

30

Prepared analogously to Example 25d from 1-methyl-2-[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

35 Yield: 76 % of theory,

R_f value: 0.17 (silica gel; dichloromethane/ethanol = 4:1)

$C_{27}H_{27}N_5O_4$ (485.6)

EKA mass spectrum: $(M+H)^+$ = 486

$(M+H+Na)^{++}$ = 254.7

5 Example 43

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(hydroxycarbonylmethyl)-amide-hydrochloride

10

Prepared analogously to Example 26 from 1-methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride and sodium hydroxide solution.

15 Yield: 58 % of theory,

$C_{25}H_{23}N_5O_4$ (457.5)

EKA mass spectrum: $(M+H)^+$ = 458

$(M+Na)^+$ = 480

$(M+2Na)^{++}$ = 251.6

20

Example 44

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride

25

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

30

Yield: 74 % of theory,

R_f value: 0.12 (silica gel; dichloromethane/ethanol = 4:1)

$C_{27}H_{28}N_6O_3$ (484.6)

EKA mass spectrum: $(M+H)^+$ = 485

35

$(M+H+Na)^{++}$ = 254

Example 45

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(hydroxycarbonylmethyl)-amide-hydrochloride

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(ethoxycarbonylmethyl)-amide-hydrochloride and sodium hydroxide solution.

Yield: 84 % of theory,

$C_{25}H_{24}N_6O_3$ (456.5)

EKA mass spectrum: $(M+H)^+ = 457$

$(M+Na)^+ = 479$

$(M+2Na)^{++} = 251$

Example 46

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-N-(4-pyrimidyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-N-(4-pyrimidyl)-N-(2-ethoxycarbonylethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 14 % of theory,

$C_{26}H_{27}N_7O_4$ (501.6)

Mass spectrum: $(M+H)^+ = 502$

Example 47

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-
5 amide-dihydrochloride

Prepared analogously to Example 25d from 1-methyl-2-
[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide and
10 ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 44 % of theory,

R_f value: 0.12 (silica gel; dichloromethane/ethanol = 4:1)

C₂₆H₂₆N₆O₄ (486.5)

15 EKA mass spectrum: (M+H)⁺ = 487
(M+2H)⁺⁺ = 244
(M+H+Na)⁺⁺ = 255

Example 48

20

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-
amide-hydrochloride

25 Prepared analogously to Example 26 from 1-methyl-2-[(4-
amidinophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-
N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide-
dihydrochloride and sodium hydroxide solution.

Yield: 85 % of theory,

30 C₂₄H₂₂N₆O₄ (458.5)

EKA mass spectrum: (M+H)⁺ = 459
(M+Na)⁺ = 481
(M+2Na)⁺⁺ = 252

Example 49

- 1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5-yl-carboxylic acid-N- (2-pyridyl) -
5 N- (ethoxycarbonylmethyl) -amide-dihydrochloride

a) 1-Methyl-2- [N- (4-cyanophenyl) -aminomethyl] -benzimidazol-
5-yl-carboxylic acid-N- (2-pyridyl) -N-ethoxycarbonylmethyl-
amide

- 10 Prepared analogously to Example 25c from N- (4-cyanophenyl) -
glycine and 3-amino-4-methylamino-benzoic acid-
N- (2-pyridyl) -N-ethoxycarbonylmethyl-amide.

Yield: 24 % of theory,

R_f value: 0.56 (silica gel; dichloromethane/methanol = 4:1)

15

b) 1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -
N- (ethoxycarbonylmethyl) -amide-dihydrochloride

- Prepared analogously to Example 25d from 1-methyl-2- [N- (4-
20 cyanophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (ethoxycarbonylmethyl) -amide and
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 70 % of theory,

- 25 R_f value: 0.16 (silica gel; dichloromethane/ethanol = 4:1)
C₂₆H₂₇N₇O₃ (485.6)

EKA mass spectrum: (M+H)⁺ = 486

(M+2H)⁺⁺ = 243.7

(M+H-Na)⁺⁺ = 254.6

Example 50

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-
5 N-(hydroxycarbonylmethyl)-amide-hydrochloride

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
10 acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide-dihydrochloride and sodium hydroxide solution.

Yield: 91 % of theory,

C₂₄H₂₃N₇O₃ (457.5)

EKA mass spectrum: (M+H)⁺ = 458

(M+Na)⁺ = 480

15 (M+2Na)⁺⁺ = 251.7

Example 51

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-
20 amide-dihydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[2-(4-cyanophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide, ethanolic
25 hydrochloric acid, ethanol and ammonium carbonate.

Yield: 90 % of theory,

R_f value: 0.17 (silica gel; dichloromethane/ethanol = 4:1)

C₂₇H₂₈N₆O₃ (484.6)

30 EKA mass spectrum: (M+H)⁺ = 485

(M+2H)⁺⁺ = 243

(M+H+Na)⁺⁺ = 254

Example 52

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-
5 amide-hydrochloride

Prepared analogously to Example 26 from 1-methyl-2-[2-(4-
amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-
(2-pyridyl)-N-(ethoxycarbonylmethyl)-amide-dihydrochloride
10 and sodium hydroxide solution.

Yield: 89 % of theory,

$C_{25}H_{24}N_6O_3$ (456.5)

EKA mass spectrum: $(M+H)^+$ = 457

$(M+Na)^+$ = 479

15

Example 53

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-
20 amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-
(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide and
25 methanolic hydrochloric acid, methanol and ammonium
carbonate.

Yield: 87 % of theory,

R_f value: 0.11 (silica gel; dichloromethane/ethanol = 4:1)

$C_{27}H_{28}N_6O_3$ (484.6)

30 EKA mass spectrum: $(M+H)^+$ = 485

$(M+2H)^{++}$ = 243

$(M+H+Na)^{++}$ = 254

Example 54

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-
5 hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-
[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide and ethanolic
10 hydrochloric acid, ethanol and ammonium carbonate.

Yield: 79.5 % of theory,

C₂₈H₂₉N₅O₄ (499.6)

R_f value: 0.15 (silica gel; dichloromethane/ethanol = 4:1)

EKA mass spectrum: (M+H)⁺ = 500.0

15 (M+H+Na)⁺⁺ = 261.7

Example 55

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-
20 carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-
hydrochloride

Prepared analogously to Example 26 from 1-methyl-2-[(4-
amidinophenyl)oxymethyl]-benzimidazol-5-yl-carboxylic acid-
25 N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and
sodium hydroxide solution.

Yield: 82 % of theory,

C₂₆H₂₅N₅O₄ (471.5)

R_f value: 0.11 (silica gel; dichloromethane/ethanol = 4:1)

30 EKA mass spectrum: (M+H)⁺ = 472

(M+H+Na)⁺⁺ = 247.6

(M+Na)⁺ = 494

(M+2Na)⁺⁺ = 258.6

35

Example 56

1-Methyl-2-[2-(2-amidinothiophen-5-yl)ethyl]-benzimidazol-
5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

a) 1-Methyl-2-[2-(2-cyanothiophen-5-yl)-ethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide

Prepared analogously to Example 25c from 3-(2-
cyanothiophen-5-yl)-propionic acid and 3-amino-
4-methylamino-benzoic acid-N-(2-pyridyl)-
N-(2-ethoxycarbonylethyl)amide.

Yield: 18 % of theory,
R_f value: 0.66 (silica gel; dichloromethane/methanol = 9:1)

b) 1-Methyl-2-[2-(2-amidinothiophen-5-yl)ethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[2-(2-
cyanothiophen-5-yl)ethyl]-benzimidazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide and
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 53 % of theory,

C₂₆H₂₈N₆O₃S (504.6)

R_f value: 0.22 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: (M+H)⁺ = 505

(M+H+Na)⁺⁺ = 264

Example 57

1-Methyl-2-[2-(2-amidinothiophen-5-yl)ethyl]-benzimidazol-
5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
5 hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-methyl-2-[2-(2-
amidinothiophen-5-yl)ethyl]-benzimidazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-
10 hydrochloride and sodium hydroxide solution.

Yield: 98 % of theory,

C₂₄H₂₄N₆O₃S (476.6)

EKA mass spectrum: (M+H)⁺ = 477

(M+Na)⁺ = 499

15 (M+2H)⁺⁺ = 239

Example 58

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
20 5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

a) 1-Methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
25 ethoxycarbonylethyl)-amide

Prepared analogously to Example 25c from N-(4-cyanophenyl)-
glycine and 3-amino-4-methylamino-benzoic acid-N-(2-
pyridyl)-N-(2-ethoxycarbonylethyl)-amide.

Yield: 61 % of theory,

30 R_f value: 0.62 (silica gel; dichloromethane/methanol =
19:1)

b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
35 ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic

acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide and
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 71 % of theory,

5 $C_{27}H_{29}N_7O_3$ (499.6)

R_f value: 0.28 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: (M+H)⁺ = 500

(M+H+Na)⁺⁺ = 261.8

(M+2H)⁺⁺ = 250.8

10

Example 59

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
15 hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-
20 hydrochloride and sodium hydroxide solution.

Yield: 91 % of theory,

$C_{25}H_{25}N_7O_3$ (471.5)

EKA mass spectrum: (M+H)⁺ = 472

(M+H+Na)⁺⁺ = 247.6

25

(M+2H)⁺⁺ = 236.7

(M+2Na)⁺⁺ = 258.6

Example 60

30 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
amide-hydrochloride

a) 1-Methyl-2-[2-(4-cyanophenyl)-ethyl]-benzimidazol-5-yl-
35 carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
amide

Prepared analogously to Example 149a from 3-(4-cyanophenyl)-propionic acid and 3-amino-4-methylamino-benzoic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide. Yield: 22 % of theory,

5 R_f value: 0.68 (silica gel; dichloromethane/methanol = 19:1)

b) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[2-(4-cyanophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

15 Yield: 85 % of theory,

C₂₈H₃₀N₆O₃ (498.6)

R_f value: 0.30 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: (M+H)⁺ = 499

(M+H+Na)⁺⁺ = 261

20

Example 61

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide

25

Prepared analogously to Example 26 from 1-methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.

30

Yield: 97 % of theory,

C₂₆H₂₆N₆O₃ (470.5)

EKA mass spectrum: (M+H)⁺ = 471

(M+H+Na)⁺⁺ = 247

35

(M+Na)⁺ = 493

Example 62

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
5 carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-
hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[2-(4-
cyanophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-
10 phenyl-N-(2-ethoxycarbonylethyl)-amide and ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 86 % of theory,

$C_{29}H_{31}N_5O_3$ (497.6)

R_f value: 0.11 (silica gel; dichloromethane/ethanol = 4:1)

15 EKA mass spectrum: $(M+H)^+$ = 498
 $(M+2H)^{++}$ = 249.8

Example 63

20 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-
hydrochloride

Prepared analogously to Example 26 from 1-methyl-2-[2-(4-
25 amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-
phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and
sodium hydroxide solution.

Yield: 71 % of theory,

$C_{27}H_{27}N_5O_3$ (469.6)

30 EKA mass spectrum: $(M+H)^+$ = 470
 $(M+H+Na)^{++}$ = 246.6
 $(M+Na)^+$ = 492
 $(M+2H)^{++}$ = 235.6

Example 64

- 1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5-yl-carboxylic acid-N- (2-pyridyl) -N-
5 (methoxycarbonylmethyl) -amide-dihydrochloride

Prepared analogously to Example 25d from 1-methyl-2- [N- (4-
cyanophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (methoxycarbonylmethyl) -amide and
10 methanolic hydrochloric acid, methanol and ammonium
carbonate.

Yield: 73 % of theory,

C₂₅H₂₅N₇O₃ (471.5)

R_f value: 0.12 (silica gel; dichloromethane/ethanol = 4:1)

- 15 EKA mass spectrum: (M+H)⁺ = 472
(M+H+Na)⁺⁺ = 247.8

Example 65

- 20 1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5-yl-carboxylic acid-N- (2-pyridyl) -N- (2-
methoxycarbonylethyl) -amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2- [N- (4-
25 cyanophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (2-methoxycarbonylethyl) -amide and
methanolic hydrochloric acid, methanol and ammonium
carbonate.

Yield: 78 % of theory,

- 30 C₂₆H₂₇N₇O₃ (485.6)

R_f value: 0.31 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: (M+H)⁺ = 486

(M+H+Na)⁺⁺ = 254.8

Example 66

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-
5 amide-hydrochloride

a) 1-Methyl-2-[2-(4-cyanophenyl)ethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-
amide

10 Prepared analogously to Example 25c from 3-(4-cyanophenyl)-
propionic acid and 3-amino-4-methylamino-benzoic acid-
N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide.

Yield: 67 % of theory,

IR Mass spectrum (KBr): characteristic bands at

15 3439.5 cm^{-1} (N-H); 2235.5 cm^{-1}
C \equiv N);

1631.6 cm^{-1} (C=O)

b) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
20 carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-
amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[2-(4-
cyanophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-
phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide and ethanolic
25 hydrochloric acid, ethanol and ammonium carbonate.

Yield: 92 % of theory,

C₂₇H₂₇N₉O (493.6)

EKA mass spectrum: (M+H)⁺ = 494

(M+Na)⁺ = 516

30 (M+2H)⁺⁺ = 258.7

Example 67

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 29 % of theory,

$C_{26}H_{26}N_{10}O$ (494.6)

EKA mass spectrum: $(M+H)^+ = 495$

Example 68

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-n-hexyloxycarbonyl)ethyl)-amide-hydrochloride

0.60 g (1.1 mMol) of 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonyl)ethyl)-amide-hydrochloride were added to about 30 ml of n-hexanol saturated with hydrogen chloride and the mixture was stirred for 19 hours at room temperature. Then the hexanol was distilled off *in vacuo*, the residue was mixed with about 5 ml of 1N ammonia solution with stirring and evaporated down once more. The crude product thus obtained was purified by column chromatography (silica gel, dichloromethane/methanol = 5:1).

Yield: 53 % of theory,

$C_{31}H_{37}N_7O_3$ (555.7)

R_f value: 0.36 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: $(M+H)^+ = 556$

Example 69

5 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

10 a) 1-Methyl-2-[N-(4-cyanophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide

Prepared analogously to Example 25c from N-(4-cyanophenyl)-
N-methylglycine and 3-amino-4-methylamino-benzoic acid-N-
(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide.

15 Yield: 71 % of theory,

R_f value: 0.66 (silica gel; dichloromethane/methanol =
19:1)

20 b) 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyanophenyl)-N-methyl-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
25 amide and ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 77 % of theory,

C₂₈H₃₁N₇O₃ (513.6)

EKA mass spectrum: $(M+H)^+ = 514$

30 $(M+H+Na)^{++} = 268.7$

Example 70

1-Methyl-2- [N- (4-amidinophenyl) -N-methyl-aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N- (2-
5 hydroxycarbonylethyl) -amide

Prepared analogously to Example 26 from 1-methyl-2- [N- (4-
amidinophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -
10 amide-hydrochloride and sodium hydroxide solution.

Yield: 66 % of theory,

$C_{26}H_{27}N_7O_3$ (485.6)

EKA mass spectrum: $(M+H)^+$ = 486
 $(M+Na)^+$ = 508
15 $(M+2Na)^{++}$ = 265.6

Example 71

1-Methyl-2- [2- (4-amidinophenyl) ethyl] -benzimidazol-5-yl-
20 carboxylic acid-N-cyclopentyl-N- (2-ethoxycarbonylethyl) -
amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2- [2- (4-
cyanophenyl) ethyl] -benzimidazol-5-yl-carboxylic acid-N-
25 cyclopentyl-N- (2-ethoxycarbonylethyl) -amide and ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 65 % of theory,

$C_{28}H_{35}N_5O_3$ (489.6)

EKA mass spectrum: $(M+H)^+$ = 490

Example 72

1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-
carboxylic acid-N-cyclopentyl-N-(2-hydroxycarbonylethyl)-
5 amide

Prepared analogously to Example 26 from 1-methyl-2-[2-(4-
amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-
cyclopentyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
10 and sodium hydroxide solution.

Yield: 89 % of theory,

C₂₆H₃₁N₅O₃ (461.6)

EKA mass spectrum: (M+H)⁺ = 462
(M+H+Na)⁺⁺ = 242.6
15 (M+Na)⁺ = 484
(M+2H)⁺⁺ = 231.6

Example 73

20 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-cyclopentyl-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
25 cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-cyclopentyl-N-(2-ethoxycarbonylethyl)-amide and
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 60 % of theory,

30 C₂₇H₃₄N₆O₃ (490.6)

EKA mass spectrum: (M+H)⁺ = 491

Example 74

1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5-yl-carboxylic acid-N-cyclopentyl-N- (2-
5 hydroxycarbonylethyl) -amide

Prepared analogously to Example 26 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
10 acid-N-cyclopentyl-N- (2-ethoxycarbonylethyl) -amide-
hydrochloride and sodium hydroxide solution.

Yield: 45 % of theory,

$C_{25}H_{30}N_3O_4$ (462.6)

EKA mass spectrum: $(M+H)^+$ = 463
 $(M+H+Na)^{++}$ = 243
15 $(M+Na)^+$ = 485
 $(M+2Na)^{++}$ = 254

Example 75

20 1-Methyl-2- [N- (4-amidinophenyl) -N-methyl-aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N-
(ethoxycarbonylmethyl) -amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2- [N- (4-
25 cyanophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
carboxylic acid-N- (2-pyridyl) -N- (ethoxycarbonylmethyl) -
amide and ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 54 % of theory,

30 $C_{27}H_{29}N_7O_3$ (499.6)

EKA mass spectrum: $(M+H)^+$ = 500
 $(M+2H)^{++}$ = 250.7

Example 76

1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-
5 (hydroxycarbonylmethyl)-amide

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-
amidinophenyl)-N-methyl-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(ethoxycarbonylmethyl)-
10 amide-hydrochloride and sodium hydroxide solution.

Yield: 68 % of theory,

$C_{25}H_{25}N_7O_3$ (471.5)

EKA mass spectrum: $(M+H)^+$ = 472

$(M+Na)^+$ = 494

15 $(M+2Na)^{++}$ = 258.6

Example 77

1-Methyl-2-[2-(4-amidinophenyl)-ethyl]-benzimidazol-5-yl-
20 carboxylic acid-N-(3-pyridyl)-N-(2-ethoxycarbonylethyl)-
amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[2-(4-
cyanophenyl)-ethyl]-benzimidazol-5-yl-carboxylic acid-N-(3-
25 pyridyl)-N-(2-ethoxycarbonylethyl)-amide and ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 91 % of theory,

$C_{28}H_{30}N_6O_3$ (498.6)

R_f value: 0.19 (silica gel; dichloromethane/ethanol = 4:1)

30 EKA mass spectrum: $(M+H)^+$ = 499

Example 78

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-(3-pyridyl)-N-(2-
5 ethoxycarbonylethyl)-amide-dihydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-(3-pyridyl)-N-(2-ethoxycarbonylethyl)-amide and
10 ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 86 % of theory,

$C_{27}H_{29}N_7O_3$ (499.6)

R_f value: 0.09 (silica gel; dichloromethane/ethanol = 4:1)

15 EKA mass spectrum: $(M+H)^+ = 500$

Example 79

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
20 5-yl-carboxylic acid-N-(3-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
25 acid-N-(3-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-
dihydrochloride and sodium hydroxide solution.

Yield: 85 % of theory,

$C_{25}H_{25}N_7O_3$ (471.5)

EKA mass spectrum: $(M+H)^+ = 472$

30 $(M+2H)^{++} = 236.6$

$(M+2Na)^{++} = 258.6$

Example 80

1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(3-pyridyl)-N-(2-
5 ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-Methyl-2-[N-(4-
cyanophenyl)-N-methyl-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(3-pyridyl)-N-(2-ethoxycarbonylethyl)-
10 amide and ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 64 % of theory,

$C_{28}H_{31}N_7O_3$ (513.6)

EKA mass spectrum: $(M+H)^+ = 514$

15

Example 81

1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(3-pyridyl)-N-(2-
20 hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-Methyl-2-[N-(4-
amidinophenyl)-N-methyl-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(3-pyridyl)-N-(2-ethoxycarbonylethyl)-
25 amide-hydrochloride and sodium hydroxide solution.

Yield: 70 % of theory,

$C_{26}H_{27}N_7O_3$ (485.6)

EKA mass spectrum: $(M+H)^+ = 486$

$(M+Na)^+ = 508$

30

$(M+2Na)^{++} = 265.6$

Example 82

1-Methyl-2- [N- (4-amidinophenyl) -N-methyl-aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-
5 ethoxycarbonylethyl) -amide-hydrochloride

a) 1-Methyl-2- [N- (4-cyanophenyl) -N-methyl-aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-pyridyl) -N-
(2-ethoxycarbonylethyl) -amide

10 Prepared analogously to Example 25c from N- (4-cyanophenyl) -
N-methylglycine and 3-amino-4-methylamino-benzoic acid-
N-phenyl-N- (2-ethoxycarbonylethyl) -amide.

Yield: 71 % of theory,

15 R_f value: 0.38 (silica gel; dichloromethane/methanol =
19:1)

b) 1-Methyl-2- [N- (4-amidinophenyl) -N-methyl-aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-
ethoxycarbonylethyl) -amide-hydrochloride

20 Prepared analogously to Example 25d from 1-methyl-2- [N- (4-
cyanophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide
and ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

25 Yield: 74 % of theory,

C₂₉H₃₂N₆O₃ (512.6)

EKA mass spectrum: (M+H)⁺ = 513

(M+H+Na)⁺⁺ = 268

(M+2H)⁺⁺ = 257

Example 83

1-Methyl-2- [N- (4-amidinophenyl) -N-methyl-aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-
5 hydroxycarbonylethyl) -amide

Prepared analogously to Example 26 from 1-methyl-2- [N- (4-
amidinophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide-
10 hydrochloride and sodium hydroxide solution.

Yield: 80 % of theory,

$C_{27}H_{28}N_6O_3$ (484.6)

EKA mass spectrum: (M+H)⁺ = 485
(M+H+Na)⁺⁺ = 254
15 (M+Na)⁺ = 507
(M+2Na)⁺ = 265

Example 84

20 1-ethyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-5-
yl-carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -
amide-hydrochloride

Prepared analogously to Example 25d from 1-ethyl-2- [N- (4-
25 cyanophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide and
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 85 % of theory,

30 $C_{28}H_{31}N_7O_3$ (513.6)

R_f value: 0.21 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: (M+H)⁺ = 514
(M+H+Na)⁺⁺ = 268.6
(M+2H)⁺⁺ = 257.7
35

Example 89

1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5-yl-carboxylic acid-N- (3-methylphenyl) -N- (2-
5 hydroxycarbonylethyl) -amide

Prepared analogously to Example 26 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (3-methylphenyl) -N- (2-ethoxycarbonylethyl) -amide-
10 hydrochloride and sodium hydroxide solution.

Yield: 62 % of theory,

C₂₇H₂₈N₆O₃ (484.6)

EKA mass spectrum: (M+H)⁺ = 485
(M+H+Na)⁺⁺ = 254
15 (M+Na)⁺ = 507
(M+2Na)⁺⁺ = 265

Example 90

20 1-Methyl-2- [N- [4- (N-n-hexyloxycarbonylamidino) phenyl] -
aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N-
(2-ethoxycarbonylethyl) -amide

1.1 g (2.06 mMol) of 1-methyl-2- [N- (4-amidinophenyl) -
25 aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N-
(2-ethoxycarbonylethyl) -amide-hydrochloride was dissolved
in a mixture of 40 ml of tetrahydrofuran and 10 ml of
water, then 570 mg (4.12 mMol) of potassium carbonate and
362 mg (2.2 mMol) of n-hexyl chloroformate were added and
30 stirred for two hours at room temperature. The solvent was
then distilled off, the residue was mixed with about 50 ml
of saturated saline solution and the resulting solution was
extracted three times with 20 ml of dichloromethane. The
extracts were dried over sodium sulphate and evaporated
35 down. The crude product thus obtained was purified by
column chromatography (100 g silica gel; dichloromethane +
5% ethanol).

Yield: 78 % of theory,

$C_{35}H_{42}N_6O_5$ (626.8)

R_f value: 0.49 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+$ = 627

5 $(M+H+Na)^{++}$ = 325

$(M+2H)^{++}$ = 314

Example 91

10 1-Methyl-2-[N-[4-(N-methoxycarbonylamidino)phenyl]-amino-
methyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
15 amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
and methyl chloroformate.

Yield: 41 % of theory,

$C_{30}H_{32}N_6O_5$ (556.6)

20 R_f value: 0.85 (silica gel; dichloromethane/ethanol = 4:1)

EKA mass spectrum: $(M+H)^+$ = 557

$(M+H+Na)^{++}$ = 290

$(M+Na)^+$ = 579

25 Example 92

1-Methyl-2-[N-[4-(N-ethoxycarbonylamidino)phenyl]-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-
(2-methoxycarbonylethyl)-amide

30 Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-
hydrochloride and ethyl chloroformate.

35 Yield: 62 % of theory,

$C_{30}H_{32}N_6O_5$ (556.6)

R_f value: 0.51 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: (M+H)⁺ = 557

(M+H+Na)⁺⁺ = 290

(M+2H)⁺⁺ = 279

5

Example 93

1-Methyl-2-[N-[4-(N-cyclohexyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

10

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-

15 hydrochloride and cyclohexyl chloroformate.

Yield: 25 % of theory,

C₃₄H₃₈N₆O₅ (610.7)

R_f value: 0.44 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: (M+H)⁺ = 611

20

(M+2H)⁺⁺ = 306

Example 94

1-Methyl-2-[N-[4-[N-[2-(methylsulphonyl)ethyloxycarbonyl]-amidino]phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

25

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic

30 acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and 2-(methylsulphonyl)-ethyl chloroformate.

Yield: 66 % of theory,

C₃₂H₃₆N₆O₇S (648.8)

R_f value: 0.44 (silica gel; dichloromethane/ethanol = 19:1)

35 EKA mass spectrum: (M+H)⁺ = 649

(M+H+Na)⁺⁺ = 336

$$(M+2H)^{++} = 325$$

Example 95

- 5 1-Methyl-2-[N-[4-(N-n-octyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

10 Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-hydrochloride and n-octyl chloroformate.

Yield: 41 % of theory,

$C_{36}H_{44}N_6O_5$ (640.8)

- 15 R_f value: 0.43 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+ = 641$

$(M+Na)^+ = 663$

Example 96

20

1-Methyl-2-[N-[4-(N-hydroxylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

-
- 25 1.44 g (3.0 mMol) of 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide, 0.625 g (9.0 mMol) of hydroxylamine hydrochloride and 0.425 g (4.0 mMol) of sodium carbonate were dissolved in 80 ml of ethanol and
- 30 refluxed for 7 hours. Then a further 210 mg of hydroxylamine hydrochloride and 170 mg of sodium carbonate were added, the mixture was boiled for a further 5 hours and then evaporated down *in vacuo*. The residue was
- 35 dissolved in about 30 ml of dichloromethane, the solution obtained was washed with 20 ml of water, the organic phase was dried and evaporated down. The crude product thus

obtained was purified by column chromatography (200 g silica gel, dichloromethane + 4% ethanol).

Yield: 39 % of theory,

$C_{28}H_{30}N_6O_4$ (514.6)

5 R_f value: 0.15 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+$ = 515

$(M+Na)^+$ = 537

$(2M+H)^+$ = 1029

$(2M+Na)^+$ = 1051

10

Example 97

1-Methyl-2-[N-[4-(N-n-heptyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

15

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-

20 hydrochloride and n-heptyl chloroformate.

Yield: 43 % of theory,

$C_{35}H_{42}N_6O_5$ (626.8)

R_f value: 0.40 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+$ = 627

25 $(M+H+Na)^{++}$ = 325

$(M+Na)^+$ = 649

Example 98

30 1-Methyl-2-[N-[4-(N-benzoylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

35 Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic

acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-
hydrochloride and benzoyl chloride.

Yield: 88 % of theory,

$C_{34}H_{32}N_6O_4$ (588.7)

- 5 R_f value: 0.37 (silica gel; dichloromethane/ethanol = 19:1)
 1H -NMR spectrum (D_6 -DMSO): 2.61 (t,2H), 3.54 (s,3H), 3.76
(s,3H), 4.10 (t,2H), 4.61 (d,2H), 6.83 (d,2H), 7.05 to 7.55
(m,12H), 8.03 (d,2H), 8.25 (dd,2H), 8.98 (s,1H), 10.48
(s,1H)

10

Example 99

- 1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-
15 (2-methoxycarbonylethyl)-amide

-
- Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-
20 hydrochloride and n-hexyl chloroformate.

Yield: 54 % of theory,

$C_{34}H_{40}N_6O_5$ (612.7)

R_f value: 0.45 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+ = 613$

25

Example 100

- 1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-
30 (2-n-propyloxycarbonylethyl)-amide

-
- Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-n-propyloxycarbonylethyl)-amide-
35 hydrochloride and n-hexyl chloroformate.

Yield: 31 % of theory,

C₃₆H₄₄N₆O₅ (640.8)

R_f value: 0.42 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: (M+H)⁺ = 641

(M+H+Na)⁺⁺ = 332

5 (M+Na)⁺ = 663

Example 101

10 1-Methyl-2-[N-[4-(N-ethoxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
15 acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide-hydrochloride and ethyl chloroformate.

Yield: 72 % of theory,

C₂₉H₃₁N₇O₅ (557.6)

20 R_f value: 0.58 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 558

(M+H+Na)⁺⁺ = 290.8

(M+Na)⁺ = 580

25 Example 102

1-Methyl-2-[N-[4-(N-n-octyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide

30 Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide-hydrochloride and n-octyl chloroformate.

35 Yield: 57 % of theory,

C₃₅H₄₃N₇O₅ (641.8)

R_f value: 0.60 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 642

(M+H+Na)⁺⁺ = 332.8

(M+Na)⁺ = 664

5

Example 103

1-Methyl-2-[N-[4-(N-methoxycarbonylamidino)phenyl]-amino-
methyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-
10 N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-
15 hydrochloride and methyl chloroformate.

Yield: 48 % of theory,

C₂₉H₃₁N₇O₅ (557.6)

R_f value: 0.62 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 558

20 (M+H+Na)⁺⁺ = 290.7

(M+Na)⁺ = 580

Example 104

25 1-Methyl-2-[N-[4-(N-n-octyloxycarbonylamidino)phenyl]-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-
pyridyl)-N-(2-hydroxycarbonylethyl)-amide

0.7 g (1.1 mMol) of 1-methyl-2-[N-[4-(N-n-
30 octyloxycarbonylamidino)-phenyl]-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
methoxycarbonylethyl)-amide was stirred in a mixture of
0.12 g (3.0 mMol) of sodium hydroxide, 5 ml of water and
10 ml of methanol for one hour at room temperature. Then
35 the mixture was diluted with 20 ml of water and adjusted to
pH 6 with glacial acetic acid. Then about 5 ml of

diethylether were added and the mixture was vigorously stirred for one hour. The product thus precipitated was suction filtered, washed with a little water, then with diethylether and dried.

5 Yield: 80 % of theory,

$C_{34}H_{41}N_7O_5$ (627.8)

EKA mass spectrum: $(M+H)^+ = 628$

$(M+H+Na)^{++} = 325.7$

$(M+Na)^+ = 650$

10 $(M+2Na)^{++} = 337.7$

Example 105

1-Methyl-2-[N-[4-[N-(2-methylsulphonyl-
15 ethyloxycarbonyl)amidino]-phenyl]-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-
N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
20 amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-
hydrochloride and 2-(methylsulphonyl)-ethyl chloroformate.
Yield: 65 % of theory,

$C_{31}H_{35}N_7O_7S$ (649.7)

25 R_f value: 0.54 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 650$

$(M+H+Na)^{++} = 336.6$

$(M+Na)^+ = 672$

$(M+2Na)^{++} = 347.6$

30

Example 106

1-Methyl-2-[N-[4-(N-n-butyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide-hydrochloride and n-butyl chloroformate.

Yield: 30 % of theory,

$C_{31}H_{35}N_7O_5$ (585.7)

R_f value: 0.62 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 586$
 $(M+H+Na)^{++} = 304.7$
 $(M+2H)^{++} = 293.7$

Example 107

1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide-hydrochloride and n-hexyl chloroformate.

Yield: 51 % of theory,

$C_{33}H_{39}N_7O_5$ (613.7)

R_f value: 0.56 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 614$
 $(M+H+Na)^{++} = 318.7$
 $(M+2H)^{++} = 307.6$

Example 108

1-Methyl-2- [N- [4- (N-n-heptyloxycarbonylamidino) -phenyl] -
aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-
5 pyridyl) -N- (2-methoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (2-methoxycarbonylethyl) -amide-
10 hydrochloride and n-heptyl chloroformate.
Yield: 21 % of theory,
 $C_{34}H_{41}N_7O_5$ (627.8)
 R_f value: 0.60 (silica gel; dichloromethane/methanol = 9:1)
EKA mass spectrum: $(M+H)^+$ = 628
15 $(M+H+Na)^{++}$ = 325.7
 $(M+2H)^{++}$ = 314.7

Example 109

20 1-Methyl-2- [N- [4- (N-n-pentyloxycarbonylamidino) -phenyl] -
aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-
pyridyl) -N- (2-methoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
25 amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (2-methoxycarbonylethyl) -amide-
hydrochloride and n-pentyl chloroformate.
Yield: 66 % of theory,
 $C_{32}H_{37}N_7O_5$ (599.7)
30 R_f value: 0.58 (silica gel; dichloromethane/methanol = 9:1)
EKA mass spectrum: $(M+H)^+$ = 600
 $(M+H+Na)^{++}$ = 311.7
 $(M+Na)^+$ = 622

Example 110

1-Methyl-2-[N-[4-(N-n-nonyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide-hydrochloride and n-nonyl chloroformate.

Yield: 60 % of theory,

$C_{36}H_{45}N_7O_5$ (655.8)

R_f value: 0.48 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 656$
 $(M+H+Na)^{++} = 339.8$
 $(M+Na)^+ = 678$

Example 111

1-Methyl-2-[N-[4-(N-benzoylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonylethyl)-amide-hydrochloride and benzoyl chloride.

Yield: 62 % of theory,

$C_{33}H_{31}N_7O_4$ (589.7)

R_f value: 0.50 (silica gel; dichloromethane/methanol = 9:1)
EKA mass spectrum: $(M+H)^+ = 590$
 $(M+Na)^+ = 612$

Example 112

1-Methyl-2- [N- [4- (N-nicotinoylamidino)phenyl] aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N- (2-
5 methoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (2-methoxycarbonylethyl) -amide-
10 hydrochloride and nicotinic acid chloride.

Yield: 40 % of theory,

$C_{32}H_{30}N_8O_4$ (590.7)

R_f value: 0.47 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 591
15 (M+H+Na)⁺⁺ = 307
(M+Na)⁺ = 613

Example 113

20 1-Methyl-2- [N- [4- (N-n-hexyloxycarbonylamidino)phenyl] -
aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-
pyridyl) -N- (2-ethoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
25 amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide-
hydrochloride and n-hexyl chloroformate.

Yield: 51 % of theory,

$C_{34}H_{41}N_7O_5$ (627.8)

30 R_f value: 0.53 (silica gel; dichloromethane/methanol = 9:1)
EKA mass spectrum: (M+H)⁺ = 628
(M+H+Na)⁺⁺ = 325.7
(M+2H)⁺⁺ = 314.7

Example 114

1-Methyl-2- [N- [4- (N-n-octyloxycarbonylamidino)phenyl] -
aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-
5 pyridyl) -N- (2-ethoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide-
10 hydrochloride and n-octyl chloroformate.

Yield: 57 % of theory,

$C_{36}H_{45}N_7O_5$ (655.8)

R_f value: 0.46 (silica gel; dichloromethane/methanol
= 9:1)

15 EKA mass spectrum: $(M+H)^+$ = 656
 $(M+H+Na)^{++}$ = 339.7
 $(M+2H)^{++}$ = 328.7

Example 115

20

1-Methyl-2- [N- [4- [N- (2-methylsulphonyl -
ethyloxycarbonyl)amidino] -phenyl] -aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N-
ethoxycarbonylmethyl-amide

25

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N-ethoxycarbonylmethyl-amide-
hydrochloride and 2- (methylsulphonyl) -ethyl chloroformate.

30 Yield: 72 % of theory,

$C_{30}H_{33}N_7O_7S$ (635.7)

R_f value: 0.23 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+$ = 636
 $(M+H+Na)^{++}$ = 329.8

35

Example 116

1-Methyl-2-[N-[4-(N-cyclohexyloxycarbonylamidino)-
phenyl]aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-
5 pyridyl)-N-methoxycarbonylmethyl-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-(2-pyridyl)-N-methoxycarbonylmethyl-amide-
10 hydrochloride and cyclohexyl chloroformate.

Yield: 40 % of theory,

$C_{32}H_{35}N_7O_5$ (597.7)

R_f value: 0.26 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+ = 598$

15 $(M+Na)^+ = 620$

Example 117

1-Methyl-2-[N-[4-(N-methoxycarbonylamidino)-phenyl]-
20 aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-
pyridyl)-N-ethoxycarbonylmethyl-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
25 acid-N-(2-pyridyl)-N-ethoxycarbonylmethyl-amide-
hydrochloride and methyl chloroformate.

Yield: 62 % of theory,

$C_{28}H_{29}N_7O_5$ (543.6)

R_f value: 0.19 (silica gel; dichloromethane/ethanol = 19:1)

30 EKA mass spectrum: $(M+H)^+ = 544$

$(M+H+Na)^{++} = 283.8$

$(M+Na)^+ = 566$

Example 118

1-Methyl-2- [N- [4- (N-ethoxycarbonylamidino) -phenyl] -amino-
methyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N-
5 methoxycarbonylmethyl-amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (2-pyridyl) -N-methoxycarbonylmethyl-amide-
10 hydrochloride and ethyl chloroformate.
Yield: 42 % of theory,
 $C_{28}H_{29}N_7O_5$ (543.6)
 R_f value: 0.20 (silica gel; dichloromethane/ethanol = 19:1)
EKA mass spectrum: $(M+H)^+ = 544$

15

Example 119

1-Methyl-2- [N- [4- (N-n-octyloxycarbonyl-amidino) -
phenyl] aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (3-
20 pyridyl) -N- (2-ethoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
acid-N- (3-pyridyl) -N- (2-ethoxycarbonylethyl) -amide-
25 hydrochloride and n-octyl chloroformate.
Yield: 35 % of theory,
 $C_{36}H_{45}N_7O_5$ (655.8)
 R_f value: 0.28 (silica gel; dichloromethane/ethanol = 19:1)
EKA mass spectrum: $(M+H)^+ = 656$
30 $(M+2H)^{++} = 328.7$

Example 120

1-Methyl-2- [N- [4- (N-n-hexyloxycarbonylamidino) -phenyl] -
N-methyl-aminomethyl] -benzimidazol-5-yl-carboxylic acid-
5 N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -
10 amide-hydrochloride and n-hexyl chloroformate.

Yield: 58 % of theory,

$C_{35}H_{43}N_7O_5$ (641.2)

R_f value: 0.42 (silica gel; dichloromethane/ethanol = 19:1)

EKA mass spectrum: $(M+H)^+$ = 642

15 $(M+H+Na)^{++}$ = 332.7

Example 121

1-Methyl-2- [N- [4- (N-n-octyloxycarbonylamidino) -phenyl] -
20 N-methyl-aminomethyl] -benzimidazol-5-yl-carboxylic acid-
N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
25 carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -
amide-hydrochloride and n-octyl chloroformate.

Yield: 36 % of theory,

$C_{37}H_{47}N_7O_5$ (669.8)

EKA mass spectrum: $(M+H)^+$ = 670

30 $(M+H+Na)^{++}$ = 346.8

$(M+2H)^{++}$ = 335.6

Example 122

1-Methyl-2- [N- [4- (N-n-butyloxycarbonylamidino) -phenyl] -
N-methyl-aminomethyl] -benzimidazol-5-yl-carboxylic acid-
5 N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -
10 amide-hydrochloride and n-butyl chloroformate.

Yield: 34 % of theory,

$C_{33}H_{39}N_7O_5$ (613.7)

EKA mass spectrum: $(M+H)^+$ = 614

$(M+H+Na)^{++}$ = 318.7

15 $(M+Na)^+$ = 636

Example 123

1-Methyl-2- [N- [4- (N-benzoylamidino)phenyl] -N-methyl-amino-
20 methyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -
N- (2-ethoxycarbonylethyl) -amide

Prepared analogously to Example 90 from 1-methyl-2- [N- (4-
amidinophenyl) -N-methyl-aminomethyl] -benzimidazol-5-yl-
25 carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -
amide-hydrochloride and benzoyl chloride.

Yield: 63 % of theory,

$C_{35}H_{35}N_7O_4$ (617.7)

EKA mass spectrum: $(M+H)^+$ = 618

30 $(M+H+Na)^{++}$ = 320.7

$(M+Na)^+$ = 640

Example 124

1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-
(1-ethoxycarbonylmethyl-cyclohex-1-yl)-ketone-hydrochloride

5

a) 4-Chlorophenyl-(1-hydroxycarbonylmethyl-cyclohex-1-yl)-
ketone

8.4 g (40 mMol) of 3-(4-chlorobenzoyl)-propionic acid were
dissolved in 300 ml of tetrahydrofuran and 5.8 g (120 mMol)
10 of sodium hydride (50-60% suspension in paraffin oil) were
added in batches. Then the mixture was refluxed for 1.5
hours with stirring, after which 8.9 ml (60 mMol) of 1,5-
diiodopentane were added dropwise and boiling was continued
for a further three hours. After cooling the solution was
15 stirred into 200 ml of ice-water, then the tetrahydrofuran
was distilled off *in vacuo*, the resulting aqueous solution
was acidified with 2N hydrochloric acid and extracted three
times with 150 ml of dichloromethane. The organic phase
was dried and evaporated down, the crude product thus
20 obtained was purified by column chromatography (500 g
silica gel; eluant: dichloromethane with 1-2% ethanol).
Yield: 6.2 g (55% of theory) of oily product,
 $C_{15}H_{17}ClO_3$ (280.8)

R_f value: 0.56 (silica gel; dichloromethane/ethanol = 19:1)

25

b) 4-Chloro-3-nitrophenyl-(1-hydroxycarbonylmethyl-
cyclohex-1-yl)-ketone

7.0 g (25 mMol) of 4-chlorophenyl-(1-hydroxycarbonyl-
methylcyclohex-1-yl)-ketone were added in batches, with
30 stirring, at -5 to -10°C, to 80 ml of fuming nitric acid.
The solution was then stirred for a further 10 minutes,
then stirred into 200 ml of ice-water, the precipitated
product was then washed with water and dried.
Yield: 7.8 g (96% of theory),
35 $C_{15}H_{16}ClNO_5$ (325.8)

R_f value: 0.41 (silica gel; petroleum ether/ethyl acetate
4:6)

c) 4-Methylamino-3-nitrophenyl-(1-hydroxycarbonylmethyl-cyclohex-1-yl)-ketone

7.8 g (23.9 mMol) of 4-chloro-3-nitrophenyl-(1-hydroxycarbonylmethyl-cyclohex-1-yl)-ketone were stirred in 100 ml of a 40% aqueous methylamine solution at room temperature for 14 hours, then diluted with about 150 ml of water and made slightly acidic with glacial acetic acid. The precipitated product was suction filtered, washed with water and dried.

Yield: 7.1 g (93% of theory),

$C_{16}H_{20}N_2O_5$ (320.4)

R_f value: 0.34 (silica gel; dichloromethane/ethanol = 19:1)

d) 4-Methylamino-3-nitrophenyl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone

4.9 g (15 mMol) of 4-methylamino-3-nitrophenyl-(1-hydroxycarbonylmethyl-cyclohex-1-yl)-ketone were dissolved in 100 ml of tetrahydrofuran, 2.4 g (15 mMol) of 1,1'-carbonyl-diimidazole were added and the mixture was refluxed for 15 minutes. Then the solvent was evaporated off, 30 ml of methanol were added and the mixture was boiled for three hours with stirring. After the methanol had been distilled off the crude product thus obtained was purified by column chromatography (250 g silica gel, eluant: dichloromethane with 1 to 5% ethanol).

Yield: 2.4 g (48% of theory),

$C_{17}H_{22}N_2O_5$ (334.4)

R_f value: 0.76 (silica gel; dichloromethane/ethanol = 19:1)

e) 3-Amino-4-methylaminophenyl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone

2.4 g (7.2 mMol) of 4-methylamino-3-nitrophenyl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone were catalytically hydrogenated in 100 ml of methanol at room temperature under 5 bar hydrogen pressure (10% palladium on

charcoal). The crude product thus obtained was further reacted without purification.

Yield: 2.1 g (96% of theory),

R_f value: 0.34 (silica gel; dichloromethane/ethanol = 19:1)

5

f) 3-(4-Cyanophenyloxyacetyl-amino)-4-methylaminophenyl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone

620 mg (3.5 mMol) of 4-cyanophenyloxyacetic acid and 570 mg (3.5 mMol) of 1,1'-carbonyl-diimidazole were refluxed in 50 ml of tetrahydrofuran for 15 minutes. Then 1.0 g (3.28 mMol) of 3-amino-4-methylaminophenyl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone were added and the mixture was boiled for a further 4 hours. Then the solvent was evaporated off and the crude product thus obtained was purified by column chromatography (150 g silica gel; eluant: dichloromethane with 0 to 2% ethanol).

Yield: 1.4 g (93% of theory),

C₂₆H₂₉N₃O₅ (463.5)

R_f value: 0.44 (silica gel; dichloromethane/ethanol = 19:1)

20

g) 1-Methyl-2-[(4-cyanophenyl)oxymethyl]-benzimidazol-5-yl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone

1.4 g (3.02 mMol) of 3-(4-cyanophenyloxyacetyl-amino)-4-methylaminophenyl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone were refluxed in 50 ml of glacial acetic acid for one hour. Then the glacial acetic acid was distilled off, the residue was mixed with 20 ml of water and made alkaline with concentrated ammonia. This solution was extracted three times with 20 ml of dichloromethane, the organic extracts were dried and evaporated down. The crude product thus obtained was purified by column chromatography (100 g silica gel; eluant: dichloromethane with 0 to 2% ethanol). Yield: 700 mg (52% of theory),

C₂₆H₂₇N₃O₄ (445.5)

35

h) 1-Methyl-2-[(4-amidinophenyl)oxymethyl]-benzimidazol-5-yl-(1-ethoxycarbonylmethyl-cyclohex-1-yl)-ketone-hydrochloride

Prepared analogously to Example 25d from 700 mg (1.57 mMol)
5 of 1-methyl-2-(4-cyanophenyloxymethyl)-benzimidazol-5-yl-(1-methoxycarbonylmethyl-cyclohex-1-yl)-ketone with ethanolic hydrochloric acid and ammonium carbonate.
Yield: 390 mg (50% of theory),
C₂₇H₃₂N₄O₄ (476.6)

10 EKA mass spectrum: (M+H)⁺ = 477

¹H-NMR spectrum(d₆-DMSO): 1.10 (t,3H); 1.0-2.15 (m,10H);
3.36 (s,3H); 3.90 (s,2H); 3.94 (q,2H); 5.60 (s,2H);
7.25-7.40 (m,3H); 7.56-7.75 (m,2H); 7.90 (d,2H); 9.20
(broad s,4H) ppm.

15

Example 125

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-tert.butyl-ketone-hydrochloride

20

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-tert.butyl-ketone, ethanolic hydrochloric acid, ethanol and ammonium carbonate.

25 Yield: 59 % of theory,

C₂₁H₂₅N₅O (363.5)

EKA mass spectrum: (M+H)⁺ = 364

Example 126

30

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-(1-methylcyclopent-1-yl)-ketone-hydrochloride

35

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-(1-

methylcyclopent-1-yl)-ketone, ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 63.5 % of theory,

C₂₃H₂₇N₅O (389.5)

5 EKA mass spectrum: (M+H)⁺ = 390

Example 127

2-[(4-amidinophenyl)sulphinylmethyl]-benzothiazol-5-yl-
10 carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-
hydrochloride

A solution of 0.15 g (0.27 mMol) of 2-[(4-
amidinophenyl)thiomethyl]-benzothiazol-5-yl-carboxylic
15 acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
in 10 ml of acetic acid was mixed with 0.09 ml (about 0.81
mMol) of 30% hydrogen peroxide solution and stirred at room
temperature. After 4 days a further 0.18 ml of hydrogen
peroxide solution was added and the resulting mixture was
20 stirred for a further two days. After removal of the
solvent *in vacuo* the crude product obtained was purified by
flash chromatography (silica gel; methylene
chloride/ethanol = 10:1 to 4:1).

Yield: 58 % of theory,

25 C₂₇H₂₆N₄O₄S₂ (534.66)

R_f value: 0.24 (silica gel; methylene chloride/ethanol
= 4:1

+ a few drops of acetic acid)

EKA mass spectrum: (M+H)⁺ = 535

30

Example 128

1-Methyl-2-[(4-amidinophenyl)sulphonylmethyl]-benzimidazol-
5-yl-carboxylic acid-N-(n-propyl)-N-(2-
35 ethoxycarbonylethyl)-amide-hydrochloride

26820-06952060

A solution of 0.40 g (0.70 mMol) of 1-methyl-2-[(4-amidinophenyl)thiomethyl]-benzimidazol-5-yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride in 10 ml of formic acid was mixed with 2 ml
5 of 30% hydrogen peroxide solution and the mixture was stirred for 16 hours at room temperature. Then the solvent was distilled off *in vacuo*, whereupon the desired compound was obtained as a beige solid (contaminated with some 1-methyl-2-[(4-amidinophenyl)sulfinylmethyl]-benzimidazol-
10 5-yl-carboxylic acid-N-(n-propyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride).
Yield: 95 % of theory,
C₂₅H₃₁N₆O₅S (513.62)
R_f value: 0.50 (silica gel; ethyl acetate/ethanol/1N
15 hydrochloric acid
= 50:45:5)
EKA mass spectrum: (M+H)⁺ = 514

Example 129

20 2-[N-(4-amidinophenyl)-aminomethyl]-thiazolo[5,4-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

25 a) Methyl 5-amino-6-chloro-nicotinate

A solution of 1.08 g (5.00 mMol) of methyl 6-chloro-5-nitro-nicotinate (see A.H. Berrie, G.T. Newbold, F.S. Spring in J. Chem. Soc., 2590, 1951) in 25 ml of absolute ethanol was mixed successively with 0.53 ml (29 mMol) of
30 water, 3.2 g (57 mMol) of iron powder and 0.030 ml of concentrated hydrochloric acid and heated to boiling for one hour. Then equal quantities of water, iron powder and hydrochloric acid were added and the mixture was heated to boiling for 30 minutes. The precipitate formed on cooling
35 was filtered off and washed with ethanol and the solvent was distilled off *in vacuo*.

Yield: 0.75 g (81% of theory) of greenish-yellow solid,
R_f value: 0.31 (silica gel; ethyl acetate/petroleum ether =
1:4)

C₇H₇ClN₂O₂ (186.60)

5 YEF- Mass spectrum: M⁺ = 186 and 188 (chlorine isotopes).

b) Methyl 6-chloro-5-methoxyacetamido-nicotinate

10 A solution of 0.75 g (4.02 mMol) of methyl 5-amino-6-chloro-nicotinate and 0.43 g = 0.35 ml (4.5 mMol) of methoxyacetylchloride in 20 ml of chlorobenzene was stirred for one hour at 110°C. After the solvent had been removed
15 in vacuo the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol = 100:1), evaporated down again in vacuo and then digested with petroleum ether.

Yield: 0.55 g (53% of theory) light yellow amorphous solid,
R_f value: 0.33 (silica gel; ethyl acetate/petroleum ether =
20 1:4)

c) Methyl 2-methoxymethyl-thiazolo[5,4-b]pyridin-6-yl-carboxylate

A mixture of 0.53 g (2.05 mMol) of methyl 6-chloro-5-methoxyacetamido-nicotinate and 0.42 g (1.0 mMol) of
25 Lawessons reagent was refluxed for 16 hours in 25 ml of xylene. After the solvent had been removed in vacuo the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol = 100:1) and
30 evaporated down again in vacuo.

Yield: 0.33 g (67% of theory) of yellow amorphous solid,
R_f value: 0.52 (silica gel; ethyl acetate/petroleum ether =
1:4)

35 d) 2-Methoxymethyl-thiazolo[5,4-b]pyridin-6-yl-carboxylic acid

A mixture of 1.1 g (4.62 mMol) of methyl 2-methoxymethyl-thiazolo[5,4-b]pyridine-6-carboxylate and 9.2 ml of 2N sodium hydroxide solution were stirred into 50 ml of ethanol for one hour at room temperature. Then 9.2 ml of 2N hydrochloric acid were added, the alcohol was distilled off, and it was diluted with 20 ml of water. The aqueous phase was acidified with concentrated hydrochloric acid whilst cooling with ice, the beige precipitate formed was filtered off, then washed with water and dried.

Yield: 1.03 g (100% of theory),
R_f value: 0.10 (silica gel; ethyl acetate/petroleum ether = 3:7)

e) 2-Methoxymethyl-thiazolo[5,4-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

A suspension of 1.03 g (4.62 mMol) of 2-methoxymethyl-thiazolo[5,4-b]pyridin-6-yl-carboxylic acid in 40 ml of methylene chloride was mixed with 1.6 g = 1.0 ml (13.5 mMol) of thionyl chloride and refluxed for 90 minutes, during which time the solid gradually dissolved. After the liquid components had been distilled off the crude product was taken up twice more in methylene chloride and concentrated again. The resulting crude acid chloride (1.2 g) was taken up in 40 ml of tetrahydrofuran, added dropwise to a mixture of 0.94 g (4.86 mMol) of N-(2-ethoxycarbonylethyl)aniline and 2.1 ml (13.8 mMol) of triethylamine in 30 ml of tetrahydrofuran and stirred for 2 hours at room temperature. Then it was diluted with 200 ml of ethyl acetate, washed with 100 ml of 14% saline solution and the organic phase was dried with sodium sulphate. After the solvent had been removed *in vacuo* the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol = 100:1).
Yield: 1.57 g (87% of theory) of yellow oil,
R_f value: 0.55 (silica gel; methylene chloride/ethanol = 19:1)

f) 2-[N-(4-Cyanophenyl)-aminomethyl]-thiazolo[5,4-b]-pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

A mixture of 1.54 g (3.85 mMol) of 2-methoxymethyl-
5 thiazolo[5,4-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide and 4.3 ml (4.3 mMol) of a 1 molar solution of boron tribromide in methylene chloride was dissolved in a further 30 ml of methylene chloride and stirred for 5 hours at room temperature. Then the mixture
10 was washed with 40 ml of saturated sodium hydrogen carbonate solution, the organic phase was dried with sodium sulphate and the solvent was distilled off. The crude product (1.9 g) was taken up in 15.0 ml of N,N-diisopropylethylamine, mixed with 0.50 g (4.2 mMol) of
15 4-aminobenzonitrile and heated to boiling for one hour. Then the solvent was distilled off *in vacuo*, the crude product was taken up in 100 ml of methylene chloride, the organic phase was washed with 100 ml of water and dried with sodium sulphate. After the solvent had been removed
20 *in vacuo* the crude product obtained was purified by flash chromatography (silica gel; ethyl acetate/petroleum ether = 35:65 to 1:1) and evaporated down again *in vacuo*.
Yield: 0.45 g (24% of theory) of yellow amorphous solid,
R_f value: 0.34 (silica gel; ethyl acetate/petroleum ether =
25 1:1)

g) 2-[N-(4-amidinophenyl)-aminomethyl]-thiazolo[5,4-b]-pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

30 0.39 g (0.803 mMol) of 2-[N-(4-cyanophenyl)-aminomethyl]-thiazolo[5,4-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide were stirred in 40 ml of ethanol saturated with hydrogen chloride for 5 hours first at 0°C and then at room temperature, until no more starting
35 material could be detected by thin layer chromatography. Then the solvent was distilled off at a maximum bath temperature of 30°C, the oily residue was taken up in 40 ml

of absolute ethanol and mixed with 0.5 g ammonium carbonate. After 18 hours the solvent was removed *in vacuo* and the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol =

5 9:1 to 4:1).

Yield: 78 % of theory of yellow foam,

$C_{26}H_{26}N_6O_3S$ (502.60)

R_f value: 0.19 (silica gel; methylene chloride/ethanol
= 4:1

10 + a few drops of acetic acid)

EKA mass spectrum: $(M+H)^+ = 503$

Example 130

15 1-Methyl-2-[(4-amidinophenyl)methylthio]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

a) 1-Methyl-2-mercapto-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

20 A solution of 6.5 g (19 mMol) of 3-amino-4-methylamino-benzoic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide and 4.5 g (22.8 mMol) of N,N'-thiocarbonyldiimidazole were dissolved in 100 ml of tetrahydrofuran under a nitrogen
25 atmosphere, the solution was heated to 90°C for 4 hours and left to stand for 16 hours at room temperature. After removal of the solvent *in vacuo* the crude product obtained was purified by flash chromatography (silica gel; petroleum ether/ethyl acetate = 100:0 to 65:35).

30 Yield: 6.8 g (93 % of theory) of beige crystalline solid,
 R_f value: 0.55 (silica gel; ethyl acetate)

b) 1-Methyl-2-[(4-cyanophenyl)methylthio]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

35 A solution of 1.30 g (3.4 mMol) of 1-methyl-2-mercapto-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide, 0.52 g (3.74 mMol) of potassium

carbonate and 0.66 g (3.4 mMol) of 4-bromo-methylbenzonitrile were dissolved in 40 ml of absolute ethanol, stirred for 4 hours at 60°C and 16 hours at room temperature. Then the solvent was distilled off *in vacuo*,
5 the crude product was taken up in 30 ml of methylene chloride, washed with 40 ml of water and dried with sodium sulphate. After filtration and distillation of the solvent the desired compound was obtained as a beige-white solid. Yield: 1.8 g (100 % of theory),
10 R_f value: 0.64 (silica gel; ethyl acetate)

c) 1-Methyl-2-[(4-amidinophenyl)methylthio]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

15 1.5 g (3.0 mMol) of 1-methyl-2-[(4-cyanophenyl)methylthio]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide were stirred in 80 ml of ethanol saturated with hydrogen chloride for 6.5 hours first at 0°C, then at room temperature, until no more starting
20 material could be detected by thin layer chromatography. Then the solvent was distilled off at a maximum bath temperature of 30°C, the oily residue taken up in 80 ml of absolute ethanol and mixed with 1.0 g (10.5 mMol) of ammonium carbonate. After 18 hours the solvent was
25 distilled off *in vacuo* and the crude product obtained was purified by flash chromatography (silica gel; methylene chloride/ethanol = 19:1 to 10:1). Yield: 78 % of theory of light beige solid,
 $C_{28}H_{29}N_5O_3S$ (515.63)
30 R_f value: 0.19 (silica gel; methylene chloride/ethanol = 4:1)

EKA mass spectrum: $(M+H)^+$ = 516
 $(M+H+Na)^{++}$ = 269.7
 $(M+2H)^{++}$ = 258.7

35

Example 131

1-Methyl-2-[(4-amidinophenyl)methylthio]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-
5 hydrochloride

Prepared analogously to Example 10 from 1-methyl-2-[(4-
amidinophenyl)methylthio]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
10 and sodium hydroxide solution.

Yield: 57 % of theory,

$C_{26}H_{25}N_5O_3S$ (487.58)

R_f value: 0.23 (Reversed Phase silica gel RP-8; Methanol/5%
saline solution = 6:4)

15 EKA mass spectrum: $(M+H)^+$ = 488
 $(M+Na)^+$ = 510
 $(M+Na+H)^{++}$ = 255.6

Example 132

20

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-propargyl-N-(2-ethoxycarbonylethyl)-
amide-hydrochloride

25 Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-propargyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 81 % of theory,

30 $C_{25}H_{28}N_6O_3$ (460.6)

R_f value: 0.094 (silica gel; dichloromethane/ethanol = 4:1)

EKA mass spectrum: $(M+H)^+$ = 461
 $(M+H+Na)^{++}$ = 242
 $(M+2H)^{++}$ = 231

35

Example 133

1-Methyl-2-[2-[4-(N-n-hexyloxycarbonylamidino)phenyl]ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and n-hexyl chloroformate.

Yield: 72 % of theory,

$C_{35}H_{42}N_6O_5$ (626.8)

R_f value: 0.54 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 627$

$(M+Na)^+ = 649$

Example 134

1-Methyl-2-[2-[4-(N-benzoylamidino)phenyl]ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and benzoyl chloride.

Yield: 79 % of theory,

$C_{35}H_{34}N_6O_4$ (602.7)

R_f value: 0.52 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 603$

$(M+Na)^+ = 625$

Example 135

1-Methyl-2-[2-[4-(N-nicotinoylamidino)phenyl]ethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
5 ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[2-(4-
amidinophenyl)ethyl]-benzimidazol-5-yl-carboxylic acid-N-
(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
10 and nicotinic acid chloride.

Yield: 56 % of theory,

C₃₄H₃₃N₇O₄ (603.7)

R_f value: 0.52 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 604

15 (M+Na)⁺ = 626

Example 136

20 1-Cyclopropyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-Cyclopropyl-2-
25 [N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide,
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 31 % of theory,

30 C₃₀H₃₃N₆O₃ (524.6)

R_f value: 0.40 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: (M+H)⁺ = 525

(M+H+Na)⁺⁺ = 274

(M+2H)⁺⁺ = 263

35

Example 137

1-Cyclopropyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
5 hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-cyclopropyl-2-[N-
(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
10 and sodium hydroxide solution.

Yield: 64 % of theory,

$C_{28}H_{28}N_6O_3$ (496.6)

EKA mass spectrum: $(M+H)^+$ = 497

$(M+H+Na)^{++}$ = 260

15 $(M+Na)^+$ = 519

$(M+2Na)^{++}$ = 271

Example 138

20 1-Methyl-2-[N-(4-amidinophenyl)-N-(n-butyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
25 cyanophenyl)-N-(n-butyl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide,
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 62 % of theory,

30 $C_{32}H_{38}N_6O_3$ (554.7)

EKA mass spectrum: $(M+H)^+$ = 555

$(M+H+Na)^{++}$ = 289

$(M+2H)^{++}$ = 278

Example 139

1-Methyl-2-[N-(4-amidino-2-chloro-phenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
5 ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyano-2-chloro-phenyl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide,
10 ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 82 % of theory,

C₂₈H₂₉ClN₆O₃ (533.1)

EKA mass spectrum: (M+H)⁺ = 533/5

15 (M+H+Na)⁺⁺ = 278/9

Example 140

1-Methyl-2-[N-[4-(n-octyloxycarbonylamidino)phenyl]-
20 aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-
(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
25 acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
and n-octyl chloroformate.

Yield: 34 % of theory,

C₃₇H₄₆N₆O₅ (654.8)

R_f value: 0.15 (silica gel; dichloromethane/ethanol = 19:1)

30 EKA mass spectrum: (M+H)⁺ = 655

(M+H+Na)⁺⁺ = 339

(M+Na)⁺ = 677

Example 141

1-Methyl-2- [N- (4-amidino-2-ethyl-phenyl) -aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-
5 ethoxycarbonylethyl) -amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2- [N- (4-
cyano-2-ethyl-phenyl) -aminomethyl] -benzimidazol-5-yl-
carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide,
10 ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 61 % of theory

$C_{30}H_{34}N_6O_3$ (526.6)

EKA mass spectrum: $(M+H)^+$ = 527
15 $(M+H+Na)^{++}$ = 275
 $(M+2H)^{++}$ = 264

Example 142

20 1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5-yl-carboxylic acid-benzylamide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2- [N- (4-
cyanophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic
25 acid-benzylamide, ethanolic hydrochloric acid, ethanol and
ammonium carbonate.

Yield: 63 % of theory,

$C_{24}H_{24}N_6O$ (412.5)

R_f value: 0.76 (silica gel; dichloromethane/ethanol = 4:1)

30 EKA mass spectrum: $(M+H)^+$ = 413

Example 143

1-Methyl-2- [N- [4- (N- (2- (2-ethoxyethoxy) ethyloxy) -
35 carbonylamidino) -phenyl] -aminomethyl] -benzimidazol-5-yl-

carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and diethyleneglycolmonoethylether chloroformate.

Yield: 43 % of theory,

10 $C_{34}H_{41}N_7O_7$ (659.8)

R_f value: 0.56 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 660$

$(M+H+Na)^{++} = 341.7$

15 Example 144

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(1-methylpyrazol-4-yl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

20

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide, ethanolic hydrochloric acid, ethanol and ammonium carbonate.

25

Yield: 60 % of theory,

$C_{26}H_{30}N_8O_3$ (502.6)

R_f value: 0.13 (silica gel; dichloromethane/ethanol = 4:1)

EKA mass spectrum: $(M+H)^+ = 503$

30

$(M+H+Na)^{++} = 263$

$(M+2H)^{++} = 252$

Example 145

3-Methyl-2-[(4-amidinophenyl)-thiomethyl]-imidazo[4,5-b]-
pyridin-6-yl-carboxylic acid-N-phenyl-N-(2-
5 ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 1 from 3-methyl-2-[(4-
cyanophenyl)thiomethyl]-imidazo[4,5-b]pyridin-6-yl-
carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide,
10 ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 88 % of theory,

C₂₇H₂₈N₆O₃S (516.63)

R_f value: 0.23 (silica gel; ethyl acetate/ethanol/ammonia =
15 50:45:5)

EKA mass spectrum: (M+H)⁺ = 517

(M+H+Na)⁺⁺ = 270

20 Example 146

3-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-
(2-ethoxycarbonylethyl)-amide-hydrochloride

25 Prepared analogously to Example 1 from 3-methyl-2-[N-(4-
cyanophenyl)-aminomethyl]-imidazo[4,5-b]pyridin-6-yl-
carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide,
ethanolic hydrochloric acid, ethanol and ammonium
30 carbonate.

Yield: 82 % of theory,

C₂₇H₂₉N₇O₃ (499.58)

R_f value: 0.20 (silica gel; ethyl acetate/ethanol/ammonia =
50:45:5)

35 EKA mass spectrum: (M+H)⁺ = 500

(M+H+Na)⁺⁺ = 261.7

Example 147

3-Methyl-2-[(4-amidinophenyl)-thiomethyl]-
5 imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-
(2-hydroxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 2 from 3-methyl-2-[(4-
amidinophenyl)-thiomethyl]-imidazo[4,5-b]pyridin-6-yl-
10 carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-
hydrochloride and sodium hydroxide solution.

Yield: 88 % of theory,

C₂₅H₂₄N₆O₃S (488.56)

R_f value: 0.21 (silica gel; ethyl acetate/ethanol/ammonia =
15 50:45:5)

EKA mass spectrum: (M+H)⁺ = 489

(M+Na)⁺ = 511

20

Example 148

3-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
imidazo[4,5-b]pyridin-6-yl-carboxylic acid-N-phenyl-N-
25 (2-hydroxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 2 from 3-methyl-2-[N-(4-
amidinophenyl)-aminomethyl]-imidazo[4,5-b]pyridin-6-yl-
carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-
30 hydrochloride and sodium hydroxide solution.

Yield: 80 % of theory,

C₂₅H₂₅N₇O₃ (471.52)

R_f value: 0.19 (silica gel; ethyl acetate/ethanol/ammonia =
50:45:5)

35 EKA mass spectrum: (M+H)⁺ = 472

(M+Na)⁺ = 494

$$(M+2Na)^{++} = 258.6$$

Example 149

5 1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-
5-yl-sulphonic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -
amide-hydrochloride

a) 1-Methyl-2 [N- (4-cyanophenyl) -aminomethyl] -benzimidazol-
10 5-yl-sulphonic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -
amide

2.54 g (6,2 mMol) of 3-nitro-4-methylamino-benzenesulphonic
acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide were
hydrogenated at room temperature under 5 bar hydrogen
15 pressure over palladium/charcoal (10%) in a mixture of
75 ml of ethanol and 75 ml of dichloromethane. The
resulting crude 3-amino-4-methylamino-benzenesulphonic
acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide was taken up
in 30 ml of phosphorus oxychloride, without purification,
20 then 1.1 g (6,2 mMol) of N- (4-cyanophenyl) -glycine were
added and the mixture was refluxed for two hours. After
cooling to room temperature the reaction mixture was added
to about 70 ml of water with cooling and in this way the
excess phosphorus oxychloride was destroyed. The resulting
25 solution was neutralised with solid sodium carbonate and
extracted three times with 30 ml of ethyl acetate. After
evaporation of the solvent the crude product was purified
by column chromatography (100 g silica gel; eluant:
cyclohexane/ethyl acetate = 2:3).

30 Yield: 860 mg (26.8 % of theory),

Melting point: 188-191°C

C₂₇H₂₇N₅O₃S (517.6)

R_f value: 0.52 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 518

35 (M+Na)⁺ = 540

b) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-sulphonic acid-N-phenyl-N-
(2-ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
5 cyanophenyl)-aminomethyl]-benzimidazol-5-yl-sulphonic acid-
N-phenyl-N-(2-ethoxycarbonylethyl)-amide, ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 87 % of theory,

$C_{27}H_{30}N_6O_4S$ (534.6)

10 R_f value: 0.13 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: $(M+H)^+$ = 535

$(M+H+Na)^{++}$ = 279

Example 150

15

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-sulphonic acid-N-(1-methylpyrazol-4-yl)-
N-(2-ethoxycarbonylethyl)-amide-hydrochloride

20 Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyanophenyl)-aminomethyl]-benzimidazol-5-yl-sulphonic acid-
N-(1-methylpyrazol-4-yl)-N-(2-ethoxycarbonylethyl)-amide,
ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

25 Yield: 38 % of theory,

$C_{25}H_{30}N_8O_4S$ (538.6)

R_f value: 0.09 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: $(M+H)^+$ = 539

30 Example 151

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
5-(2.3-dihydroindol-1-yl-sulphonyl)-benzimidazole-
hydrochloride

35

Prepared analogously to Example 25d from 1-methyl-2-[N-
(4-cyanophenyl)-aminomethyl]-5-(2.3-dihydroindol-1-yl-

sulphonyl)-benzimidazole and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 15 % of theory,

R_f value: 0.36 (silica gel; dichloromethane/methanol = 4:1)

5 C₂₄H₂₄N₆O₂S (460.6)

EKA mass spectrum: (M+H)⁺ = 461

Example 152

10 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazole-5-yl-sulphonic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-methyl-
15 2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-sulphonic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.

Yield: 24 % of theory,

R_f value: 0.55 (Reverse-Phase RP-18 silica gel; methanol/5%
20 saline solution = 3:2)

C₂₅H₂₆N₆O₄S (506.6)

EKA mass spectrum: (M+H)⁺ = 507

(M+Na)⁺ = 529

(M+2Na)⁺⁺ = 276

25

Example 153

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-(isoindolin-2-yl-sulphonyl)-benzimidazol-hydrochloride

30

Prepared analogously to Example 25d from 1-methyl-
2-[N-(4-cyanophenyl)-aminomethyl]-5-(isoindolin-2-yl-sulphonyl)-benzimidazole and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

35 Yield: 33 % of theory,

R_f value: 0.32 (silica gel; dichloromethane/methanol = 4:1)

C₂₄H₂₄N₆O₂S (460.6)

EKA mass spectrum: (M+H)⁺ = 461

5 Example 154

2-[2-(4-Amidinophenyl)-ethyl]-quinazolin-7-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonyl-ethyl)-amide-hydrochloride

10 a. Ethyl 4-methyl-3-nitro-benzoate

To a solution of 3 ml of concentrated hydrochloric acid and
4 ml of concentrated sulphuric acid, 4.9 g (0.03 mol) of
ethyl p-tolylate were added dropwise with stirring at 5°C
and stirred for 1 hour whilst cooling in an ice-bath. After
15 heating to ambient temperature the mixture was poured onto
ice-water and extracted with ethyl acetate. The organic
extracts were washed with sodium hydrogen carbonate
solution, dried and evaporated down.

Yield: 5.7 g (90 % of theory),

20 R_f value: 0.81 (silica gel, ethyl acetate/cyclohexane =
1:1)

b. Methyl 4-(2-dimethylaminovinyl)-3-nitro-benzoate

1.0 g (4.8 mmol) of ethyl 4-methyl-3-nitro-benzoate, 0.74 g
25 (6.2 mmol) of dimethylformamide dimethylacetal and 2 ml of
dimethylformamide were heated to 140°C with stirring for 3
hours. Then the solvent was distilled off and the crude
product thus obtained was reacted without any further
purification.

30 Yield: 1.2 g (100 % of theory),

R_f value: 0.54 (silica gel, ethyl acetate/cyclohexane =
1:1)

c. Methyl 4-formyl-3-nitro-benzoate

35 1.2 g (4.8 mmol) of methyl 4-(2-dimethylaminovinyl)-3-
nitro-benzoate were dissolved in 120 ml of
tetrahydrofuran/water (1:1) and after the addition of 3.0 g

(14.3 mmol) of sodium metaperiodate the mixture was stirred for 20 hours at ambient temperature. The suspension was then diluted with water and methylene chloride and extracted with methylene chloride. The combined organic
5 extracts were washed with sodium hydrogen carbonate solution, dried and evaporated down. The residue was chromatographed on silica gel and eluted with ethyl acetate/cyclohexane (1:3).

Yield: 0.6 g (63 % of theory),

10 R_f value: 0.63 (silica gel, ethyl acetate/cyclohexane = 1:1)

d. Methyl 3-Amino-4-formyl-benzoate

To a solution of 25 ml of ethanol/glacial acetic acid/water
15 (2:2:1) were added 0.6 g (2.9 mmol) of methyl 4-formyl-3-nitro-benzoate, 1.2 g (21.4 mmol) of iron powder and 0.01 ml of concentrated hydrochloric acid and the mixture was refluxed with stirring for 15 minutes. Then the iron was separated off, the solution was diluted with water and
20 extracted with methylene chloride. The combined organic extracts were washed with water, dried and evaporated down.

Yield: 0.3 g (58 % of theory),

R_f value: 0.74 (silica gel, methylene chloride/methanol =
25 9.5:0.5)

e. Methyl 3-[3-(4-cyanophenyl)-propionylamino]-4-formyl-benzoate

1.0 g (5.6 mmol) of methyl 3-amino-4-formyl-benzoate and
30 1.1 g (5.6 mmol) of 4-cyanophenylpropionic acid chloride were dissolved in 50 ml of methylene chloride and after the addition of 0.7 g (5.6 mmol) of N-ethyl-diisopropylamine the mixture was stirred for 24 hours at ambient temperature. Then it was extracted with sodium hydrogen
35 carbonate solution, the combined organic extracts were dried and evaporated down. The residue was chromatographed

on silica gel and eluted with ethyl acetate/cyclohexane (1:3).

Yield: 0.6 g (32 % of theory),

R_f value: 0.60 (silica gel, ethyl acetate/cyclohexane = 1:1)

f. Methyl 2-[2-(4-cyanophenyl)-ethyl]-quinazoline-7-carboxylate

10 0.6 g (1.8 mmol) of ethyl 3-[3-(4-cyanophenyl)-propionylamino]-4-formyl-benzoate and 10 ml of methanolic ammonia solution were agitated in a pressure vessel for 36 hours. Then the solvent was distilled off, the residue was chromatographed on silica gel and eluted with methylene chloride containing 0 to 1 % methanol.

Yield: 0.35 g (62 % of theory),

R_f value: 0.38 (silica gel, ethyl acetate/cyclohexane = 1:1)

20 g. 2-[2-(4-Cyanophenyl)-ethyl]-quinazolin-7-carboxylic acid
0.3 g (0.94 mmol) of methyl 2-[2-(4-cyanophenyl)-ethyl]-quinazoline-7-carboxylate were dissolved in 4.7 ml of 1N lithium hydroxide solution and 4 ml of tetrahydrofuran and stirred for 3 hours at ambient temperature. Then 4.7 ml of 1N hydrochloric acid were added and the mixture was stirred for 30 minutes. The product precipitated was suction filtered, washed with water and dried.

Yield: 0.30 g (100 % of theory),

R_f value: 0.1 (silica gel, ethyl acetate/cyclohexane = 1:1)

30

h. 2-[2-(4-Cyanophenyl)-ethyl]-quinazolin-7-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

0.4 g (1.3 mmol) of 2-[2-(4-cyanophenyl)-ethyl]-quinazoline-7-carboxylic acid and 5 ml of thionyl chloride were stirred for 60 minutes at 50°C. Then the thionyl chloride was distilled off, the residue was dissolved in

methylene chloride, mixed with 0.24 g (1.3 mmol) of methyl 3-(N-phenylamino)-propionate and 0.22 ml of (1.3 mmol) of N-ethyldiisopropylamine and stirred for 18 hours at ambient temperature. After evaporation of the solvent *in vacuo* the

5 residue was chromatographed on silica gel and eluted with methylene chloride containing 1 % methanol.

Yield: 230 mg (37 % of theory),

R_f value: 0.64 (silica gel, methylene chloride/methanol = 9:1)

10

i. 2-[2-(4-Amidinophenyl)-ethyl]-quinazolin-7-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

15

230 mg (0.5 mmol) of 2-[2-(4-cyanophenyl)-ethyl]-quinazolin-7-yl-carboxylic acid-N-phenyl-

N-(2-methoxycarbonylethyl)-amide were stirred in 30 ml of saturated ethanolic hydrochloric acid for 8 hours at ambient temperature. Then the mixture was evaporated to dryness *in vacuo*, the residue was taken up in 20 ml of

20

ethanol, combined with 0.5 g (5.0 mmol) of ammonium carbonate and stirred overnight at ambient temperature. After evaporation of the solvent the crude product was chromatographed on silica gel and eluted with methylene chloride/ethanol (4:1).

25

Yield: 100 mg (39 % of theory),

R_f value: 0.5 (silica gel, methylene chloride/ethanol = 4:1)

C₂₉H₂₉N₅O₃ (495.59)

Mass spectrum: (M+H)⁺ = 496

30

Example 155

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-sulphonic acid-N-(1-methylpyrazol-4-yl)-N-(2-hydroxycarbonylethyl)-amide

35

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-sulphonic acid-N-(1-methylpyrazol-4-yl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.

Yield: 95 % of theory,
 $C_{23}H_{26}N_8O_4S$ (510.6)

R_f value: 0.53 (Reversed Phase silica gel RP-18, methanol + 5% saline solution)

EKA mass spectrum: $(M+H)^+ = 511$
 $(M+Na)^+ = 533$
 $(M+2Na)^{++} = 278$

Example 156

1-Methyl-2-[N-(3-amidino-pyridin-6-yl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

a) 3-[(N-tert.Butoxycarbonyl-amino)acetyl-amino]-4-methylamino-benzoic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

19.2 g (0.11 mol) of N-tert.butylloxycarbonylglycine were dissolved in 175 ml of dimethylformamide, mixed with 35.2 g (0.11 mol) of O-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, 11.0 g of triethylamine and 34.2 g (0.10 mol) of 3-amino-4-methyl-amino-benzoic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide and stirred for 2.5 hours at ambient temperature. Then the reaction solution was mixed with 5 l of ice water and stirred for 2 hours. The grey precipitate formed was filtered off, washed with water, dried and recrystallised from ethyl acetate with the addition of activated charcoal.

Yield: 39.85 g (80 % of theory),

C₂₅H₃₃N₅O₆ (499.6)

R_f value: 0.55 (silica gel; methylene chloride/ethanol = 19:1)

- 5 b) 1-Methyl-2-(N-tert.butoxycarbonyl-aminomethyl)-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

10.0 g (0.02 mol) of 3-[(N-tert.butoxycarbonyl-amino)acetyl-amino]-4-methylamino-benzoic acid-
10 N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide were dissolved in 50 ml of glacial acetic acid and refluxed for one hour. Then the solvent was distilled off, the residue was mixed with ice water and adjusted to pH 8 by the addition of 2N ammonia. After extraction three times with
15 ethyl acetate the combined organic phases were washed with saline solution and dried over sodium sulphate. After evaporation of the solvent the crude product was chromatographed on silica gel, eluting first with methylene chloride, then with methylene chloride/ethanol (50:1) and
20 (25:1). The desired fractions were combined and evaporated down.

Yield: 5.85 g (61 % of theory),

C₂₅H₃₁N₅O₅ (481.6)

R_f value: 0.70 (silica gel; methylene chloride/ethanol =
25 9:1)

- c) 1-Methyl-2-aminomethyl-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-trifluoroacetate
- 30 4.81 g (0.10 mol) of 1-methyl-2-(N-tert.butoxycarbonyl-aminomethyl)-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide were dissolved in 25 ml of methylene chloride, mixed with 5 ml of trifluoroacetic acid and stirred for 5 hours at ambient
35 temperature. Then the solvent was evaporated off and the residue was stirred with ether. The crystals thus formed were filtered off, washed with ether and dried.

Yield: 3.15 g (68 % of theory),

C₂₀H₂₃N₅O₃ (381.4)

R_f value: 0.18 (silica gel; methylene chloride/ethanol = 9:1)

5

d) 1-Methyl-2-[N-(3-cyano-pyridin-6-yl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

- 10 1.5 g (3.25 mmol) of 1-methyl-2-aminomethyl-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-trifluoroacetate were stirred into 10 ml of N-ethyl-diisopropylamine and heated to 100°C for 15 minutes. After the addition of 720 mg
15 (5.25 mmol) of 2-chloro-5-cyano-pyridine the reaction mixture was heated to 125°C for 2 hours. After cooling to ambient temperature and stirring with about 20 ml of water, the pH was adjusted to 4 by the addition of 1N hydrochloric acid and the mixture was extracted 3 times with ethyl
20 acetate. The combined organic phases were washed with saline solution and dried over sodium sulphate. After evaporation of the solvent the crude product was chromatographed on silica gel, eluting first with methylene chloride, later with methylene chloride/ethanol (25:1) and
25 (19:1). The desired fractions were combined and evaporated down.

Yield: 1.05 g (67 % of theory),

C₂₆H₂₅N₇O (483.6)

Mass spectrum: (M+H)⁺ = 484

30

e) 1-Methyl-2-[N-(3-amidino-pyridin-6-yl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

- Prepared analogously to Example 25d from 1-Methyl-2-[N-(3-cyano-pyridin-6-yl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
35

amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 38 % of theory,

$C_{28}H_{28}N_8O_3$ (500.6)

5 Mass spectrum: $(M+H)^+ = 501$

Example 157

10 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-hydroiodide

a) 4-Nitro-benzoic acid-N-phenyl-N-(2-methoxycarbonylethyl)amide

15 16.7 g (0.1 mol) of 4-nitrobenzoic acid were refluxed in 50 ml of thionyl chloride and 3 drops of dimethylformamide for 1 hour. After the solvent had been distilled off in vacuo the crude product was dissolved in 150 ml of tetrahydrofuran and added dropwise to a solution of 18 g
20 (0.1 mol) of N-(2-methoxycarbonylethyl)aniline in 250 ml of tetrahydrofuran and 42 ml 0.3 mol) of triethylamine. After being stirred for one hour at ambient temperature the reaction mixture was diluted with 250 ml of ethyl acetate and washed 2x with 200 ml of 14% saline solution. After the
25 solvent had been distilled off and the residue chromatographed (silica gel; methylene chloride) a yellow oil was obtained which slowly solidified.
Yield: 32.6 g (100 % of theory),
R_f value: 0.37 (silica gel; methylene chloride/methanol =
30 50:1)

b) 4-Amino-benzoic acid-N-phenyl-N-(2-methoxycarbonylethyl)amide

22 g (67 mmol) of 4-nitro-benzoic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide were hydrogenated in 500 ml of
35 methanol with 2 g of 10% palladium on charcoal at 3 bar hydrogen pressure for 3 hours. After filtration and

distillation of the solvent the reaction mixture was washed with 100 ml of ether and the white crystalline product was further reacted directly.

Yield: 18.6 g (94 % of theory),

- 5 R_f value: 0.70 (silica gel; methylene chloride/ethanol = 19:1)

c) 2-Methyl-3-thiomethyl-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

- 10 26.8 g (91 mmol) of 4-amino-benzoic acid-N-phenyl-N-(2-methoxycarbonylethyl)amide were dissolved in 500 ml of methylene chloride, cooled to -70°C and mixed within 30 minutes with freshly prepared tert.butylhypochlorite (M. J. Mintz et al., Organic Synthesis, Coll. Vol. 5, page 184).
- 15 The mixture was stirred for 2 hours at -70°C, then 9.46 g (91 mmol) of methylthioacetone in 40 ml of methylene chloride were added dropwise within 10 minutes and stirring was continued for a further 1.5 hours. Then 12.7 ml (9.1 g, 91 mmol) of triethylamine in 25 ml of methylene chloride
- 20 were added. The mixture was left for 30 minutes at -78°C and then slowly warmed to ambient temperature overnight. After washing twice with 50 ml of water the organic phase was separated off and dried with sodium sulphate. After removal of the solvent *in vacuo* a white amorphous substance
- 25 is obtained after purification by chromatography (silica gel; ethyl acetate/petroleum ether = 2:8 to 3:7). Yield: 24.1 g (69 % of theory), R_f value: 0.58 (silica gel; ethyl acetate/petroleum ether = 1:1)
- 30 C₂₁H₂₂N₂O₃S (382.49)
Mass spectrum: (M)⁺ = 382

d) 1-tert-Butoxycarbonyl-2-methyl-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

8.9 g (23 mmol) of 2-Methyl-3-thiomethyl-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide
5 were dissolved in 600 ml of ethanol, mixed with about 150 mg of Raney nickel and stirred for 2 hours at ambient temperature (analogously to P.G. Gassman et al., Organic Synthesis Coll. Vol. 6, page 601). Then the mixture was filtered and the solvent eliminated *in vacuo*. The crude
10 product thus obtained (8 g) was dissolved in 200 ml of absolute tetrahydrofuran, mixed with 150 mg of dimethylaminopyridine and 6.84 g (32 mmol) of di-tert.butyl pyrocarbonate and stirred for 2.5 hours at 50°C. Then the solvent was distilled off *in vacuo* and the crude product
15 was purified by chromatography (silica gel, ethyl acetate/petroleum ether = 1:4).
Yield: 10.0 g (98 % of theory),
R_f value: 0.40 (silica gel; ethyl acetate/petroleum ether = 3:7)

20

e) 2-[N-(4-Cyanophenyl)aminomethyl]-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

3.5 g (8 mmol) of 1-tert.butoxycarbonyl-2-methyl-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-
25 amide were dissolved in 80 ml of carbon tetrachloride, mixed with 1.5 g (8.4 mmol) of N-bromo-succinimide and 20 mg of azobisisobutyronitrile and refluxed for 2.5 hours. Then the still warm solution was filtered, the filtrate obtained was washed with saturated sodium hydrogen
30 carbonate solution and dried with sodium sulphate. After distillation of the solvent the crude product was dissolved in 30 ml of N-ethyl-diisopropylamine, mixed with 1.0 g (8 mmol) of 4-aminobenzonitrile and refluxed for 2.5 hours. The solvent was distilled off *in vacuo* and the residue
35 obtained was purified by chromatography (silica gel; ethyl acetate/petroleum ether = 1:4 to 1:1).

Yield: 1.1 g (30 % of theory),

R_f value: 0.21 (silica gel; ethyl acetate/petroleum ether = 1:1)

5 f. 1-Methyl-2-[N-(4-thiocarbamoyl-phenyl)aminomethyl]-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

1.5 g (3.3 mmol) of 2-[N-(4-cyanophenyl)aminomethyl]-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide were dissolved in 60 ml of xylene, mixed with 0.45 g (3.3 mmol) of potassium carbonate and 0.5 ml of (3.3 mmol) of methyl p-toluenesulphonate and refluxed for 4 hours. Then the same amounts of potassium carbonate and methyl toluenesulphonate were added a second time and the mixture was refluxed overnight. It was filtered and washed with acetone. After concentration of the filtrate thus obtained, the residue obtained was purified by chromatography (silica gel; ethyl acetate/petroleum ether = 1:4 to 2:3). The N-methylated indole obtained (yield: 0.64 g, 41 % of theory) was dissolved in 20 ml of pyridine and mixed with 0.67 ml (1.37 mmol) of triethylamine. Then hydrogen sulphide gas was introduced into the solution thus obtained. After 4.5 days nitrogen was passed through the reaction solution for 30 minutes, the solvent was distilled off and the residue obtained was purified by chromatography (silica gel; methylene chloride/ethanol 99:1 to 98:2). Yield: 0.30 g (43 % of theory),

C₂₈H₂₈N₄O₃S (500.62)

EKA mass spectrum: (M+H)⁺ = 501

30 (M+Na)⁺ = 523

g) 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide-hydroiodide

35 0.30 g (0.60 mmol) of 1-methyl-2-[N-(4-thiocarbamoyl)-phenyl)aminomethyl]-indol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide were dissolved in 20 ml of

acetone together with 0.75 ml (12 mmol) of methyl iodide and stirred for 2 hours at ambient temperature. Then the solvent was distilled off and the crude product was stirred together with 1.0 g of ammonium acetate in 12 ml of ethanol and 5 ml of methylene chloride for 20 hours at 40°C. The solvent was distilled off *in vacuo* and the residue obtained was purified by chromatography (silica gel; methylene chloride/ethanol = 9:1 to 4:1).

Yield: 55 % of theory,

10 $C_{28}H_{29}N_5O_3$ (483.58)

R_f value: 0.20 (silica gel; methylene chloride/ethanol = 4:1 + 1 drop of acetic acid)

EKA mass spectrum: $(M+H)^+ = 484$

15 Example 158

1-Methyl-2- [N- (4-amidinophenyl) aminomethyl] -
thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

20

a) Iminoethyl methoxyacetate hydrochloride

A solution of 35.5 g (0.50 mol) of methoxyacetonitrile in 29 ml (23 g, 0.50 mol) of ethanol and 30 ml of absolute diethylether was cooled to 0°C and over 1 hour 22.5 g (0.62 mol) of hydrogen chloride gas was introduced, whilst towards the end of the introduction of gas the reaction product crystallised out. To complete the precipitation 130 ml of diethylether were added and the colourless needles were filtered off.

30 Yield: 66.4 g (86 % of theory),

Melting point: 117-118°C.

b) 4-Hydroxymethyl-2-methoxymethyl-imidazole

A mixture of 30.6 g (0.20 mol) of iminoethyl methoxyacetate-hydrochloride, 18 g (0.20 mol) of 1.3-dihydroxyacetone and 200 ml of liquid ammonia was heated to 68°C for 3 hours in a stirred autoclave at a pressure of 27

bar (analogously to: P. Dziuron et al. Arch. Pharm. 307, 1974, p.470). Then the ammonia was eliminated and 200 ml of methylene chloride were added. The white precipitate formed was filtered off and washed with methylene chloride. The filtrate was evaporated down and the residue obtained was purified by chromatography (aluminium oxide; methylene chloride/ethanol = 90:10 to 85:15).

Yield: 26.7 g (94 % of theory),

R_f value: 0.43 (silica gel; methylene chloride/ethanol = 9:1)

C₆H₁₀N₂O₂ (142.20)

Mass spectrum: (M)⁺ = 142

c) 4-Hydroxymethyl-2-methoxymethyl-1-methyl-imidazole as a 1:1 mixture with 5-hydroxymethyl-2-methoxymethyl-1-methyl-imidazole

A mixture of 7.1 g (50 mmol) of 4-hydroxymethyl-2-methoxymethylimidazole, 3.0 g (53 mmol) of powdered potassium hydroxide and 3.4 ml (0.55 mmol) of methyl iodide was heated to 50°C in 100 ml of dimethylformamide for 4 hours (analogously to I. Sinclair et al., J. Med. Chem., 29, 1986, 261). Then the solvent was distilled off *in vacuo* and the crude product purified by column chromatography (aluminium oxide; methylene chloride/ethanol = 99:1 to 95:5).

Yield: 6.1 g (78 % of theory; 1:1 mixture of the two regioisomers)

R_f value: 0.32 (silica gel; methylene chloride/ethanol = 19:1)

d) 5-Chloro-4-hydroxymethyl-2-methoxymethyl-1-methyl-imidazole

A 1:1 mixture of 7.7 g (49 mmol) of 4-hydroxymethyl-2-methoxymethyl-1-methyl-imidazole and 5-hydroxymethyl-2-methoxymethyl-1-methyl-imidazole and 7.3 g (55 mmol) of N-chloro-succinimide was heated to 50°C in 48 ml of ethylene glycol monoethylether and 70 ml of dioxan for 10

hours. Then the solvent was distilled off *in vacuo* and the crude product purified by chromatography (silica gel; methylene chloride/ethanol = 99:1 to 90:10) to obtain the isomerically pure title compound.

- 5 Yield: 3.4 g (36 % of theory),
R_f value: 0.40 (silica gel; methylene chloride/ethanol = 19:1)

e) 5-chloro-4-formyl-2-methoxymethyl-1-methyl-imidazole

- 10 3.4 g (18 mmol) of 5-chloro-4-hydroxymethyl-2-methoxymethyl-1-methyl-imidazole were dissolved in 100 ml of methylene chloride and at two-hour intervals manganese dioxide was added (2 x 6.0 g, a total of 0.14 mol). After 4 hours the inorganic component was filtered off, the solvent
15 was eliminated and the crude product obtained was further reacted without any further purification.
Yield: 3.0 g (89 % of theory),
R_f value: 0.44 (silica gel; methylene chloride/ethanol = 50:1)

20

f) Ethyl 1-methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylate

- To a freshly prepared sodium ethoxide solution (from 391 mg, 17 mMol of sodium) in 15 ml of ethanol were added
25 dropwise 1.9 ml (2.1 g, 17 mmol) of ethyl thioglycolate. After 1 hour stirring at ambient temperature 1.6 g (8.5 mmol) of 5-chloro-4-formyl-2-methoxymethyl-1-methyl-imidazole in 20 ml of absolute ethanol were added and the mixture was heated to 80°C (analogously to B. Iddon et al.,
30 J. Chem. Soc. Perkin Trans. I, 1987, 1457). After 5 hours the solvent was distilled off, the residue was taken up in 50 ml of methylene chloride and washed with 20 ml of water. The aqueous phase was washed again with 20 ml of methylene chloride and then the combined organic phases were dried
35 with sodium sulphate. After removal of the solvent *in vacuo* the crude product obtained was purified by column chromatography (aluminium oxide; methylene chloride).

Yield: 1.0 g (46 % of theory),

R_f value: 0.48 (silica gel; methylene chloride/ethanol = 50:1)

C₁₁H₁₄N₂O₃S (254.31)

5 EKA mass spectrum: (M+H)⁺ = 255

(M+Na)⁺ = 277

g) 1-Methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylic acid

10 To a solution of 0.90 g (3.54 mmol) of ethyl 1-methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylate in 30 ml of ethanol were added dropwise 5 ml of 2 N sodium hydroxide solution and the mixture was stirred for 2 hours at ambient temperature. Then the solvent was distilled off

15 *in vacuo*, the residue was taken up in 5 ml of water and washed with 10 ml of diethylether. The aqueous phase was acidified with 6 ml of 2N hydrochloric acid, cooled to 0°C and the precipitated crystals are filtered off.

Yield: 0.50 g (63% of theory)

20 R_f value: 0.21 (silica gel; methylene chloride/ethanol = 9:1 + a few drops of acetic acid)

C₉H₁₀N₂O₃S (226.26)

Mass spectrum: (M)⁺ = 226

25 h) 1-Methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

A suspension of 0.50 g (2.2 mmol) of 1-methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylic acid in 20 ml of methylene chloride was mixed with 2.0 ml (3.2 g, 27 mmol) of thionyl chloride and refluxed for 60 minutes,

30 during which time the solid gradually dissolved. After distillation of the liquid components the crude product was taken up twice more in methylene chloride. After the solvent had been eliminated once more the crude acid

35 chloride was taken up in 20 ml of tetrahydrofuran and added dropwise to a mixture of 0.42 g (2.3 mmol) of

N-(2-methoxycarbonylethyl)aniline and 0.92 ml (6.6 mmol) of triethylamine in 30 ml of tetrahydrofuran. After 16 hours' stirring at 50°C the solvent was eliminated and the crude product obtained was purified by chromatography (silica gel; methylene chloride/ethanol = 100:1).
Yield: 0.66 g (77% of theory),
R_f value: 0.47 (silica gel; methylene chloride/ethanol = 19:1)

10 i) 1-Methyl-2-(N-4-cyanophenylaminomethyl)-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide

To a solution of 0.73 g (1.88 mmol) of 1-methyl-2-methoxymethyl-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide in 30 ml of methylene chloride were added dropwise at 5°C 2.9 ml (2.9 mmol) of a 1-molar solution of boron tribromide in methylene chloride. After 16 hours' stirring at ambient temperature the mixture was washed with 20 ml of saturated sodium hydrogen carbonate solution, the organic phase was separated off, dried with sodium sulphate and filtered. The filtrate was mixed with 14 ml of N-ethyl-diisopropylamine and 0.43 g (3.64 mmol) of 4-aminobenzonitrile. Then the methylene chloride was distilled off *in vacuo*, the residue obtained was heated to 50°C for 1 hour and then the residual solvent was distilled off *in vacuo*. After chromatography (silica gel; methylene chloride/ethanol = 99:1 to 97:3) a yellow oil was obtained which slowly solidified.
Yield: 0.37 g (42% of theory),
R_f value: 0.29 (silica gel; methylene chloride/ethanol = 50:1 + a few drops of ammonia)

35 j) 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

0.38 g (0.80 mmol) of 1-methyl-2-(N-4-cyanophenylaminomethyl)-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide were stirred in 40 ml of ethanol saturated with hydrogen chloride for 5 hours first at 0°C, then later at ambient temperature until no more starting material could be detected by thin layer chromatography. Then the solvent was distilled off at a maximum 28°C bath temperature, the oily residue was taken up in 40 ml of absolute ethanol and mixed with 1.1 g of ammonium carbonate. After 18 hours the solvent was distilled off *in vacuo* and the crude product was purified by chromatography (silica gel; methylene chloride/ethanol = 9:1 to 4:1).
Yield : 57 % of theory
C₂₆H₂₈N₆O₃S (504.62)
R_f value: 0.21 (silica gel; methylene chloride/ethanol = 4:1 + a few drops of acetic acid)
EKA mass spectrum: (M+H)⁺ = 505
(M+H+Na)⁺⁺ = 264

Example 159

1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 2 from 1-methyl-2-[N-(4-amidinophenyl)aminomethyl]-thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.

Yield: 85 % of theory,
C₂₄H₂₄N₆O₃S (476.56)
R_f value: 0.36 (Reversed Phase silica gel RP-8; methanol + 5 % saline solution)
EKA mass spectrum: (M+H)⁺ = 477
(M+Na)⁺ = 499

$$(M+2Na)^{++} = 250$$

Example 160

5 1-Methyl-3- [N- (4-amidinophenyl)thiomethyl]-quinoxalin-2-on-
6-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -
amide-hydrochloride

10 a) 1-Methyl-3- [N- (4-cyanophenyl)thiomethyl]-quinoxalin-2-
on-6-yl-carboxylic acid-N-phenyl-N- (2-
methoxycarbonylethyl) -amide

A solution of 2.5 g (7.6 mmol) of 3-amino-4-methylamino-
benzoic acid-N-phenyl-N- (2-methoxycarbonylethyl) -amide and
2.4 g (9.6 mmol) of ethyl 3- (4-cyanophenyl)thio-2-oxo-
15 propionate were heated to boiling in 50 ml of ethanol for
30 minutes. After removal of the solvent the crude product
obtained was purified by chromatography (silica gel;
methylene chloride).

Yield: 1.6 g (40 % of theory),

20 R_f value: 0.63 (silica gel; EtOAc/EtOH/ammonia = 90:10:1)

b) 1-Methyl-3- [N- (4-amidinophenyl)thiomethyl]-quinoxalin-2-
on-6-yl-carboxylic acid-N-phenyl-N- (2-ethoxycarbonylethyl) -
amide-hydrochloride

25 Prepared analogously to Example 1 from 1-methyl-3- [N- (4-
cyanophenyl)thiomethyl]-quinoxalin-2-on-6-yl-carboxylic
acid-N-phenyl-N- (2-ethoxycarbonylethyl) -amide and ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 23 % of theory,

30 C₂₈H₂₇N₅O₄S (543.64)

R_f value: 0.25 (silica gel; ethyl acetate/ethanol/ammonia
= 50:45:5)

EKA mass spectrum: (M+H)⁺ = 544

(M+Na)⁺ = 566

35

Example 161

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-
imidazo[1.2-a]pyridin-7-yl-carboxylic acid-N-phenyl-N-(2-
5 ethoxycarbonylethyl)-amide-hydrochloride

a) 3-Methyl-2-[2-(4-cyanophenyl)ethyl]-
imidazo[1.2-a]pyridin-7-yl-carboxylic acid-N-phenyl-N-(2-
ethoxycarbonylethyl)-amide

10 1.4 g (4.6 mmol) of 3-methyl-2-[2-(4-cyanophenyl)ethyl]-
imidazo[1.2-a]pyridin-7-yl-carboxylic acid (prepared from
4-bromo-1-(4-cyanophenyl)-1-penten-3-one and methyl 2-
aminopyridine-4-carboxylate analogously to Y. Katsura et
al. Chem. Pharm. Bull. 1992, 40, 1424-1438) were suspended
15 in 15 ml of thionyl chloride and heated to boiling for 1
hour until fully dissolved. After the thionyl chloride had
been distilled off the acid chloride was dissolved in 15 ml
of pyridine without any further purification and at 0°C
mixed with 1.0 g (5.2 mmol) of N-(2-ethoxycarbonylethyl)-
20 aniline. After 1 hour the solvent was distilled off, the
residue was taken up in 30 ml of methylene chloride, washed
with 15 ml of 1N hydrochloric acid and dried with sodium
sulphate. After distillation of the solvent and
chromatography (silica gel; methylene chloride/ethanol = 0
25 to 2 %) a brown oil was obtained.

Yield: 1.48 g (64 % of theory),

R_f value: 0.73 (silica gel; ethyl acetate/ethanol/ammonia =
90:10:1)

30 b) 3-Methyl-2-[2-(4-amidinophenyl)ethyl]-
imidazo[1.2-a]pyridin-7-yl-carboxylic acid-N-phenyl-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 1 from 3-methyl-2-[2-(4-
cyanophenyl)ethyl]-imidazo[1.2-a]pyridin-7-yl-carboxylic
35 acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide and ethanolic
hydrochloric acid, ethanol and ammonium carbonate.

Yield: 62 % of theory,

C₂₉H₃₁N₅O₃ (497.60)

R_F value: 0.23 (silica gel; ethyl acetate/ethanol/ammonia
= 50:45:5)

EKA mass spectrum: (M+H)⁺ = 498

5

Example 162

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-
imidazo[1.2-a]pyridin-7-yl-carboxylic acid-N-phenyl-N-(2-
10 hydroxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 2 from 3-methyl-2-[2-(4-
amidinophenyl)ethyl]-imidazo[1.2-a]pyridin-7-yl-carboxylic
acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride
15 and sodium hydroxide solution.

Yield: 92 % of theory,

C₂₇H₂₇N₅O₃ (469.55)

R_F value: 0.19 (silica gel; ethyl
acetate/ethanol/ammonia = 50:45:5)

20 EKA mass spectrum: (M+H)⁺ = 470
(M+Na)⁺ = 492
(M+2H)⁺⁺ = 235.7
(M+H+Na)⁺⁺ = 246.7
(M+2Na)⁺⁺ = 257.7

25

Example 163

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-phenyl-N-[(N-ethoxycarbonylethyl-N-
30 methyl)-2-aminoethyl]-amide-dihydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
acid-N-phenyl-N-[(N-ethoxycarbonylethyl-N-methyl)-2-
35 aminoethyl]-amide and ethanolic hydrochloric acid, ethanol
and ammonium carbonate.

Yield: 80 % of theory,

$C_{31}H_{37}N_7O_3$ (555.7)

R_f value: 0.24 (silica gel; dichloromethane/methanol = 4:1)

EKA mass spectrum: $(M+H)^+$ = 556

5 $(M+H+Na)^{++}$ = 289.8

$(M+2H)^{++}$ = 278.8

Example 164

10 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[(N-hydroxycarbonylethyl-N-methyl)-2-aminoethyl]-amide-hydrochloride

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
15 acid-N-phenyl-N-[(N-ethoxycarbonylethyl-N-methyl)-2-aminoethyl]-amide-dihydrochloride and sodium hydroxide solution.

Yield: 79 % of theory,

20 $C_{29}H_{33}N_7O_3$ (527.6)

R_f value: 0.43 (Reversed Phase silica gel RP-18; methanol/5% aqueous saline solution = 6:4)

EKA mass spectrum: $(M+H)^+$ = 528

$(M+H+Na)^{++}$ = 275.6

25 $(M+2H)^{++}$ = 264.6

Example 165

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
30 5-yl-carboxylic acid-N-phenyl-N-(3-hydroxy-n-propyl)-amide-hydrochloride

Prepared from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-benzyloxy-n-propyl)-amide-hydrochloride by hydrogenation over
35

palladium/charcoal (10%) at 5 bar hydrogen pressure and at ambient temperature.

Yield: 61 % of theory,

$C_{26}H_{28}N_6O_2$ (456.6)

5 R_f value: 0.70 (Reversed Phase silica gel RP-18;

methanol/5% aqueous saline solution = 9:1)

EKA mass spectrum: $(M+H)^+$ = 457

$(M+H+Na)^{++}$ = 240

10 Example 166

1-Methyl-2- [N- [4- (N-n-hexyloxycarbonylamidino)phenyl] -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N- (2-hydroxycarbonylethyl) -amide

15

Prepared analogously to Example 26 from 1-methyl-2- [N- [4- (N-n-hexyloxycarbonylamidino)phenyl] -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (2-pyridyl) -N- (2-ethoxycarbonylethyl) -amide and sodium hydroxide solution.

20 Yield: 97 % of theory,

$C_{32}H_{37}N_7O_5$ (599.7)

R_f value: 0.22 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: $(M+H)^+$ = 600

$(M+H+Na)^{++}$ = 311.7

25

$(M+2H)^{++}$ = 300.8

$(M+2Na)^{++}$ = 322.8

Example 167

30 1-Methyl-2- [N- [4- (N-n-hexyloxycarbonylamidino)phenyl] -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (3-hydroxy-n-propyl) -amide

35 Prepared analogously to Example 165 from 1-methyl-2- [N- [4- (N-n-hexyloxycarbonylamidino)phenyl] -aminomethyl] -

benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-benzyloxy-n-propyl)-amide by catalytic debenzylation.

Yield: 26 % of theory,

$C_{33}H_{40}N_6O_4$ (584.7)

5 R_f value: 0.39 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: $(M+H)^+$ = 585

$(M+H+Na)^{++}$ = 304

$(M+Na)^+$ = 607

10 Example 168

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(3-fluorophenyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

15

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(3-fluorophenyl)-N-(2-ethoxycarbonylethyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium

20

carbonate.

Yield: 42 % of theory,

$C_{28}H_{29}FN_6O_3$ (516.6)

R_f value: 0.31 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: $(M+H)^+$ = 517

25

$(M+H+Na)^{++}$ = 270

Example 169

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(4-fluorophenyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride

30

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(4-fluorophenyl)-N-(2-ethoxycarbonylethyl)-amide and

35

ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 90 % of theory,

$C_{28}H_{29}FN_6O_3$ (516.6)

5 R_f value: 0.29 (silica gel; dichloromethane/methanol = 5:1)

EKA mass spectrum: $(M+H)^+$ = 517

$(M+H+Na)^{++}$ = 270

Example 170

10

1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (3-fluorophenyl) -N- (2-hydroxycarbonylethyl) -amide

15 Prepared analogously to Example 26 from 1-methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (3-fluorophenyl) -N- (2-ethoxycarbonylethyl) -amide-hydrochloride and sodium hydroxide solution.

Yield: 97 % of theory,

20 $C_{26}H_{25}FN_6O_3$ (488.5)

R_f value: 0.13 (silica gel; dichloromethane/ethanol = 4:1)

EKA mass spectrum: $(M+H)^+$ = 489

$(M+Na)^+$ = 511

$(M+2Na)^{++}$ = 267

25

Example 171

1-Methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (4-fluorophenyl) -N- (2-hydroxycarbonylethyl) -amide

Prepared analogously to Example 26 from 1-methyl-2- [N- (4-amidinophenyl) -aminomethyl] -benzimidazol-5-yl-carboxylic acid-N- (4-fluorophenyl) -N- (2-ethoxycarbonylethyl) -amide-hydrochloride and sodium hydroxide solution.

35

Yield: 89 % of theory,

R_f value: 0.15 (silica gel; dichloromethane/ethanol = 4:1)

$$(M+Na)^+ = 511$$

5

1-Methyl-2- [N- (4-amidino-2-methoxy-phenyl) -aminomethyl] -
benzimidazol-5-yl-carboxylic acid-N-phenyl-N- (2-
ethoxycarbonylethyl) -amide-hydrochloride

15

$$\text{C}_{29}\text{H}_{32}\text{N}_6\text{O}_4 \quad (528.6)$$

20

$$(M+H+Na)^{++} = 276$$

25 Example 173

30

35

Attorney Docket No. 5/1213

C₃₆H₃₇N₇O₄ (631.7)

R_f value: 0.78 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 632
(M+H+Na)⁺⁺ = 327.8
(M+Na)⁺ = 654

Example 174

1-Methyl-2-[N-[4-(N-benzyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and benzyl chloroformate.

Yield: 64 % of theory,

C₃₅H₃₅N₇O₅ (633.6)

R_f value: 0.60 (silica gel; dichloromethane/methanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 634
(M+H+Na)⁺⁺ = 328.8
(M+Na)⁺ = 656

Example 175

25

1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and sodium hydroxide solution.

Yield: 71 % of theory,

C₂₇H₂₈N₆O₄ (500.6)

R_f value: 0.15 (silica gel; dichloromethane/ethanol = 4:1)

EKA mass spectrum: (M+H)⁺ = 501

(M+Na)⁺ = 523

(M+2Na)⁺⁺ = 273

5

Example 176

1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
10 ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-2-[N-(4-
cyano-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
15 amide and ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 67 % of theory,

C₂₈H₃₁N₇O₄ (529.6)

R_f value: 0.16 (silica gel; dichloromethane/ethanol = 4:1)

20 EKA mass spectrum: (M+H)⁺ = 530

Example 177

1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-
25 benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-methyl-2-[N-(4-
amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-
30 carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
amide-hydrochloride and sodium hydroxide solution.

Yield: 78 % of theory,

C₂₆H₂₇N₇O₄ (501.6)

R_f value: 0.12 (silica gel; dichloromethane/ethanol = 4:1)

35 EKA mass spectrum: (M+H)⁺ = 502

Example 178

1-Methyl-2-[N-[4-(N-benzyloxycarbonylamidino)phenyl]-amino-
5 methyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide

Prepared analogously to Example 104 from 1-methyl-2-[N-[4-(N-benzyloxycarbonylamidino)phenyl]-aminomethyl]-
10 benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide and sodium hydroxide solution.
Yield: 62 % of theory,

$C_{33}H_{31}N_7O_5$ (605.7)

R_f value: 0.26 (silica gel; dichloromethane/methanol = 9:1)

15 EKA mass spectrum: (M+H)⁺ = 606
(M+Na)⁺ = 628
(M-H+2Na)⁺ = 650
(M+2H)⁺⁺ = 303.8
(M+H+Na)⁺⁺ = 314.8
20 (M+2Na)⁺⁺ = 325.7

Example 179

1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-
25 5-yl-carboxylic acid-N-phenyl-N-(3-benzyloxy-n-propyl)-amide-hydrochloride

Prepared analogously to Example 25 from 1-methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic
30 acid-N-phenyl-N-(3-benzyloxy-n-propyl)-amide and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 61 % of theory,

$C_{33}H_{34}N_6O_2$ (546.7)

R_f value: 0.19 (silica gel; dichloromethane/ethanol = 4:1)

35 EKA mass spectrum: (M+H)⁺ = 547

(M+H+Na)⁺⁺ = 285

Example 180

1-Methyl-2-[N-[4-(N-n-hexyloxycarbonylamidino)phenyl]-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-benzyloxy-n-propyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-benzyloxy-n-propyl)-amide-hydrochloride and n-hexyl chloroformate.

Yield: 73 % of theory,

C₄₀H₄₆N₆O₄ (674.9)

R_f value: 0.46 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 675
(M+H+Na)⁺⁺ = 349
(M+Na)⁺ = 697
(M+K)⁺ = 713

Example 181

3-Methyl-2-[2-(4-amidinophenyl)ethyl]-imidazo[1.2-a]pyridin-7-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonyl-ethyl)-amide-hydrochloride

Prepared analogously to Example 1 from 3-methyl-2-[2-(4-cyanophenyl)ethyl]-imidazo[1.2-a]pyridin-7-yl-carboxylic acid-N-(2-pyridyl)-N-(2-methoxycarbonyl-ethyl)-amide-hydrochloride and ethanolic hydrochloric acid, ethanol and ammonium carbonate.

Yield: 53 % of theory,

C₂₈H₃₀N₆O₃ (498.59)

R_f value: 0.42 (silica gel; ethyl acetate/ethanol/ammonia = 50:45:5)

EKA mass spectrum: (M+H)⁺ = 499

$$(M+2Na)^{++} = 272$$

$$(M+H+Na)^{++} = 261$$

$$(M+2H)^{++} = 250$$

5 Example 182

1-Methyl-2-[N-(3-amidino-pyridin-6-yl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide

10

Prepared analogously to Example 26 from 1-methyl-
2-[N-(3-cyanopyridin-6-yl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-
amide and sodium hydroxide solution.

15 Yield: 40 % of theory,

$C_{24}H_{24}N_8O_3$ (472.9)

R_f value: 0.67 (Reversed Phase silica gel RP-8; methanol/5%
saline solution = 1:1)

EKA mass spectrum: $(M+H)^+ = 473$

20

Example 183

1-Methyl-2-[N-[4-(N-hydroxylamidino)phenyl]-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-[2-
25 (methansulphonylaminocarbonyl)-ethyl]-amide

a. 1-Methyl-2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-(2-pyridyl)-N-[2-
(methanesulphonylaminocarbonyl)-ethyl]-amide

30 2.0 g (4.5 mmol) of 1-methyl-2-[N-(4-cyanophenyl)-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-
N-(2-pyridyl)-N-(2-hydroxycarbonylethyl)-amide and 0.73 g
(4.7 mmol) of carbonyldiimidazole were dissolved in 80 ml
of tetrahydrofuran and 5 ml of dimethylformamide and
35 stirred for 30 minutes at ambient temperature and for
2 hours at 90°C. In parallel 0.55 g (5.8 mmol) of

methansulphonic acid amide and 0.28 g (5.8 mmol) of sodium
hydride were suspended in 15 ml of dimethylformamide and
stirred for 2 hours at ambient temperature. Then this
suspension was added at ambient temperature to the
5 tetrahydrofuran solution. After 12 hours at ambient
temperature 50 ml of water were added and the pH value was
adjusted to 6.8. The solution was extracted 4x with
methylene chloride, the combined organic phases were dried
over sodium sulphate and evaporated down. The crude product
10 was chromatographed on silica gel (methylene
chloride/ethanol (40:1)). The desired fractions were
combined and evaporated down. Yield: 1.05 g (44 % of
theory),

$C_{26}H_{25}N_7O_4S$ (531.6)

15 R_f value: 0.72 (silica gel; dichloromethane/methanol = 9:1)

b. 1-Methyl-2-[N-[4-(N-hydroxylamidino)phenyl]-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-
N-(2-pyridyl)-N-[2-(methansulphonylaminocarbonyl)-ethyl]-
20 amide

Prepared analogously to Example 96 from 1-methyl-
2-[N-(4-cyanophenyl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-[2-
(methanesulphonylaminocarbonyl)-ethyl]-amide and
25 hydroxylamine.

Yield: 27% of theory,

$C_{26}H_{28}N_8O_5S$ (564.6)

R_f value: 0.75 (silica gel; dichloromethane/ethanol = 7:3 +
1% glacial acetic acid)

30 EKA mass spectrum: $(M+H)^+ = 565$

$(M+Na)^+ = 587$

Example 184

35 1-Methyl-2-[N-(5-amidino-thiazol-2-yl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonyl-ethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-
2-[N-(5-cyano-thiazol-2-yl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
5 amide and ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: % of theory,

$C_{24}H_{26}N_8O_3S$ (506.6)

R_f value: (silica gel; dichloromethane/methanol = 4:1)

10

Example 185

1-Methyl-2-[N-(5-amidino-thiazol-2-yl)-aminomethyl]-
15 benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide

Prepared analogously to Example 26 from 1-methyl-
2-[N-(5-amidino-thiazol-2-yl)-aminomethyl]-benzimidazol-
20 5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride and sodium
hydroxide solution.

Yield: % of theory,

$C_{22}H_{22}N_8O_3S$ (478.5)

25 R_f value: (silica gel; dichloromethane/methanol = 4:1)

Example 186

1-Methyl-2-[N-(2-amidino-pyrazin-5-yl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
5 ethoxycarbonylethyl)-amide-hydrochloride

Prepared analogously to Example 25d from 1-methyl-
2-[N-(2-cyano-pyrazin-5-yl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
10 amide and ethanolic hydrochloric acid, ethanol and ammonium
carbonate.

Yield: 19 % of theory,

C₂₅H₂₇N₉O₃ (501.6)

R_f value: 0.28 (silica gel; dichloromethane/methanol = 4:1
15 + 1% glacial acetic acid)

EKA mass spectrum: (M+H)⁺ = 502

(M+H+Na)⁺ = 262.5

Example 187

20

1-Methyl-2-[N-(2-amidino-pyrazin-5-yl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide

25 Prepared analogously to Example 26 from 1-methyl-
2-[N-(2-amidino-pyrazin-5-yl)-aminomethyl]-benzimidazol-
5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
ethoxycarbonylethyl)-amide-hydrochloride and sodium
hydroxide solution.

30 Yield: 11 % of theory,

C₂₃H₂₃N₉O₃ (473.5)

R_f value: 0.55 (Reversed Phase silica gel RP-8; 5% saline
solution/methanol = 6:4)

EKA mass spectrum: (M+H)⁺ = 474

35

(M+H+Na)⁺ = 496.6

Example 188

1-Methyl-2-[2-[4-(N-n-hexyloxycarbonylamidino)phenyl]-ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)-ethyl]-amide

Prepared analogously to Example 90 from 1-methyl-2-[2-(4-amidinophenyl)-ethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)-ethyl]-amide and n-hexyl chloroformate.

Yield: % of theory,

C₃₄H₃₉N₉O₃ (621.7)

R_f value: (silica gel; dichloromethane/methanol = 4:1)

Example 189

1-Methyl-2-[N-(2-methoxy-4-n-pentoxycarbonylamidino-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and n-pentyl chloroformate.

Yield: 53 % of theory,

C₃₅H₄₂N₆O₆ (642.7)

R_f value: 0.54 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: (M+H)⁺ = 643

(M+H+Na)⁺⁺ = 333.4

Example 190

1-Methyl-2-[N-(4-n-heptyloxycarbonylamidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and n-heptyl chloroformate.

Yield: 68 % of theory,
 $C_{37}H_{46}N_6O_6$ (670.8)

R_f value: 0.56 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 671$
 $(M+H+Na)^{++} = 347.4$

Example 191

1-Methyl-2-[N-(4-ethoxycarbonylamidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide-hydrochloride and ethyl chloroformate.

Yield: 43 % of theory,
 $C_{31}H_{35}N_7O_6$ (601.7)

R_f value: 0.44 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: $(M+H)^+ = 602$
 $(M+H+Na)^{++} = 312.8$

Example 192

1-Methyl-2-[N-(2-methoxy-4-n-pentoxycarbonylamidino-
phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-
5 (2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-
carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
10 amide-hydrochloride and n-pentyl chloroformate.

Yield: 72 % of theory,

$C_{34}H_{41}N_7O_6$ (643.7)

R_f value: 0.49 (silica gel; dichloromethane/ethanol = 9:1)

EKA mass spectrum: $(M+H)^+$ = 644

15 $(M+H+Na)^{++}$ = 333.9

Example 193

1-Methyl-2-[N-(2-methoxy-4-n-heptyloxycarbonylamidino-
20 phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-
(2-pyridyl)-N-(2-ethoxycarbonylethyl)-amide

Prepared analogously to Example 90 from 1-methyl-2-[N-(4-
amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-
25 carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)-
amide-hydrochloride and n-heptyl chloroformate.

Yield: 55 % of theory,

$C_{36}H_{45}N_7O_6$ (671.8)

R_f value: 0.54 (silica gel; dichloromethane/ethanol = 9:1)

30 EKA mass spectrum: $(M+H)^+$ = 672

$(M+H+Na)^{++}$ = 347.9

Example 194

Dry ampoule containing 75 mg of active substance per 10 ml

5

Composition:

Active substance	75.0 mg
Mannitol	50.0 mg
10 water for injections	ad 10.0 ml

Preparation:

Active substance and mannitol are dissolved in water.
After packaging the solution is freeze-dried. To produce
15 the solution ready for use, the product is dissolved in
water for injections.

Example 195

20 Dry ampoule containing 35 mg of active substance per 2 ml

Composition:

25 Active substance	35.0 mg
Mannitol	100.0 mg
water for injections	ad 2.0 ml

Preparation:

30 Active substance and mannitol are dissolved in water. After
packaging, the solution is freeze-dried.

To produce the solution ready for use, the product is
dissolved in water for injections.

35

Example 196

Tablet containing 50 mg of active substance

5

Composition:

	(1) Active substance	50.0 mg
	(2) Lactose	98.0 mg
10	(3) Maize starch	50.0 mg
	(4) Polyvinylpyrrolidone	15.0 mg
	(5) Magnesium stearate	<u>2.0 mg</u>
		215.0 mg

15 Preparation:

(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch
20 on one side.
Diameter of the tablets: 9 mm.

Example 197

25 Tablet containing 350 mg of active substance

Preparation:

30	(1) Active substance	350.0 mg
	(2) Lactose	136.0 mg
	(3) Maize starch	80.0 mg
	(4) Polyvinylpyrrolidone	30.0 mg
	(5) Magnesium stearate	<u>4.0 mg</u>
35		600.0 mg

(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 12 mm.

Example 198

10 Capsules containing 50 mg of active substance

Composition:

	(1) Active substance	50.0 mg
15	(2) Dried maize starch	58.0 mg
	(3) Powdered lactose	50.0 mg
	(4) Magnesium stearate	<u>2.0 mg</u>
		160.0 mg

20 Preparation:

(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing.

This powder mixture is packed into size 3 hard gelatin capsules in a capsule filling machine.

Example 199

Capsules containing 350 mg of active substance

5

Composition:

	(1) Active substance	350.0 mg
	(2) Dried maize starch	46.0 mg
10	(3) Powdered lactose	30.0 mg
	(4) Magnesium stearate	<u>4.0 mg</u>
		430.0 mg

Preparation:

- (1) is triturated with (3). This trituration is added to
15 the mixture of (2) and (4) with vigorous mixing.

This powder mixture is packed into size 0 hard gelatin capsules in a capsule filling machine.

20 Example 200


Suppositories containing 100 mg of active substance

25 1 suppository contains:

	Active substance	100.0 mg
	Polyethyleneglycol (M.W. 1500)	600.0 mg
	Polyethyleneglycol (M.W. 6000)	460.0 mg
	Polyethylenesorbitan monostearate	<u>840.0 mg</u>
30		2,000.0 mg

What is claimed is:

1. A compound of the formula I



wherein

A denotes a carbonyl or sulphonyl group linked to the
benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno
10 moiety of the group Het, whilst moreover the abovementioned
moieties may not contain an R_1 group,

B denotes an ethylene group, wherein a methylene group,
linked either to the group Het or Ar, may be replaced by an
15 oxygen or sulphur atom or by a sulphinyl, sulphonyl,
carbonyl or $-NR_1$ group, wherein

R_1 denotes a hydrogen atom or a C_{1-6} -alkyl group,


20 E denotes a cyano or $R_b\text{NH}-\text{C}(=\text{NH})-$ group wherein

R_b denotes a hydrogen atom, a hydroxy group, a
 C_{1-3} -alkyl group or a group which may be cleaved *in*
vivo,

25 Ar denotes a phenylene or naphthylene group optionally
substituted by a fluorine, chlorine or bromine atom or by a
trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,

30 a thienylene, thiazolylene, pyridinylen, pyrimidinylen,
pyrazinylen or pyridazinylen group optionally substituted
in the carbon skeleton by a C_{1-3} -alkyl group,

Het denotes a bicyclic heterocycle of formula
35



X is a nitrogen atom and




5 Y is an oxygen or sulphur atom or a nitrogen atom optionally substituted by a C₁₋₆-alkyl or C₃₋₇-cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the above-mentioned bicyclic heterocycle may each be
10 replaced by a nitrogen atom,

or X denotes a methyne group optionally substituted by the group R₁, wherein R₁ is as hereinbefore defined, and



15 Y denotes a nitrogen atom optionally substituted by a C₁₋₆-alkyl or C₃₋₇-cycloalkyl group,

or Het denotes a group of the formula


20



25



or



, wherein

R_1 is as hereinbefore defined,

Z denotes an oxygen or sulphur atom,

one of the groups D or G denotes a nitrogen atom and the other group D or G denotes a methyne group,

and R_a denotes a C_{1-6} -alkyl group, a C_{3-7} -cycloalkyl group optionally substituted by a C_{1-3} -alkyl group, wherein the C_{1-3} -alkyl group may additionally be substituted by a carboxyl group or by a group which may be converted *in vivo* into a carboxy group,

or an R_2NR_3 - group wherein

R_2 denotes a C_{1-4} -alkyl group, which may be substituted by a carboxy, C_{1-6} -alkyloxycarbonyl, benzyloxycarbonyl, C_{1-3} -alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, trifluorosulphonylamino, trifluorosulphonylaminocarbonyl or 1H-tetrazolyl group,

a C₂₋₄-alkyl group substituted by a hydroxy, phenyl-C₁₋₃-alkoxy, carboxy-C₁₋₃-alkylamino, C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl)-carboxy-C₁₋₃-alkylamino or N-(C₁₋₃-alkyl)-C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino group, whilst in the abovementioned groups the carbon atom in the α -position relative to the adjacent nitrogen atom may not be substituted, or

a piperidinyl group optionally substituted by a C₁₋₃-alkyl group and

R₃ denotes a hydrogen atom, a C₁₋₆-alkyl group, a C₃₋₇-cycloalkyl group optionally substituted by a C₁₋₃-alkyl group, a C₃₋₆-alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R₂NR₃- group, a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, thienyl or imidazolyl group or

R₂ and R₃ together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxymethyl or C₁₋₄-alkoxycarbonyl group, onto which a phenyl ring may additionally be fused,

or a tautomer or salt thereof.

2. A compound of the formula I according to claim 1, wherein

A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno

moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R_1 group,

B denotes an ethylene group, in which a methylene group,
5 linked either to the group Het or Ar, may be replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, carbonyl or $-NR_1-$ group, wherein

R_1 denotes a hydrogen atom or a C_{1-5} -alkyl group,
10


E denotes an $R_bNH-C(=NH)-$ group wherein

R_b denotes a hydrogen atom, a hydroxy group, a
 C_{1-3} -alkyl group or a group which may be cleaved in
15 *vivo*,

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,
20

a thienylene, thiazolylene, pyridinylen, pyrimidinylene, pyrazinylen or pyridazinylene group optionally substituted in the carbon skeleton by a C_{1-3} -alkyl group,

25 Het denotes a bicyclic heterocycle of formula



, wherein

X is a nitrogen atom and
30

Y is an oxygen or sulphur atom or a nitrogen atom optionally substituted by a C_{1-6} -alkyl or C_{3-7} -cycloalkyl group, whilst additionally one or two non-angular methyne groups in the phenyl moiety of the



above-mentioned bicyclic heterocycle may each be replaced by a nitrogen atom,

5 or X denotes a methyne group optionally substituted by the group R_1 , wherein R_1 is as hereinbefore defined, and



Y denotes a nitrogen atom optionally substituted by a C_{1-6} -alkyl or C_{3-7} -cycloalkyl group,

10


or Het denotes a group of the formulae




15



20



or



wherein

5 R_1 is as hereinbefore defined,

Z denotes an oxygen or sulphur atom

10 one of the groups D or G denotes a nitrogen atom and
the other group D or G denotes a methyne group,

and R_a denotes a C_{1-6} -alkyl group, a C_{3-7} -cycloalkyl group
optionally substituted by a C_{1-3} -alkyl group, wherein the
 C_{1-3} -alkyl group may additionally be substituted by a
15 carboxyl group or by a group which may be converted *in vivo*
into a carboxy group,

or a R_2NR_3 - group wherein

20 R_2 denotes a C_{1-4} -alkyl group, which may be substituted
by a carboxy, C_{1-6} -alkyloxycarbonyl, benzyloxycarbonyl,
 C_{1-3} -alkylsulphonylaminocarbonyl,
phenylsulphonylaminocarbonyl, trifluorosulphonylamino,
trifluorosulphonylaminocarbonyl or 1H-tetrazolyl
25 group,

a C_{2-4} -alkyl group substituted by a hydroxy, phenyl-
 C_{1-3} -alkoxy, carboxy- C_{1-3} -alkylamino, C_{1-3} -
alkoxycarbonyl- C_{1-3} -alkylamino, N-(C_{1-3} -alkyl)-carboxy-
30 C_{1-3} -alkylamino or N-(C_{1-3} -alkyl)- C_{1-3} -alkoxycarbonyl- C_{1-3} -
alkylamino group, whilst in the abovementioned groups
the carbon atom in the α -position relative to the
adjacent nitrogen atom may not be substituted, or

a piperidinyl group optionally substituted by a C₁₋₃-alkyl group and

5 R₃ denotes a hydrogen atom, a C₁₋₆-alkyl group, a C₃₋₇-cycloalkyl group optionally substituted by a C₁₋₃-alkyl group, a C₃₋₆-alkenyl or alkynyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R₂NR₃- group,

10 a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a C₁₋₃-alkyl or C₁₋₃-alkoxy group, a benzyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl,
15 imidazolyl or piperidinyl group or

R₂ and R₃ together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxymethyl or
20 C₁₋₄-alkoxycarbonyl group, onto which additionally a phenyl ring may be fused,

or a tautomer or salt thereof.

25

3. A compound of the formula I according to claim 1, wherein

30 A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido, pyrimido, pyrazino, pyridazino or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R₁ group,

35 B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an -NR₁- group, wherein

R_1 denotes a hydrogen atom or a C_{1-4} -alkyl group,

E denotes an $R_bNH-C(=NH)-$ group wherein

5 R_b denotes a hydrogen atom, a hydroxy,
 C_{1-9} -alkoxycarbonyl, cyclohexyloxycarbonyl, phenyl-
 C_{1-3} -alkoxycarbonyl, benzoyl, p- C_{1-3} -alkyl-benzoyl or
 pyridinoyl group, whilst the ethoxy moiety in the
 2-position of the abovementioned C_{1-9} -alkoxycarbonyl
10 group may additionally be substituted by a C_{1-3} -alkyl-
 sulfonyl or 2-(C_{1-3} -alkoxy)-ethyl group,

Ar denotes a 1,4-phenylene group optionally substituted by
a chlorine atom or by a methyl, ethyl or methoxy group or
15 it denotes a 2,5-thienylene group,

Het denotes a 1-(C_{1-3} -alkyl)-2,5-benzimidazolylene, 1-
cyclopropyl-2,5-benzimidazolylene, 2,5-benzothiazolylene,
1-(C_{1-3} -alkyl)-2,5-indolylene, 1-(C_{1-3} -alkyl)-
20 2,5-imidazo[4,5-b]pyridinylene, 3-(C_{1-3} -alkyl)-
 2,7-imidazo[1,2-a]pyridinylene or 1-(C_{1-3} -alkyl)-
 2,5-thieno[2,3-d]imidazolylene group and

R_a denotes an R_2NR_3- group wherein

25 R_2 is a C_{1-4} -alkyl group substituted by a carboxy,
 C_{1-6} -alkyloxycarbonyl, benzyloxycarbonyl,
 C_{1-3} -alkylsulphonylaminocarbonyl or 1H-tetrazol-5-yl
 group,

30 a C_{2-4} -alkyl group substituted by a hydroxy, benzyloxy,
 carboxy- C_{1-3} -alkylamino, C_{1-3} -alkoxycarbonyl-
 C_{1-3} -alkylamino, N-(C_{1-3} -alkyl)-carboxy- C_{1-3} -alkylamino
 or N-(C_{1-3} -alkyl)- C_{1-3} -alkoxycarbonyl- C_{1-3} -alkylamino
35 group, whilst in the abovementioned groups the carbon

atom in the α -position to the adjacent nitrogen atom may not be substituted,

5 R_3 denotes a C_{3-7} -cycloalkyl group, a propargyl group, wherein the unsaturated part may not be linked directly to the nitrogen atom of the R_2NR_3 group, a phenyl group optionally substituted by a fluorine or chlorine atom, or by a methyl or methoxy group, a pyrazolyl, pyridazolyl or pyridinyl group optionally substituted by
10 a methyl group or

R_2 and R_3 together with the nitrogen atom between them denote a 5- to 7-membered cycloalkyleneimino group, optionally substituted by a carboxy or C_{1-4} -alk-
15 oxycarbonyl group, to which a phenyl ring may additionally be fused,

or a tautomer or salt thereof.

20

4. A compound of the formula I according to claim 1, wherein

25 A denotes a carbonyl or sulphonyl group linked to the benzo, pyrido or thieno moiety of the group Het, whilst moreover the abovementioned moieties may not contain an R_1 group,

30 B denotes an ethylene group in which the methylene group linked to the group Ar may be replaced by an oxygen or sulphur atom or by an $-NR_1-$ group, wherein

R_1 denotes a hydrogen atom or a methyl group,

35 E denotes an $R_bNH-C(=NH)-$ group, wherein

5 R_b denotes a hydrogen atom or a hydroxy,
 C_{1-9} -alkoxycarbonyl, cyclohexyloxycarbonyl,
 benzyloxycarbonyl, benzoyl, p- C_{1-3} -alkylbenzoyl or
 nicotinoyl group, whilst the ethoxy moiety in the 2-
 position of the abovementioned C_{1-9} -alkoxycarbonyl
 group may additionally be substituted by a C_{1-3} -
 alkylsulphonyl or 2-(C_{1-3} -alkoxy)-ethyl group,

10 Ar denotes a 1,4-phenylene group optionally substituted by
 a chlorine atom or by a methyl, ethyl or methoxy group, or
 it denotes a 2,5-thienylene group,

15 Het denotes a 1-methyl-2,5-benzimidazolylylene, 1-
 cyclopropyl-2,5-benzimidazolylylene, 2,5-benzothiazolylylene,
 1-methyl-2,5-indolylylene, 1-methyl-
 2,5-imidazo[4,5-b]pyridinylylene, 3-methyl-
 2,7-imidazo[1,2-a]pyridinylylene or 1-methyl-
 2,5-thieno[2,3-d]imidazolylylene group and

20 R_a denotes a R_2NR_3 - group wherein

R_2 denotes a C_{1-3} -alkyl group which may be substituted
 by a carboxy, C_{1-6} -alkyloxycarbonyl, benzyloxycarbonyl,
 methylsulphonylaminocarbonyl or 1H-tetrazol-5-yl group,

25 a C_{2-3} -alkyl group substituted by a hydroxy, benzyloxy,
 carboxy- C_{1-3} -alkylamino, C_{1-3} -alkoxycarbonyl-
 C_{1-3} -alkylamino, N-(C_{1-3} -alkyl)-carboxy- C_{1-3} -alkylamino
 or N-(C_{1-3} -alkyl)- C_{1-3} -alkoxycarbonyl- C_{1-3} -alkylamino
30 group, whilst in the abovementioned groups the carbon
 atom in the α -position to the adjacent nitrogen atom
 may not be substituted, and

35 R_3 denotes a propargyl group, wherein the unsaturated
 moiety may not be linked directly to the nitrogen atom
 of the R_2NR_3 group, a phenyl group optionally

substituted by a fluorine or chlorine atom, or by a methyl or methoxy group or it denotes a pyridinyl group,

5 or a tautomer or salt thereof.

5. A compound of the formula I according to claim 1, wherein

10

A denotes a carbonyl group linked to the benzo or thieno moiety of the group Het,

15

B denotes an ethylene group wherein the methylene group attached to the group Ar may be replaced by an $-NR_1$ group, whilst

R_1 denotes a hydrogen atom or a methyl group,

20

E denotes an $R_bNH-C(=NH)-$ group wherein

25

R_b is a hydrogen atom, a hydroxy, C_{1-9} -alkoxycarbonyl, cyclohexyloxycarbonyl, benzyloxycarbonyl, benzoyl, p - C_{1-3} -alkyl-benzoyl or nicotinoyl group, whilst the ethoxy moiety in the 2-position of the abovementioned C_{1-9} -alkoxycarbonyl group may additionally be substituted by a methylsulfonyl or 2-ethoxy-ethyl group,

30

Ar denotes a 1,4-phenylene group optionally substituted by a methoxy group or it denotes a 2,5-thienylene group,

35

Het denotes a 1-methyl-2,5-benzimidazolylenes, 2,5-benzothiazolylenes, 1-methyl-2,5-indolylenes or 1-methyl-2,5-thieno[2,3-d]imidazolylenes group and

R_a denotes an R₂NR₃- group wherein

5 R₂ denotes a C₁₋₃-alkyl group which may be substituted by a carboxy, C₁₋₆-alkyloxycarbonyl, benzyloxycarbonyl, methylsulfonylaminocarbonyl or 1H-tetrazol-5-yl group,

10 a C₂₋₃-alkyl group substituted by a hydroxy, benzyloxy, carboxy-C₁₋₃-alkylamino, C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl)-carboxy-C₁₋₃-alkylamino or N-(C₁₋₃-alkyl)-C₁₋₃-alkoxycarbonyl-C₁₋₃-alkylamino group, whilst in the abovementioned groups the carbon atom in the α-position to the adjacent nitrogen atom may not be substituted, and

15 R₃ denotes a phenyl group optionally substituted by a fluorine atom, or it denotes a 2-pyridinyl group,

or a tautomer or salt thereof.

20

6. A compound selected from the group consisting of:

25 (a) 2-[N-(4-amidinophenyl)-aminomethyl]-benzthiazole-5-carboxylic acid-N-phenyl-N-(2-carboxyethyl)-amide,

(b) 2-[N-(4-midinophenyl)-N-methyl-aminomethyl]-benzthiazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide,

30 (c) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-amide,

35 (d) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(3-hydroxycarbonylpropyl)-amide,

(e) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-
N-(hydroxycarbonylmethyl)-amide,

5

(f) 1-Methyl-2-[2-(2-amidinothiophen-5-yl)ethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide,

10 (g) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide,

15 (h) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-
yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide,

20 (i) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-
yl-carboxylic acid-N-phenyl-N-(2-hydroxycarbonylethyl)-
amide,

(j) 1-Methyl-2-[2-(4-amidinophenyl)ethyl]-benzimidazol-5-
yl-carboxylic acid-N-phenyl-N-[2-(1H-tetrazol-5-yl)ethyl]-
amide,

25

(k) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[2-(1H-
tetrazol-5-yl)ethyl]-amide,

30 (l) 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide,

35 (m) 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(3-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide,

(n) 1-Methyl-2-[N-(4-amidinophenyl)-N-methyl-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
hydroxycarbonylethyl)-amide,

5 (o) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-[(N-
hydroxycarbonylethyl-N-methyl)-2-aminoethyl]-amide,

(p) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
10 benzimidazol-5-yl-carboxylic acid-N-(3-fluorophenyl)-N-(2-
hydroxycarbonylethyl)-amide,

(q) 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(4-fluorophenyl)-N-(2-
15 hydroxycarbonylethyl)-amide,

(r) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-
(2-hydroxycarbonylethyl)-amide,

20 (s) 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-
pyridyl)-N-(2-hydroxycarbonylethyl)-amide,

25 (t) 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-indol-5-yl-
carboxylic acid-N-phenyl-N-(2-methoxycarbonylethyl)-amide
and

(u) 1-Methyl-2-[N-(4-amidinophenyl)aminomethyl]-
30 thieno[2.3-d]imidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
hydroxycarbonylethyl)-amide,

or a prodrug, double prodrug or salt thereof.

35

7. 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
hydroxycarbonylethyl)-amide, or a prodrug, double prodrug
or salt thereof.

5

8. 1-Methyl-2-[N-(4-amidinophenyl)-aminomethyl]-
benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-
hydroxycarbonylethyl)-amide or a prodrug, double prodrug or
salt thereof.

10

9. 1-Methyl-2-[N-(4-amidino-2-methoxy-phenyl)-
aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-
pyridyl)-N-(2-hydroxycarbonylethyl)-amide, or a prodrug,
double prodrug or salt thereof.

15

10. 1-Methyl-2-[N-[4-(N-n-
hexyloxycarbonylamidino)phenyl]aminomethyl]-benzimidazol-5-
yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)
amide.

20

11. A physiologically acceptable salt of a compound
according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 wherein
E denotes an $R_bNH-C(=NH)-$ group.

25

12. A pharmaceutical composition containing a compound
according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10,
wherein E denotes an $R_bNH-C(=NH)-$ group, or a
physiologically acceptable salt thereof, together with a
pharmaceutically acceptable carrier or diluent.

30

35

13. A method for preventing or treating venous and
arterial thrombotic disease which comprises administering
an antithrombotic amount of a compound according claim 1,
2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein E denotes an
5 $R_bNH-C(=NH)-$ group, or a physiologically acceptable salt
thereof.

14. The method of claim 13 wherein said thrombotic disease
10 is selected from the group consisting of deep leg vein
thrombosis, reocclusion after a bypass operation or
angioplasty (PT(C)A), occlusion in peripheral arterial
disease, pulmonary embolism, disseminated intravascular
coagulation, coronary thrombosis, stroke, and the occlusion
15 of a shunt or stent.

15. A method for providing antithrombotic support in
thrombolytic treatment utilizing rt-PA or streptokinase,
20 which comprises administering a therapeutically effective
amount of a compound according claim 1, 2, 3, 4, 5, 6, 7,
8, 9, or 10, wherein E denotes an $R_bNH-C(=NH)-$ group, or a
physiologically acceptable salt thereof.

25
16. A method for preventing metastasis or the growth of
clot-dependent tumours, which comprises administering a
therapeutically effective amount of a compound according
claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein E denotes
30 an $R_bNH-C(=NH)-$ group, or a physiologically acceptable salt
thereof.


17. A method for treating or preventing fibrin-dependent inflammatory processes, which comprises administering a therapeutically effective amount of a compound according claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, wherein E denotes
5 an $R_bNH-C(=NH)-$ group, or a physiologically acceptable salt thereof.

10

852120" 06932068

Abstract

New disubstituted bicyclic heterocycles of general formula



Compounds of the above general formula I, wherein E denotes an $R_b\text{NH}-\text{C}(=\text{NH})-$ group, have valuable pharmacological properties, particularly a thrombin-inhibiting effect and the effect of prolonging thrombin time, and those wherein E
10 denotes a cyano group, are valuable intermediates for preparing the other compounds of general formula I.

Exemplary compounds of formula I are:

(a) 1-Methyl-2- [N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-phenyl-N-(2-
15 hydroxycarbonylethyl)-amide,

(b) 1-Methyl-2- [N-(4-amidinophenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide,

(c) 1-Methyl-2- [N-(4-amidino-2-methoxy-phenyl)-aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(hydroxycarbonylmethyl)-amide, and
20

(d) 1-Methyl-2- [N-[4-(N-n-hexyloxycarbonylamidino)phenyl]aminomethyl]-benzimidazol-5-yl-carboxylic acid-N-(2-pyridyl)-N-(2-ethoxycarbonylethyl)
25 amide.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION	Attorney Docket Number	5/1213
	First Named Inventor	Hauel, Norbert; et al
	COMPLETE IF KNOWN	
	Application Number	To Be Assigned
	Filing Date	
	Group Art Unit	
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing <input type="checkbox"/> Declaration Submitted after Initial Filing	Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**DISUBSTITUTED BICYCLIC HETEROCYCLES, THE PREPARATION AND THE USE THEREOF AS
PHARMACEUTICAL COMPOSITIONS**

the specification of which

☒ is attached hereto

or

☐ was filed on _____ as United States Application Number or PCT International Application Number

and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119 (a)-(d) or § 365(b) of any foreign application(s) or inventors certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date	Priority Not Claimed	Certified Copy Attached?	
				Yes	No
197 06 229.6	DE	02/18/97	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
197 51 939.3	DE	11/24/97	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.
60/044,421	04/29/97	

1252120 06932060

DECLARATION

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §356(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. PARENT APPLICATION NUMBER	PCT PARENT NUMBER	PARENT FILING DATE	PARENT PATENT NUMBER (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

NAME	REGISTRATION NUMBER	NAME	REGISTRATION NUMBER
Robert P. Raymond	25,089	Alan R. Stempel	28,991
Mary-Ellen M. Devlin	27,928		

☐ Additional registered practitioner(s) are listed on a supplemental sheet attached hereto.

Direct all correspondence to:


Name	Robert P. Raymond				
Address	Boehringer Ingelheim Corporation				
Address	900 Ridgebury Road, P.O. Box 368				
City	Ridgefield	State	Connecticut	Zip	06877
Country	USA	Telephone	203-798-9988	Fax	203-791-6183

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name	Norbert	Middle Initial		Family Name	Hauel	Suffix e.g. Jr.	
---------------	----------------	-------------------	--	----------------	--------------	-----------------------	--

Inventor's Signature		Date	10/2/98
-------------------------	---	------	----------------





Residence: City	Schemmerhofen	State		Country	Germany	Citizenship	DE
Post Office Address	Marderweg 12						
Post Office Address							
City	Schemmerhofen	State		Zip	D-88433	Country	Germany

☒ Additional inventors are being listed on a supplemental sheet(s) attached hereto.

1252120 06930059

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Henning	Middle Initial		Family Name	Priepke	Suffix e.g. Jr.	
Inventor's Signature					Date	9/2/98	
Residence: City	Warthausen	State		Country	Germany	Citizenship	DE
Post Office Address	Birkenharder Strasse 11						
Post Office Address							
City	Warthausen	State		Zip	D-88447	Country	Germany
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Uwe	Middle Initial		Family Name	Ries	Suffix e.g. Jr.	
Inventor's Signature					Date	8/2/98	
Residence: City	Biberach	State		Country	Germany	Citizenship	DE
Post Office Address	Tannenstrasse 3						
Post Office Address							
City	Biberach	State		Zip	D-88400	Country	Germany
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Jean Marie	Middle Initial		Family Name	Stassen	Suffix e.g. Jr.	
Inventor's Signature					Date	10/2/98	
Residence: City	Warthausen	State		Country	Germany	Citizenship	BE
Post Office Address	Berggrubenweg 11						
Post Office Address							
City	Warthausen	State		Zip	D-88447	Country	Germany
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name	Wolfgang	Middle Initial		Family Name	Wienen	Suffix e.g. Jr.	
Inventor's Signature					Date	10/2/98	
Residence: City	Biberach	State		Country	Germany	Citizenship	DE
Post Office Address	Kirschenweg 27						
Post Office Address							
City	Biberach	State		Zip	D-88400	Country	Germany
<input type="checkbox"/> Additional inventors are being listed on a supplemental sheet(s) attached hereto.							

258120 0632060